



EMORY UNIVERSITY AND ITS SUBSIDIARIES

Independent Auditors' Reports as Required by the Uniform
Guidance and State of Georgia and Related Information

Year Ended August 31, 2023

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2023 and 2022	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	38
Supplementary Schedules	
Supplementary Schedule of Expenditures of Federal Awards	40
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	67
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	68
Uniform Guidance Reports	
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	71
Schedule of Findings and Questioned Costs	74



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statements of financial position as of August 31, 2023 and 2022, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of Emory University and its subsidiaries as of August 31, 2023 and 2022, and the changes in their net assets and their cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 19, 2023 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide and opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia
December 19, 2023

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2023 AND 2022 (Dollars in thousands)

	August 31, 2023	August 31, 2022
ASSETS:		
Cash and cash equivalents	\$ 779,690	\$ 1,421,386
Patient accounts receivable, net	709,009	646,792
Student accounts receivable, net	20,466	14,383
Loans receivable, net	15,143	16,415
Contributions receivable, net	178,701	181,811
Other receivables, net	338,762	283,544
Prepaid expenses, deferred charges, and other assets	428,498	380,662
Investments	11,093,857	10,605,084
Interests in perpetual funds held by others	1,716,576	1,682,142
Operating lease right-of-use assets	211,581	245,976
Property and equipment, net	4,682,100	4,396,966
Total assets	\$ 20,174,383	\$ 19,875,161
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 1,104,301	\$ 1,043,640
CARES Act accrued liabilities	-	69,811
Deferred revenue	458,510	420,740
Interest payable	46,338	48,817
Liability for derivative instruments	39,664	87,266
Bonds and notes payable	3,343,281	2,947,446
Accrued liabilities for benefit obligations and professional liabilities	662,502	624,906
Operating lease liabilities	239,029	273,207
Finance lease liabilities	17,378	16,583
Funds held in trust for others	1,109,200	1,121,578
Annuities payable	13,245	13,951
Government advances for federal loan programs	13,834	11,887
Asset retirement obligations	93,520	89,602
Total liabilities	7,140,802	6,769,434
Net assets without donor restrictions, controlled by Emory	5,824,675	5,464,696
Net assets without donor restrictions related to noncontrolling interests	116,878	120,735
Net assets without donor restrictions	5,941,553	5,585,431
Net assets with donor restrictions	7,092,028	7,520,296
Total net assets	13,033,581	13,105,727
TOTAL LIABILITIES AND NET ASSETS	\$ 20,174,383	\$ 19,875,161

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2023 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR AUGUST 31, 2022) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2023	Total August 31, 2022
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 522,206	-	\$ 522,206	\$ 488,367
Sales and services of auxiliary enterprises, net of scholarship allowance	78,507	-	78,507	75,724
Endowment spending distribution	245,478	-	245,478	215,461
Distribution from perpetual funds	44,830	-	44,830	42,407
Other investment income designated for current operations	93,082	-	93,082	63,617
Gifts and contributions for current use	63,507	8,999	72,506	78,456
Grants and contracts	704,398	-	704,398	632,221
Indirect cost recoveries	213,104	-	213,104	189,208
Net patient service revenue	5,332,513	-	5,332,513	5,039,219
Medical services	292,244	-	292,244	310,203
Independent operations	19,221	-	19,221	14,276
Other revenue	653,956	-	653,956	794,280
Net assets released from restrictions	31,750	(13,533)	18,217	17,361
Total operating revenue	8,294,796	(4,534)	8,290,262	7,960,800
OPERATING EXPENSES				
Salaries	4,313,737	-	4,313,737	4,138,197
Fringe benefits	935,867	-	935,867	878,882
Student financial aid	22,604	-	22,604	28,166
Other operating expenses	2,846,097	-	2,846,097	2,541,235
Interest on indebtedness	92,896	-	92,896	76,178
Depreciation and amortization	359,420	-	359,420	319,714
Total operating expenses	8,570,621	-	8,570,621	7,982,372
NET OPERATING ACTIVITIES	(275,825)	(4,534)	(280,359)	(21,572)
NONOPERATING ACTIVITIES, NET				
Investment return	40,479	(57,992)	(17,513)	(898,769)
Change in undistributed income from perpetual funds held by others	-	22,918	22,918	(45,452)
Gifts and contributions for capital and long-term investment	21,891	119,206	141,097	159,999
Other losses	(1,032)	-	(1,032)	(2,033)
Loss on retirement of debt	-	-	-	(441)
Change in fair value of derivative instruments	47,602	-	47,602	163,122
Net periodic benefit cost other than service cost	(3,599)	-	(3,599)	(2,601)
Changes in pension and other postretirement obligations	23,104	-	23,104	66,693
Other nonoperating items, net	7,898	5,955	13,853	18,359
Net assets released from restrictions	495,604	(513,821)	(18,217)	(17,361)
Total nonoperating activities, net	631,947	(423,734)	208,213	(558,484)
CHANGE IN NET ASSETS	356,122	(428,268)	(72,146)	(580,056)
Less change in net assets related to noncontrolling interests	(3,857)	-	(3,857)	(19,029)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 359,979	(428,268)	\$ (68,289)	\$ (561,027)

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2022 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2022
OPERATING REVENUE			
Tuition and fees, net of scholarship allowance	\$ 488,367	-	\$ 488,367
Sales and services of auxiliary enterprises, net of scholarship allowance	75,724	-	75,724
Endowment spending distribution	215,461	-	215,461
Distribution from perpetual funds	42,407	-	42,407
Other investment income designated for current operations	63,617	-	63,617
Gifts and contributions for current use	65,380	13,076	78,456
Grants and contracts	632,221	-	632,221
Indirect cost recoveries	189,208	-	189,208
Net patient service revenue	5,039,219	-	5,039,219
Medical services	310,203	-	310,203
Independent operations	14,276	-	14,276
Other revenue	794,280	-	794,280
Net assets released from restrictions	37,970	(20,609)	17,361
Total operating revenue	7,968,333	(7,533)	7,960,800
OPERATING EXPENSES			
Salaries	4,138,197	-	4,138,197
Fringe benefits	878,882	-	878,882
Student financial aid	28,166	-	28,166
Other operating expenses	2,541,235	-	2,541,235
Interest on indebtedness	76,178	-	76,178
Depreciation and amortization	319,714	-	319,714
Total operating expenses	7,982,372	-	7,982,372
NET OPERATING ACTIVITIES	(14,039)	(7,533)	(21,572)
NONOPERATING ACTIVITIES, NET			
Investment return	(305,342)	(593,427)	(898,769)
Change in undistributed income from perpetual funds held by others	-	(45,452)	(45,452)
Gifts and contributions for capital and long-term investment	8,499	151,500	159,999
Other losses	(2,033)	-	(2,033)
Gain on defeasance of debt	(441)	-	(441)
Change in fair value of derivative instruments	163,122	-	163,122
Net periodic benefit cost other than service cost	(2,601)	-	(2,601)
Changes in pension and other postretirement obligations	66,693	-	66,693
Other nonoperating items, net	8,853	9,506	18,359
Net assets released from restrictions	27,207	(44,568)	(17,361)
Total nonoperating activities, net	(36,043)	(522,441)	(558,484)
CHANGE IN NET ASSETS	(50,082)	(529,974)	(580,056)
Less change in net assets related to noncontrolling interests	(19,029)	-	(19,029)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ (31,053)	\$ (529,974)	\$ (561,027)

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2023 AND 2022 (Dollars in thousands)

	August 31, 2023	August 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ (72,146)	\$ (580,056)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Contributions and pledge payments restricted for long-term investment and capital projects	(114,837)	(114,858)
Contributions of donated securities	(36,369)	(73,017)
Proceeds from sale of donated securities	5,006	14,122
Equity in (gains) losses of joint ventures	(2,049)	11,684
Net realized and unrealized (gains) losses on investments	(224,559)	686,070
Loss on disposal of property and equipment	1,070	2,098
Change in undistributed income from perpetual funds held by others	(22,918)	45,452
Loss on debt retirement	-	441
Depreciation and amortization	355,588	317,609
Amortization of bond premiums and issuance costs	(22,625)	(17,582)
Amortization of right-of-use assets	39,857	44,625
Change in pension and other postretirement	(18,470)	(66,693)
Change in fair value of derivative instruments	(47,602)	(123,898)
Change in operating assets:		
Accounts and other receivables, net	(123,518)	(73,569)
Contributions receivable for operations	(6,863)	(14,987)
Prepaid expenses, deferred charges, and other assets	(47,836)	34,319
Interests in perpetual funds	5,984	-
Change in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	57,660	16,194
CARES Act accrued liabilities	(69,811)	(276,018)
Asset retirement obligations	3,918	3,769
Accrued liabilities for benefit obligations and professional liabilities	56,066	(1,439)
Lease liabilities, net	(37,631)	(19,788)
Deferred revenue	37,770	27,305
Net cash used in operating activities	(284,315)	(158,217)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Distributions from partnerships	13,407	2,000
Disbursements for loans to students	(2,050)	(2,041)
Repayment of loans from students	3,322	4,067
Proceeds from sales and maturities of investments	30,567,426	4,175,363
Purchases of investments	(30,654,884)	(3,910,918)
Purchases of property, plant, and equipment	(652,127)	(682,034)
Decrease in funds held in trust for others	(43,412)	(33,934)
Net cash used in investing activities	\$ (768,318)	\$ (447,497)

(Continued)

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2023 AND 2022 (Dollars in thousands)

	August 31, 2023	August 31, 2022
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions and pledge payments restricted for long-term investment and capital projects	\$ 107,310	\$ 109,028
Payments received restricted for capital projects from trust held by others	-	140,833
Proceeds from sale of donated securities restricted for long-term investment and capital projects	31,363	58,895
Proceeds from bonds payable, including commercial paper	791,751	662,981
Principal repayments of bonds payable, including commercial paper	(371,345)	(222,077)
Payments on finance lease obligations	(1,715)	(1,041)
Change in annuities payable	(706)	(1,892)
Debt issuance costs	(1,946)	(2,454)
Change in government advances for federal loan programs	1,947	(4,832)
Net cash provided by financing activities	556,659	739,441
Net change in cash, cash equivalents, and restricted cash	(495,974)	133,727
Cash, cash equivalents, and restricted cash at beginning of year	1,461,619	1,327,892
Cash, cash equivalents, and restricted cash at end of year (Note 2a)	\$ 965,645	\$ 1,461,619
Supplemental disclosures:		
Cash paid for interest	\$ 111,765	\$ 103,410
Accrued liabilities for property, plant, and equipment purchases	25,316	42,807

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,300 undergraduate students and 7,700 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUH, EUHM, EJCH, ESJH, ERH, DMC, and DHR are sometimes referred to herein, collectively, as “the Hospitals.”

The consolidated financial statements include the University and all other entities in which Emory has a significant financial interest and control. All significant interentity accounts and transactions have been eliminated in consolidation.

(2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions.

Accordingly, net assets of the University are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Noncontrolling interests in net assets are reported in the accompanying consolidated statements of financial position as a separate component of net assets without donor restrictions.

Net assets with donor restrictions – Net assets that are subject to donor-imposed stipulations that will or may be met either by actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all, or part, of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as increases in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return, change in fair value of derivative instruments, pension- and postretirement-related changes and net periodic benefit cost other than service cost, and other activities, net.

(a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally 90 days or less that are not invested as part of the long-term investments. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. For purposes of the statements of cash flows, activity related to liabilities with original maturities of three months or less is presented net.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's accompanying consolidated statements of financial position.

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position to the amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

	2023	2022
Cash and cash equivalents	\$ 779,690	\$ 1,421,386
Restricted cash included in investments	185,955	40,233
Total cash, cash equivalents, and restricted cash	\$ 965,645	\$ 1,461,619

Included within the 2023 and 2022 cash and cash equivalents balance is \$192.5 million and \$216.3 million of bond proceeds, respectively (note 12).

(b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is recorded to reduce the contributions receivable balance to the amount reasonably expected to be collected and is based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Loans receivable represents the outstanding loan balance due under Emory-funded and various federal government loan programs offered to graduate and undergraduate students less allowances for bad debt. Loans to students are carried at the estimated net realizable value. Interest earned on these loan programs is recognized as operating revenue in the accompanying consolidated statements of activities. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the accompanying consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the

Perkins, Nursing, and Health Professions Student Loan Programs.

(d) Student Accounts and Other Receivables, Net

Student accounts and other receivables are recorded at net realizable value and include receivables from students, sponsors, other organizations, and reinsurers.

(e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and (b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by Emory Investment Management at August 31, 2023 and 2022.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on a trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on an accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the accompanying consolidated statements of activities, net of external and direct internal investment expenses. Investment return, if restricted, is reported in the accompanying consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(f) Fair Value Measurements

The University uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable input to the extent possible. The University determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 – Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs for the asset and liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

(g) Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) Interests in Perpetual Funds Held by Others

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in change in undistributed income from perpetual funds held by others and as contribution revenue at the date such funds are established. The largest fund of this type primarily holds shares of common stock of The Coca-Cola Company. The carrying

value of Emory's interest in such perpetual funds is adjusted monthly for changes in fair value.

(i) Property and Equipment, Net

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$124.3 million and \$121.4 million, such as art, museum assets, and rare books, are included in property and equipment, net as of August 31, 2023 and 2022, respectively, but are not depreciated.

If circumstances require property and equipment to be tested for impairment, the University compares undiscounted cash flows expected to be generated by the property and equipment to its carrying amount. If the carrying amount exceeds the undiscounted cash flows, an impairment is recognized to the extent that the carrying amount exceeds its fair value. There were no asset impairments for fiscal years 2023 or 2022.

(j) Health Insurance Plan

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

(k) Patient Accounts Receivable and Concentrations

Patient accounts receivable are reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

Emory Healthcare analyzes contractually due amounts and provides an allowance for implicit price concessions. Accounts

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

receivable are written off after collection efforts have been undertaken in accordance with Emory's policies.

The mix of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2023	2022
Managed care and other third-party payors	63%	61%
Medicare	28	30
Medicaid	5	4
Patients	4	5
	100%	100%

(l) Leases

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's relevant incremental borrowing rate. The University's current discount rates range from 0.3% to 5.6% depending on the term of the arrangement.

(m) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code), and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income.

The Tax Cuts and Job Acts (the Act) imposes an excise tax on net investment income and excess compensation for certain organizations and established rules for calculating unrelated business income. Based on reasonable estimates under the current regulatory guidance, Emory has recognized a current tax liability of \$9.1 million and a deferred tax asset of \$2.8 million as of August 31, 2023 and a current tax liability of \$11.7 million and a deferred tax liability of \$1.0 million as of August 31, 2022. The University also has a net operating loss carryforward related to

unrelated business income aggregating \$179.9 million, for which a valuation allowance of \$151.8 million is recorded as of August 31, 2023. As of August 31, 2022, the University had a net operating loss carryforward of \$171.4 million, with a valuation allowance of \$144.0 million.

The University regularly evaluates its tax positions and as of August 31, 2023 and 2022, there were no material uncertain tax positions.

(n) Derivative Instruments

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in either investments or liability for derivative instruments within the accompanying consolidated statements of financial position. Changes in the fair value of investment-related derivative instruments are included in investment return on the accompanying consolidated statements of activities. The University also utilizes interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements are recognized as nonoperating activities in the accompanying consolidated statements of activities.

(o) Pension and Postretirement Benefit Plans

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

(p) COVID-19 Pandemic

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The COVID-19 pandemic has resulted in financial loss, stress, and hardship for many.

In 2020 and 2021, the Coronavirus Aid, Relief and Economic Security Act (CARES), the Coronavirus Response and Relief Supplemental Appropriations Act (CRRSAA), and the American Rescue Plan (ARP), (collectively, the Acts) were enacted and signed into law to provide emergency grants to help individuals and businesses affected by the pandemic. Under the provisions of the CARES Act, Emory Healthcare received approximately \$249.7 million in provider relief funds (PRF) from the Department of Health and Human Services (HHS) through

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

August 31, 2022 in both general and targeted distributions. Emory Healthcare recognized \$0.0 million and \$30.6 million as other revenue in the accompanying consolidated statements of activities for the years ended August 31, 2023 and 2022, respectively.

During fiscal year 2020, Emory Healthcare also received approximately \$285.2 million in advance payments, that were required to be repaid, through the Centers for Medicare & Medicaid Services (CMS) COVID-19 Accelerated and Advance Payments (CAAP) Program to provide necessary funds when there is a disruption in claims submissions and processing or in circumstances such as a national emergency or natural disasters in order to accelerate cash flow to impacted healthcare providers. Repayment of outstanding CAAP amounts began in April 2021 and occurred monthly over a 29-month period. The entire amount of advanced payments has been repaid as of August 31, 2023. Approximately \$15.0 million relating to advanced payments received under the CAAP program is reflected in CARES Act accrued liabilities in the accompanying 2022 consolidated statements of financial position.

Through August 31, 2021, the Department of Education awarded \$39.5 million in Higher Education Emergency Relief Funds (HEERF) to the University under the Acts, of which \$37.5 million was approved for payment to Emory and received as of August 31, 2023. The University distributed \$0.0 million and \$12.2 million to students and allocated \$3.6 and \$0.2 million to qualifying COVID-related expenses in fiscal years 2023 and 2022, respectively. Emory recognized \$3.6 million and \$22.3 million, respectively, as grants and contracts revenue in the accompanying 2023 and 2022 consolidated statements of activities.

The CARES Act allows employers to defer deposits and payments of the employer's share of Social Security taxes incurred between March 27, 2020 and December 31, 2020. As of August 31, 2022, Emory had deferred payments of \$54.9 million of employer taxes that were included in CARES Act accrued liabilities in the accompanying consolidated statements of financial position.

(q) New Accounting Pronouncements

In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the effects of Reference Rate Reform on Financial Reporting*, which provides optional guidance to ease the burden of accounting for contract modifications related to reference rate reform due to the

discontinuation of the London Inter-Bank Offered Rate (LIBOR), a key interbank reference rate. The standard provides accounting relief to contract modifications and optional expedients for applying U.S. GAAP to legacy contracts and other transactions that reference LIBOR or other reference rates that are expected to be discontinued because of rate reform. Emory adopted ASU No. 2020-04 in fiscal year 2023 with no material impact to the accompanying consolidated financial statements.

(r) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

(s) Conflict of Interest Policies (Related Parties)

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

(t) Investments in Joint Ventures

Emory accounts for its investments in joint ventures over which it has significant influence but not a controlling interest, using the equity method. Investments in joint ventures are generally included in investments in the accompanying consolidated statements of financial position and equity income/loss is

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

recorded within other nonoperating activities in the accompanying consolidated statements of activities.

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2023	2022
UNCONDITIONAL PROMISES EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 93,170	\$ 87,640
One year to five years	92,854	94,581
Over five years	9,051	17,816
Gross contributions receivable	195,075	200,037
Less:		
Allowance for uncollectible amounts	(5,747)	(5,568)
Discount to present value	(10,627)	(12,658)
Contributions receivable, net	\$ 178,701	\$ 181,811

At August 31, 2023 and 2022, the five largest outstanding donor pledge balances represented 55.0% and 74.0%, respectively, of Emory's total contributions receivable, net. Contribution receivables are discounted at rates ranging from 1.96% to 4.25%.

As of August 31, 2023, the University had received bequest intentions and conditional promises of approximately \$34.9 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Revenue Recognition

(a) Net Tuition and Fees

Tuition and fees revenue is derived from degree programs and continuing education programs. Tuition and fees are recognized in the fiscal year in which the academic programs and residential services are provided. Revenue is reflected in the accompanying consolidated statements of activities for the portion of the program or service that is completed by the end of the fiscal year. The remaining performance obligation that will be completed in the following fiscal year remains a liability and is recorded within deferred revenue on the accompanying consolidated statements of financial position.

Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection

with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates. Institutional resources provided in excess of amounts owed by the students to Emory are recorded as scholarship expenses.

(b) Sales and Services of Auxiliary Enterprises

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises revenue primarily includes residential services, parking, and bookstore. Residential services and parking revenue is recognized over time, as the services are performed. Sales of goods occur as a point-of-sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2023 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 477,470	53,829	531,299
Graduate and professional programs	384,663	1,441	386,104
Total at published rates	862,133	55,270	917,403
Less institutional aid for undergraduate programs	(167,251)	(8,131)	(175,382)
Less institutional aid for graduate and professional programs	(182,115)	(282)	(182,397)
Tuition and fees and auxiliary enterprises, net of institutional aid	512,767	46,857	559,624
Other academic programs	9,439	-	9,439
Total tuition and fees and auxiliary enterprises	\$ 522,206	46,857	569,063

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2022 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 458,803	51,536	510,339
Graduate and professional programs	368,358	868	369,226
Total at published rates	827,161	52,404	879,565
Less institutional aid for undergraduate programs	(168,427)	(8,788)	(177,215)
Less institutional aid for graduate and professional programs	(179,234)	(191)	(179,425)
Tuition and fees and auxiliary enterprises, net of institutional aid	479,500	43,425	522,925
Other academic programs	8,867	–	8,867
Total tuition and fees and auxiliary enterprises	\$ 488,367	43,425	531,792

(c) Gifts and Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenue in the period the contribution is received, or in the period in which the unconditional promise was made. Unconditional promises to give, with payments due in future periods, are recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional.

(d) Grants and Contracts Revenue

Emory receives funding from federal, state, corporate, and private foundations (sponsors). The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public), such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right of return or release of assets and a barrier that Emory must

overcome to be entitled to the consideration. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions. Deferred revenue is recognized when cash is received from sponsors in advance of revenue being earned. Amounts recorded in other receivable, net are for services rendered or expenditures incurred in advance of the receipt of funds.

Emory considers revenue from most clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the accompanying consolidated statements of activities for the years ended August 31, 2023 and 2022 totaled \$68.4 million and \$70.1 million, respectively.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grant and contract agreements.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the years ended August 31 (in thousands):

	2023		2022	
	Grants	Contracts	Grants	Contracts
Federal government	\$ 700,164	5,703	\$ 631,726	5,757
Other government	2,104	5	2,016	54
Corporate	26,655	49,215	19,118	56,805
Private institutions	120,174	13,482	98,468	7,485
Total	\$ 849,097	68,405	\$ 751,328	70,101

As of August 31, 2023 and 2022, Emory had unexpended grant awards of \$1.0 billion and \$952.5 million, respectively, for which revenue will be recognized when conditions have been met or performance obligations have been satisfied.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(e) Royalties Revenue

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. Sales-based royalties revenue, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, is recognized over the licensing agreement.

(f) Medical Services and Other Revenue

Medical services revenue is recognized as services are performed and the customer receives and uses the benefits of the services. The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services.

The University also has affiliation and administrative services agreements with Children's Healthcare of Atlanta and the Emory + Children's Pediatric Institute, where it provides various administrative services. Revenue is recognized over time and is recorded as other revenue in the accompanying consolidated statements of activities.

Retail pharmaceutical sales are recognized at a point in time when the customer receives the product.

The major components of other sources of operating revenue for the years ended August 31 are as follows (in thousands):

	2023	2022
Retail pharmaceutical sales	\$ 300,058	\$ 267,409
CARES Act provider relief fund	-	30,616
Royalties	96,190	262,645
Other	257,708	233,610
Other revenue	\$ 653,956	\$ 794,280

(g) Independent Operations Revenue

Independent operations are activities independent of its mission, including an externally managed conference center, hotel, and fitness center. Fee charges are based on market rates for the

services provided and revenue is recognized at a point in time or over time as the services are rendered.

(h) Net Patient Service Revenue

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare's hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when services are provided to Emory Healthcare's patients.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

concessions based upon historical write-off experience by payor category and adjusts the allowance as appropriate.

Patient service revenues, net of contractual adjustments, implicit price concessions, and other discounts recognized from major payor sources for the years ended August 31 is as follows (in thousands):

	2023	2022
Medicare	\$ 1,595,229	\$ 1,526,833
Medicaid	237,420	115,418
Managed care and other third-party payors	3,425,311	3,336,066
Patients	74,553	60,902
Net patient service revenue	\$ 5,332,513	\$ 5,039,219

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2023	2022
Services lines:		
Hospital – inpatient	\$ 2,258,790	\$ 2,218,074
Hospital – outpatient	1,939,516	1,697,647
Physician services	1,134,207	1,123,498
Net patient service revenue	\$ 5,332,513	\$ 5,039,219

Emory Healthcare provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Data is maintained to identify and monitor the level of charity care provided, including the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled \$147.1 million and \$148.2 million for the years ended August 31, 2023 and 2022, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

(5) Liquidity and Availability

Emory regularly monitors the liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2023 and 2022, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2023	2022
TOTAL ASSETS	\$ 20,174,383	\$ 19,875,161
Less:		
Property and equipment, net	(4,682,100)	(4,396,966)
Interest in perpetual trusts held by others	(1,716,576)	(1,682,142)
Donor-restricted and board-designated endowment funds	(7,493,960)	(7,310,837)
Other investments	(3,122,417)	(3,242,498)
Prepaid expenses, deferred charges, and other assets	(428,498)	(380,662)
Operating lease right-of-use assets	(211,581)	(245,976)
Contributions receivable, net	(178,701)	(181,811)
Loans receivable, net	(15,143)	(16,415)
Add:		
Endowment payout in following year	232,276	223,479
Contributions receivable due within one year for operations	93,170	87,640
Financial assets	\$ 2,650,853	\$ 2,728,973

The University has \$2.7 billion of financial assets as of August 31, 2023 to meet cash needs for general expenditures, consisting of cash and cash equivalents of \$779.7 million, accounts receivable of \$1.1 billion, contributions receivable, less than one year of \$93.2 million, payout on with and without donor-

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

restricted endowment funds of \$232.3 million, and other operating investments of \$477.5 million.

(6) Investments

The following table summarizes investments as of August 31 (in thousands):

	2023	2022
Short-term investments and cash equivalents ^(a)	\$ 792,257	\$ 498,147
Public equity ^(b)	3,625,278	3,741,806
Absolute return/fixed income ^(c)	2,046,404	1,673,726
Private equity/venture capital ^(d)	3,667,516	3,726,232
Real assets ^(e)	911,800	953,170
Derivative instruments ^(f)	50,293	11,694
Total investments at fair value	11,093,548	10,604,775
Joint ventures (equity method)	309	309
Total investments	\$ 11,093,857	\$ 10,605,084

^{a)} Includes short-term U.S. and non-U.S. Treasury securities with original maturities of less than one year, as well as funds that invest in these types of investments.

^{b)} Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date. Certain fund investments in this category may not be eligible for redemptions and instead issue distributions received through liquidation of the funds' underlying assets, which is expected to occur over the next nine years.

^{c)} Includes directly-held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$1.1 billion and \$912.9 million and investments in multistrategy or credit funds, as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$909.0 million and \$760.8 million as of August 31, 2023 and 2022, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and,

therefore, offer no liquidity over the fund life. Such funds holding illiquid investments are expected to yield liquidating distributions over the next five years.

^{d)} Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these investments are held through funds and also include buyout, venture capital, private debt, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the funds' underlying assets, which are expected to occur over the next 16 years.

^{e)} Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 10 years.

^{f)} Includes investments in equity options, swaps, and forwards valued at fair value of each underlying investments

As of August 31, 2023, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$ 401,989	30 - 90 days or not eligible	31 - 92 days
Private equity/ venture capital	1,036,619	360 days or not eligible	90 days
Public equity	25,000	0-360 days or not eligible	0-180 days
Real assets	378,472	not eligible	not eligible
	\$ 1,842,080		

Unfunded commitments are generally expected to be called by funds within five years of fund inception.

(7) Endowment Net Assets

The University's endowed assets (the Endowment) consist of approximately 2,400 individual funds established for a variety of purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The University follows the State of Georgia’s Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is classified as restricted appreciation until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University. The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2023, 67.6% of the investments described in note 6 are classified as endowed net assets.

Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2023			2022		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ –	3,819,395	3,819,395	\$ –	3,878,867	3,878,867
Historical value	–	1,306,808	1,306,808	–	1,226,590	1,226,590
Total donor restricted	–	5,126,203	5,126,203	–	5,105,457	5,105,457
Funds functioning as endowments or board-designated	2,367,757	–	2,367,757	2,205,380	–	2,205,380
Total endowment net assets	\$ 2,367,757	5,126,203	7,493,960	\$ 2,205,380	5,105,457	7,310,837

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2023			2022		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Student financial aid	\$ 212,394	1,202,728	1,415,122	\$ 214,132	1,030,890	1,245,022
Academic, research, and program support	1,358,827	3,800,202	5,159,029	1,216,929	3,903,690	5,120,619
Capital maintenance, infrastructure, and real estate	796,536	123,273	919,809	774,319	170,877	945,196
Total endowment net assets	\$ 2,367,757	5,126,203	7,493,960	\$ 2,205,380	5,105,457	7,310,837

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2021	\$ 2,357,212	5,617,776	7,974,988
Investment return:			
Investment income	10,952	26,274	37,226
Net realized and unrealized losses on investments	(180,094)	(421,502)	(601,596)
Total investment return	(169,142)	(395,228)	(564,370)
Cash contributions	4,607	78,177	82,784
Additions of funds for endowments	–	65	65
Additions of institutional funds to quasi endowment without donor restrictions	111,120	–	111,120
Withdrawal of board-designated funds for strategic initiatives	(23,195)	–	(23,195)
Appropriations for expenditure	(68,485)	(177,744)	(246,229)
Appropriations for capital maintenance and infrastructure	(6,737)	(17,589)	(24,326)
Balance as of August 31, 2022	\$ 2,205,380	5,105,457	7,310,837
Investment return:			
Investment income	10,557	23,425	33,982
Net realized and unrealized gains on investments	53,628	130,521	184,149
Total investment return	64,185	153,946	218,131
Cash contributions	16,012	79,836	95,848
Additions of funds for endowments	–	1,368	1,368
Additions of institutional funds to quasi endowment without donor restrictions	176,635	–	176,635
Withdrawal of board-designated funds for strategic initiatives	(5,177)	(986)	(6,163)
Appropriations for expenditure	(77,746)	(185,714)	(263,460)
Appropriations for capital maintenance and infrastructure	(11,532)	(27,704)	(39,236)
Balance as of August 31, 2023	\$ 2,367,757	5,126,203	7,493,960

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature were \$6.3 million and \$5.8 million as of August 31, 2023 and 2022, respectively.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under

this policy, as approved by the Board of Trustees, the endowment assets are invested within risk tolerances of the University to provide an expected total return and inflation over the long term.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, and real assets to achieve its long-term return objectives within a prudent risk framework. The Endowment's long-term target asset

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs while preserving the purchasing power of the endowment over

the long term. The distribution of endowment investment return in 2023 was based on 5.0% of the average fair value of the endowment over the previous 48 months ended on August 31, and 5.0% of the average fair value of the endowment over the previous 36 months in 2022. The University considers the historical average market value in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

(8) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2023 (in thousands):

	Investments Measured at NAV ⁽¹⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ —	630,459	161,798	—	792,257
Public equity	2,923,078	697,275	4,922	3	3,625,278
Absolute return/fixed income	909,030	451,267	686,107	—	2,046,404
Private equity/venture capital	3,642,905	—	—	24,611	3,667,516
Real assets	908,907	199	1,500	1,194	911,800
Derivative instruments	—	1,020	49,273	—	50,293
Total investments at fair value	8,383,920	1,780,220	903,600	25,808	11,093,548
Interests in perpetual funds held by others	—	—	—	1,716,576	1,716,576
Total assets at fair value	8,383,920	1,780,220	903,600	1,742,384	12,810,124
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	—	—	(39,664)	—	(39,664)
Funds held in trust for others ⁽²⁾	(1,109,200)	—	—	—	(1,109,200)
Total liabilities at fair value	\$ (1,109,200)	—	(39,664)	—	(1,148,864)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2022 (in thousands):

	Investments Measured at NAV ⁽¹⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ –	169,462	328,685	–	498,147
Public equity	3,204,693	499,380	37,730	3	3,741,806
Absolute return/fixed income	760,751	550,815	362,160	–	1,673,726
Private equity/venture capital	3,684,239	–	–	41,993	3,726,232
Real assets	950,298	186	1,500	1,186	953,170
Derivative instruments	–	(1)	11,695	–	11,694
Total investments at fair value	8,599,981	1,219,842	741,770	43,182	10,604,775
Interests in perpetual funds held by others	–	–	–	1,682,142	1,682,142
Total assets at fair value	8,599,981	1,219,842	741,770	1,725,324	12,286,917
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	–	–	(87,266)	–	(87,266)
Funds held in trust for others ⁽²⁾	(1,121,578)	–	–	–	(1,121,578)
Total liabilities at fair value	\$ (1,121,578)	–	(87,266)	–	(1,208,844)

⁽¹⁾ Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying consolidated statements of financial position.

⁽²⁾ Emory uses net asset value of units held in endowment pool as an estimate for fair value.

The following tables present a summary of the University's activity for investments categorized as Level 3 for the years ended August 31, 2023 and 2022 (in thousands):

	2023			2022		
	Purchases	Sales	Transfers out ⁽¹⁾	Purchases	Sales	Transfers out ⁽¹⁾
Private equity/venture capital	\$ 6,275	(559)	–	\$ 57,698	(4,290)	–
Real assets	8	(43)	–	10	–	–
Total Investments	6,283	(602)	–	57,708	(4,290)	–
Interests in perpetual funds held by others	17,500	–	(5,984)	20,000	–	(140,833)
Total assets	\$ 23,783	(602)	(5,984)	\$ 77,708	(4,290)	(140,833)

⁽¹⁾ Transfers of interests in perpetual funds held by others is due to funds released from operations.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(9) Derivative Instruments and Hedging Activities

(a) Investments

Investment strategies employed by Emory and investment managers retained by Emory may incorporate futures, options, swaps, and other derivative instruments to adjust elements of investment exposures to various securities, markets, and

currencies without taking a position in the underlying assets. These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks.

Emory's investment-related derivative exposures, categorized by primary underlying risk, as of and for the years ended August 31 are as follows (in thousands):

2023		Notional Amount⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings⁽²⁾
Foreign exchange contracts	\$	145,367	73,194	(72,173)	824
Equity contracts ⁽³⁾		345,670	54,448	(5,176)	27,334
Total⁽⁴⁾	\$	491,037	127,642	(77,349)	28,158

2022		Notional Amount⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings⁽²⁾
Foreign exchange contracts	\$	935	467	(468)	(69,542)
Equity contracts ⁽³⁾		452,835	29,835	(18,140)	17,980
Total⁽⁴⁾	\$	453,770	30,302	(18,608)	(51,562)

⁽¹⁾ The notional amount is representative of the absolute value of the open contracts as of August 31, 2023 and 2022, except as otherwise discussed below in (3).

⁽²⁾ Gains and losses on derivative instruments incurred during the fiscal year are included in the accompanying consolidated statements of activities in investment return in nonoperating activities.

⁽³⁾ The notional value for options is presented on a net delta-adjusted basis.

⁽⁴⁾ Derivatives are held primarily with 11 counterparties. Cash collateral of \$0.7 million and \$18.4 million is pledged as of August 31, 2023 and 2022, respectively.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(b) Debt

Historically, as a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. Since the inception of the interest rate swap agreements, the debt portfolio has changed to incorporate fixed rate debt not associated with derivatives. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net liability positions. As of August 31, 2023, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2023, Emory had eight interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.2% to 3.6% in exchange for variable rate payments from the counterparties based on a percentage of the three-month

LIBOR. In adherence to the International Swaps and Derivatives Association (ISDA) 2020 Interbank Offered Rate (IBOR) Fallback Protocol, on July 1, 2023 the variable rate payments changed from being based on a percentage of three-month LIBOR to being based on a percentage of Term Secured Overnight Financing Rate (SOFR) plus a spread.

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$1.0 million and \$9.7 million and, interest expenses related to nonintegrated agreements, reflected as nonoperating loss, of \$0.0 million and \$8.9 million during 2023 and 2022, respectively. During fiscal year 2022 the University entered into and subsequently terminated an interest rate lock agreement which resulted in a favorable termination settlement payment of approximately \$39.0 million. The realized gain on the termination payment received was recorded as a change in the fair value of derivative instruments within non-operating activities, net on the accompanying consolidated statements of activities. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The following table summarizes the debt-related derivative instruments as of and for the years ended August 31 (in thousands):

Interest Rate Swaps			2023		2022	
Inception	Maturity	Notional Amount ⁽¹⁾	Liability Fair Value	Unrealized Gain	Liability Fair Value	Unrealized Gain
August 4, 2005	September 1, 2035	\$ 125,000	(4,981)	8,022	\$ (13,003)	21,359
August 25, 2005	September 1, 2035	40,000	(1,788)	2,679	(4,467)	7,090
December 1, 2007	September 1, 2035	75,000	(5,441)	5,285	(10,726)	13,906
May 1, 2008	September 1, 2038	75,000	(7,312)	6,190	(13,502)	15,864
December 1, 2008	December 1, 2042	100,000	(7,264)	9,460	(16,724)	23,426
December 1, 2009	September 1, 2035	75,000	(5,681)	5,312	(10,993)	13,964
June 23, 2015	September 1, 2035	125,000	(5,409)	7,969	(13,378)	21,205
June 23, 2015	September 1, 2035	40,000	(1,788)	2,685	(4,473)	7,084
Total		\$ 655,000	(39,664)	47,602	\$ (87,266)	123,898

⁽¹⁾ The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed.

(10) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2023	2022
Land and improvements	\$ 252,264	\$ 247,868
Buildings and improvements	4,979,437	4,203,949
Equipment	3,509,917	3,112,204
Finance lease ROU assets (note 11)	24,926	22,190
Library and museum assets	555,924	529,413
Construction in progress	503,778	1,083,361
	9,826,246	9,198,985
Less: accumulated depreciation	(5,132,809)	(4,792,917)
Less: accumulated amortization of finance leases	(11,337)	(9,102)
Total property, plant, and equipment, net	\$ 4,682,100	\$ 4,396,966

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.0% and a discount rate of 4.25%.

The following table summarizes the ARO activity for the year ended August 31 (in thousands):

	2023	2022
ARO liability at beginning of year	\$ 89,602	\$ 85,833
Accretion expense	3,918	3,769
ARO liability at end of year	\$ 93,520	\$ 89,602

(11) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases except for leases with an initial term less than 12 months for which the University made the short-term election are included in operating lease right-of-use assets and operating lease liabilities in the accompanying consolidated statements of financial position. Finance leases are included in property, plant, and equipment, net, and finance lease liabilities in the accompanying consolidated statements of financial position.

Operating lease liabilities represent the remaining fixed lease payments discounted to present value, while the right-of-use (ROU) assets include any lease payments made, lease incentives received, and are amortized over the term of the lease. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Lease costs associated with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and nonlease components being combined, and accounted for, as a

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

single lease component and included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31, are as follows (in thousands):

	2023	2022
Finance lease cost	\$ 2,917	\$ 2,131
Amortization of ROU assets	2,235	1,493
Interest on lease liabilities	682	638
Operating lease cost	42,056	39,835
Short-term lease cost	20,203	22,282
Total lease expense	\$ 65,176	\$ 64,248

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2023 are as follows (in thousands):

	Operating Leases	Finance Leases
2024	40,815	1,313
2025	34,525	1,070
2026	28,338	1,044
2027	24,180	1,042
2028	20,117	1,044
Thereafter	118,070	19,392
Total lease payments	266,045	24,905
Less: amounts representing interest	(27,016)	(7,527)
Total obligation	\$ 239,029	17,378

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	2023	2022
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 38,357	\$ 40,497
Operating cash flows from finance leases	2,235	1,494
Financing cash flows from finance leases	1,715	1,041
Right-of-use assets obtained in exchange for new lease obligations		
Operating leases	10,284	109,242
Finance leases	2,736	-
Weighted-average remaining lease term -- finance lease	20 years	22 years
Weighted-average remaining lease term -- operating lease	10 years	8 years
Weighted-average discount rate -- finance lease	3.90%	3.79%
Weighted-average discount rate -- operating lease	2.25%	2.10%

Emory is the lessor in a long-term noncancelable operating sublease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare at its Executive Park property. The lease agreement's underlying asset will continue to be classified as the original lessor's fixed asset.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(12) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2023	2022
Tax-exempt, fixed-rate revenue bonds:				
2023 Series A	5.00%	September 1, 2033	\$ 142,500	\$ –
2023 Series B	5.00	September 1, 2033	234,750	–
2022 Series A	5.00	September 1, 2032	212,055	212,055
2020 Series B	4.63	September 1, 2041	486,470	486,470
2019 Series A	4.96	September 1, 2039	194,625	201,790
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.17	October 1, 2043	189,915	192,905
2013 Series A	5.00	October 1, 2043	177,850	178,335
Total tax-exempt, fixed-rate revenue bonds			1,807,920	1,441,310
Tax-exempt, variable-rate revenue bonds:				
2022 Series B	2.92	September 1, 2052	110,380	110,380
Total tax-exempt, variable-rate revenue bonds			110,380	110,380
Taxable, fixed-rate revenue bonds:				
2020 Series A	2.41	September 1, 2050	943,750	943,750
1994 Series C	8.00	October 1, 2024	1,590	2,295
Total taxable, fixed-rate revenue bonds			945,340	946,045
Taxable, variable-rate revenue bonds:				
2022 Series C-1 ⁽¹⁾	4.75	September 1, 2052	110,450	110,450
2022 Series C-2 ⁽¹⁾	4.70	September 1, 2052	110,445	110,445
Total taxable, variable-rate revenue bonds			220,895	220,895
Unamortized bond premiums			269,923	238,788
Bond issuance costs			(11,177)	(9,972)
Total bonds and notes payable			\$ 3,343,281	\$ 2,947,446

⁽¹⁾ Average reset rates taken from Electronic Municipal Market Access (EMMA), plus credit facility and remarketing fees

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The University incurred interest expenses of \$94.9 million and \$76.2 million in 2023 and 2022, respectively, net of capitalized interest of \$8.7 million and \$7.6 million in 2023 and 2022, respectively. During 2023, the average interest rate on the University's tax-exempt variable demand bonds, including fees, was 2.92% and the average interest rate on taxable variable bonds, including fees, was 4.73%. Related indices for this period were 2.88% for tax-exempt debt Securities Industry and Financial Markets Association Index (SIFMA), and 4.35% for taxable debt.

As of August 31, 2023 the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2023
PAYABLE IN FISCAL YEAR:	
2024	\$ 11,450
2025	9,990
2026	290,610
2027	11,825
2028	12,185
Thereafter	2,748,475
	3,084,535
Unamortized net premium	269,923
Unamortized net bond issuance costs	(11,177)
	\$ 3,343,281

In June 2023, the University issued \$142.5 million in par value of 2023 Series A bonds and received \$163.0 million in proceeds from the issuance. Additionally, in August 2023, the University issued the 2023 Series B bond under a private placement,

receiving proceeds of \$234.8 million. Under the terms of the bond agreement, in March 2024, the bond will be converted to a public issuance.

The 2008 taxable Commercial Paper program of \$350.0 million had an outstanding balance of \$0.0 million, as of August 31, 2023 and 2022 under this program. In December 2022, the University issued \$225.0 million of commercial paper under this program, which has been repaid in full as of August 31, 2023.

The University has three credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. It has a direct-pay letter of credit supporting the 2022 C-1 bonds totaling \$110.5 million, a standby bond purchase agreement supporting 2022 C-2 bonds totaling \$110.5 million, and a revolving credit agreement supporting any self-liquidity debt totaling \$175.0 million. These credit facilities are committed for the sole purpose of supporting these debt instruments and cannot be used for operating needs of the University. There were no draws against any of these facilities in 2023 or 2022.

The University has a syndicated line of credit of \$750.0 million that expires in April 2026. There is no outstanding balance as of August 31, 2023, and 2022. In November 2023, the University borrowed \$100.0 million against the line of credit.

The University has a letter of credit with a commercial bank totaling \$1.1 million. There were no outstanding balances as of August 31, 2023 or 2022. The letter of credit agreement expires in March 2024.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(13) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2023			2022		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Emory undesignated funds	\$ 2,392,517	–	2,392,517	\$ 1,948,545	–	1,948,545
Endowment funds	2,367,757	5,126,203	7,493,960	2,205,380	5,105,457	7,310,837
Investment in plant	1,181,279	–	1,181,279	1,431,506	–	1,431,506
Interest in perpetual funds held by others	–	1,716,576	1,716,576	–	1,682,142	1,682,142
Contributions receivable, net	–	178,474	178,474	–	181,811	181,811
Annuity and other split-interest agreements	–	10,917	10,917	–	9,598	9,598
Capital maintenance, infrastructure, and other donor purposes	–	59,858	59,858	–	541,288	541,288
	\$ 5,941,553	7,092,028	13,033,581	\$ 5,585,431	7,520,296	13,105,727

(14) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare. Benefits to eligible employees were based on a formula defined in the plan. Benefits are paid as a monthly annuity at age 65 or an eligible employee can elect a reduced benefit as early as age 55. The benefits are vested only to the extent of the annuities purchased. Benefits were frozen as of 12/31/2011. Emory Healthcare also has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. Emory Healthcare contributes an amount equal to 2% of each eligible employee's compensation to the plan as well as a supplemental contribution of up to 5% based on a 1 to 1 match of employee contributions of up to 4% for eligible employees with less than 10 years of service and 5% if 10 or more years of service. Employer contributions cliff vest after three years of service.

TEC sponsors a defined-contribution plan under the Code, Section 403(b), The Emory Clinic, Inc. Retirement Savings Plan covering eligible employees. TEC contributes an amount equal to

6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Retirement expenses for these plans totaled \$204.7 million and \$187.0 million during 2023 and 2022, respectively, and is included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of employment from the University. As of August 31, 2023 and 2022, respectively, the University held assets of \$220.1 million and \$192.7 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$220.1 million and \$192.7 million as of August 31, 2023 and 2022, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

(15) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

On December 31, 2022, Emory Healthcare split the Plan into two separate plans. All participants with a lump sum value of less than \$5,000 at December 31, 2022 remained in the original plan and were offered to receive the present value of their pension benefit in a lump sum. The lump sum payouts reduced both the projected benefit obligation and plan assets by \$1.5 million. All other participants and beneficiaries were transferred to the new plan (Plan 2). The total amount of projected benefit obligation and the original plan assets that were transferred to Plan 2 were \$327.3 million and \$281.7 million, respectively. Effective May 1, 2023, Emory Healthcare terminated the original plan. As a result of the termination, a one-time settlement charge of \$0.4 million is reflected in other nonoperating activities in the accompanying consolidated statements of activities as of August 31, 2023. No changes were made to the plan benefits.

The Plan’s investment objectives related to its defined benefit plan are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the Plan’s investment policy framework. Asset allocation strategies and investment management structure are designed to meet the Plan’s investment objectives.

The Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan’s target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph’s Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

The SJHS Pension Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan’s target asset allocation. The accumulated benefit obligations at August 31, 2023 and 2022 are the same as the projected benefit obligations.

The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

	2023		2022	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Projected benefit obligation, beginning of year	\$ 329,276	134,574	\$ 432,841	176,584
Interest cost	15,337	6,328	9,884	4,634
Actuarial (gain) loss	(26,874)	(10,119)	(102,676)	(39,597)
Plan combinations	–	–	–	–
Plan settlements	(1,467)	–	–	–
Benefits paid	(11,952)	(7,305)	(10,773)	(7,047)
Projected benefit obligation, end of year	\$ 304,320	123,478	\$ 329,276	134,574

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2023		2022	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Fair Value of plan assets, beginning of year	\$ 283,952	128,194	\$ 369,401	163,431
Actual return on plan assets	(5,395)	2,232	(74,676)	(32,086)
Employer contributions	–	1,812	–	3,896
Plan combinations	–	–	–	–
Plan settlements	(1,467)	–	–	–
Benefits paid	(11,952)	(7,305)	(10,773)	(7,047)
Fair value of plan assets, end of year	\$ 265,138	124,933	\$ 283,952	128,194
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$ (39,182)	1,454	\$ (45,324)	(6,381)

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2023		2022	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Interest cost	\$ 15,337	6,328	\$ 9,884	4,634
Expected return on assets	(15,595)	(6,514)	(13,928)	(6,469)
Amortization of prior service cost	–	(438)	–	(438)
Settlement loss recognized	449	–	–	–
Amortization of net loss	213	2,092	3,342	2,035
Recognized actuarial loss	–	–	–	–
Net periodic pension cost	\$ 404	1,468	\$ (702)	(238)

Net periodic pension costs are recognized as employees render the services necessary to earn the pension benefits.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2023		2022	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	5.56%	5.55%	4.84%	4.84%
Expected long-term rate of return on plan assets	4.95	5.20	4.40	4.00

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2023		2022	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	4.84%	4.84%	2.73%	2.68%
Expected long-term rate of return on plan assets	4.95	5.20	4.40	4.00

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

	2023							
	Emory Healthcare	SJHS	Total	Fair Value Hierarchy			Total Fair Value	Target Allocation ⁽¹⁾
				Level 1	Level 2	NAV		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 20,491	4,854	25,345	25,345	–	–	25,345	—%
Public equity	77,134	16,739	93,873	4,327	76,881	12,665	93,873	64
Absolute return	13,963	–	13,963	–	–	13,963	13,963	4
Private equity/venture capital	12,568	–	12,568	–	–	12,568	12,568	2
Fixed income	140,982	103,340	244,322	–	219,755	24,567	244,322	30
Total investments	\$ 265,138	124,933	390,071	29,672	296,636	63,763	390,071	100%

	2022							
	Emory Healthcare	SJHS	Total	Fair Value Hierarchy			Total Fair Value	Target Allocation ⁽¹⁾
				Level 1	Level 2	NAV		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 3,942	6,141	10,083	8,343	–	1,740	10,083	—%
Public equity	89,406	34,298	123,704	10,602	75,510	37,592	123,704	64
Absolute return	15,850	–	15,850	–	–	15,850	15,850	4
Private equity/venture capital	9,829	–	9,829	–	–	9,829	9,829	2
Fixed income	164,925	87,755	252,680	6,180	239,194	7,306	252,680	30
Total investments	\$ 283,952	128,194	412,146	25,125	314,704	72,317	412,146	100%

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Cash Flows

Emory Healthcare expects to contribute \$0.0 million to the Emory Healthcare Pension Plan, and \$0.6 million to the SJHS Pension Plan during fiscal year 2024.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$14.5 million to \$19.3 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$7.9 million to \$8.9 million for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

(16) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2023			2022	
	Emory University	Emory Healthcare	Total	Total	
APBO, beginning of year	\$ 97,315	53,846	151,161	\$	215,093
Service cost	805	230	1,035		2,540
Interest cost	4,489	2,480	6,969		4,850
Actuarial gains	(4,960)	(2,609)	(7,569)		(63,990)
Benefits paid	(4,776)	(2,169)	(6,945)		(7,332)
APBO, end of year	\$ 92,873	51,778	144,651	\$	151,161

The discount rate to determine APBO as of August 31, 2023 and 2022 was 5.6% and 4.8%, respectively.

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2023			2022	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 84,437	16,697	101,134	\$	117,175
Actual return on plan assets	5,469	1,038	6,507		(16,041)
Benefits paid from plan assets	–	(2,169)	(2,169)		–
Fair value of plan assets, end of year	\$ 89,906	15,566	105,472	\$	101,134
Funded status – accrued postretirement benefit cost recognized in the consolidated statements of financial position	\$ (2,967)	(36,212)	(39,179)	\$	(50,027)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2023			2022	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 805	230	1,035	\$	2,540
Interest cost on APBO	4,489	2,480	6,969		4,850
Expected return on plan assets	(5,911)	(1,069)	(6,980)		(6,855)
Recognized net actuarial loss	1,307	432	1,739		5,546
Net periodic postretirement benefit cost	\$ 690	2,073	2,763	\$	6,081

Discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2023 and 2022 was 4.8% and 2.7%, respectively, and 7.0% and 5.9%, respectively.

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2023			2022	
	Emory University	Emory Healthcare	Total	Total	
Net unrecognized actuarial loss	\$ 22,010	5,054	27,064	\$	35,925
Prior service cost	–	–	–		(26)
Total	\$ 22,010	5,054	27,064	\$	35,899

In fiscal year 2024, net unrecognized actuarial losses of \$1.0 million for Emory University and \$0.0 million for Emory Healthcare are expected to be amortized from net assets without donor restrictions into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of Emory University’s Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations.

The secondary objective is to meet or exceed the plans’ actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

2023						
	Total Fair Value	Fair Value Hierarchy		NAV	Target	
		Level 1	Level 2		Allocation ⁽¹⁾	
Fixed income	\$ 27,923	10,148	16,775	1,000	29%	
Public equity	60,887	–	47,370	13,517	56	
Absolute return	10,753	5,047	–	5,706	10	
Private equity/venture capital	4,666	–	–	4,666	5	
Short-term investment and cash equivalent	1,243	1,243	–	–	–	
Total investments	\$ 105,472	16,438	64,145	24,889	100%	

2022						
	Total Fair Value	Fair Value Hierarchy		NAV	Target	
		Level 1	Level 2		Allocation ⁽¹⁾	
Fixed income	\$ 22,602	13,997	7,680	925	15%	
Public equity	63,126	6,650	36,597	19,879	70	
Absolute return	11,658	5,985	–	5,673	10	
Private equity/venture capital	3,621	–	–	3,621	5	
Short-term investment and cash equivalent	127	127	–	–	–	
Total investments	\$ 101,134	26,759	44,277	30,098	100%	

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

Cash Flows

Emory University and Emory Healthcare expect to contribute \$5.0 million and \$0.0 million, respectively, to the postretirement benefit plan during fiscal year 2024.

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$5.0 million to \$5.8 million for Emory University and from \$3.0 million to \$3.4 million for Emory Healthcare for the next five years.

(17) Functional Expenses

The accompanying consolidated statements of activities present expenses by natural classification. The University also summarizes expenses by functional classification, in accordance with its mission. The University’s primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

The accompanying consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

2023

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	346,496	340,719	111,937	186,237	66,583	3,143,794	117,971	4,313,737
Fringe benefits		81,888	91,128	28,103	61,870	17,602	630,693	24,583	935,867
Student financial aid		–	–	22,604	–	–	–	–	22,604
Other operating expenses		79,659	296,261	76,991	46,429	50,927	2,256,311	39,519	2,846,097
Interest on indebtedness		7,833	12,468	4,979	2,514	1,970	41,824	21,308	92,896
Depreciation and amortization		34,629	57,969	20,906	29,969	9,532	188,881	17,534	359,420
Total expenses	\$	550,505	798,545	265,520	327,019	146,614	6,261,503	220,915	8,570,621

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$6.0 billion. Healthcare administrative costs are \$720.8 million, included therein.

2022

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	322,298	298,911	101,095	164,625	63,588	3,079,183	108,497	4,138,197
Fringe benefits		81,560	79,711	27,199	50,305	17,212	589,987	32,908	878,882
Student financial aid		–	–	28,166	–	–	–	–	28,166
Other operating expenses		72,688	248,567	66,232	34,326	48,432	2,048,011	22,979	2,541,235
Interest on indebtedness		6,144	9,780	3,907	1,972	1,544	36,146	16,685	76,178
Depreciation and amortization		30,780	51,527	18,582	26,637	8,472	165,349	18,367	319,714
Total expenses	\$	513,470	688,496	245,181	277,865	139,248	5,918,676	199,436	7,982,372

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$5.7 billion. Healthcare administrative costs are \$549.0 million, included therein.

Costs related to the University’s operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program, and supporting activities based upon information reported in the space study and debt financing records. Fundraising costs were approximately \$56.2 million and \$46.7 million in 2023 and 2022, respectively.

(18) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare’s wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals,

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2023 and 2022, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$306.0 million (discounted at 2.5%) and \$274.4 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$115.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The University's management believes adequate provision has been made for the related risk.

(19) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI comprises 16 to 28 members, including its founders, and others as elected half by the University, including the University's president, and half by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws. Funds held in trust for others include \$1.042 billion and \$1.048 billion, representing CCI's investment in the University's long-term investment portfolio as of August 31, 2023 and 2022, respectively. CCI is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days' written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by CCI requires at least one year's written notice and is subject to a multi-year distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both CCI and the University.

Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, established the Emory + Children's Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the

affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by the faculty members in salaries, fringe benefits, professional fees and purchased services, and other operating expenses in the accompanying consolidated statements of activities.

(20) Commitments and Contingencies

Purchase Commitments

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2023 totaled \$153.3 million and \$126.2 million, respectively.

Federal and State Regulatory Matters

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, cannot have a material effect on the University's consolidated financial statements.

The University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the accompanying consolidated statements of financial position.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2023 AND 2022

Other Legal Matters

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel. The University also has a comprehensive program of primary and excess insurance.

Emory Healthcare and SJHS have a JOC under the name of Emory/Saint Joseph's, Inc. to further the respective missions of Emory Healthcare and CHE Trinity Health. Under the JOC Contribution Agreement, Emory Healthcare maintains a 51% controlling ownership interest in the JOC. SJHS has a noncontrolling membership interest in the JOC of 49%. Effective August 31, 2014, CHE Trinity Health has a put right, as defined in the JOC Contribution Agreement, that may be exercised at any time with written notice to Emory Healthcare. Upon the occurrence of such event, Emory Healthcare may be required to purchase from SJHS its noncontrolling interest in the JOC. On March 25, 2022, CHE Trinity Health filed a complaint against Emory Healthcare in the Superior Court of Fulton County, Georgia, alleging breach of contract relating to a potential sale of CHE Trinity Health's 49% membership interest in the JOC. In September 2023, the Superior Court of Fulton, County, Georgia granted Summary Judgment in favor of Emory Healthcare and ruled that the Memorandum of Understanding dictating the valuation process and purchase process is an unenforceable agreement. In October 2023, CHE Trinity Health filed an appeal of the ruling with the Georgia Court of Appeals. In the event Emory Healthcare closes the purchase of CHE Trinity's membership interest in the JOC, Emory Healthcare has sufficient sources of available liquidity to consummate the transaction.

The University is a defendant along with sixteen other universities in a putative class action lawsuit, *Carbone, et al. v. Brown University, et al.*, where the plaintiffs allege antitrust violations related to the award of need-based financial aid. The case is in the United States District Court for the Northern District of Illinois. In September 2023, the University reached a settlement in principle. The amount of the settlement offer has been accrued within accounts payable and accrued liabilities in the accompanying consolidated statements of financial position.

(21) Subsequent Events

Emory has evaluated subsequent events after the accompanying consolidated statements of financial position date of August 31, 2023 through December 19, 2023, the date the consolidated financial statements were issued. On November 2, 2023, the Centers for Medicare & Medicaid Services (CMS) published the final rule to remedy the Section 340B of the Public Health Service Act acquired drug payment policy for Calendar Years 2018-2022. This rule would remedy the payment rates utilized during Calendar Years 2018-2022 that the United States Supreme Court held were invalid. CMS plans to make a one-time lump sum payment to affected providers for 340B-acquired drugs over the impacted period. Based on the published payment rate, Emory Healthcare expects to receive approximately \$75.2 million from CMS which will be recognized as net patient service revenue within the accompanying consolidated statements of activities for the year ending August 31, 2024. Other than this matter, there are no other items to disclose that would have a material impact on the University's accompanying consolidated statements of financial position.



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America, the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the University's consolidated statement of financial position as of August 31, 2023, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 19, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 19, 2023

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF
FEDERAL AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture:				
Agricultural Research Basic and Applied Research	58-6040-022	10.001	\$ —	2,648
Pass-through CRDF Global	DAAG-19-65373-1	10.001	—	13,448
Total AL No. 10.001			—	16,096
Wholesale Farmers and Alternative Market Development	22-TMMSD-GA-0009	10.164	9,230	56,948
Total AL No. 10.164			9,230	56,948
Sustainable Agriculture Research and Education:				
Pass-through University of Georgia	20213864034724	10.215	3,850	43,281
Total AL No. 10.215			3,850	43,281
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	52,709
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	57,987
Agriculture and Food Research Initiative (AFRI)	20206703431728	10.310	—	70,178
Agriculture and Food Research Initiative (AFRI)	20216703435147	10.310	—	57,787
Agriculture and Food Research Initiative (AFRI)	20226701336133	10.310	485	90,156
Pass-through Kansas State University	20206701931157	10.310	—	7,600
Pass-through University of Minnesota	20216702334488	10.310	—	18,818
Pass-through University of Pittsburgh	20206701733075	10.310	—	45,172
Total AL No. 10.310			485	400,407
Beginning Farmer and Rancher Development Program:				
Pass-through North Carolina A and T State University	20227003338199	10.311	—	21,869
Total AL No. 10.311			—	21,869
Crop Protection and Pest Management Competitive Grants Program:				
Pass-through North Carolina State University	20187000828884	10.329	—	89
Total AL No. 10.329			—	89
U.S. Department of Agriculture Total			13,565	538,690
U.S. Department of Defense:				
Basic Scientific Research – Combating Weapons of Mass Destruction				
	HDTRA11810029	12.351	93,939	57,381
Total AL No. 12.351			93,939	57,381
Military Medical Research And Development	HT94252310006	12.420	—	19,080
Military Medical Research And Development	HT94252310007	12.420	—	19,080
Military Medical Research And Development	HT94252310193	12.420	—	6,578
Military Medical Research And Development	HT94252310420	12.420	—	72,111
Military Medical Research And Development	HT94252310525	12.420	—	40,533
Military Medical Research And Development	HT9425-23-1-0609	12.420	—	17,086
Military Medical Research And Development	W81XWH-17-1-0634	12.420	—	5,231
Military Medical Research And Development	W81XWH-17-C-0229	12.420	—	44,670
Military Medical Research And Development	W81XWH1810526	12.420	—	8,347
Military Medical Research And Development	W81XWH1810700	12.420	—	25,179
Military Medical Research And Development	W81XWH1910498	12.420	38,538	218,137
Military Medical Research And Development	W81XWH1910567	12.420	88,234	102,234
Military Medical Research And Development	W81XWH1910776	12.420	—	321,114
Military Medical Research And Development	W81XWH1910840	12.420	—	85,209
Military Medical Research And Development	W81XWH2010446	12.420	49,917	88,555
Military Medical Research And Development	W81XWH2010525	12.420	—	127,298
Military Medical Research And Development	W81XWH2010526	12.420	—	94,437
Military Medical Research And Development	W81XWH2110124	12.420	—	234,103
Military Medical Research And Development	W81XWH21-1-0160	12.420	—	135,338
Military Medical Research And Development	W81XWH2110237	12.420	73,113	205,984
Military Medical Research And Development	W81XWH2210073	12.420	—	209,930
Military Medical Research And Development	W81XWH2210236	12.420	—	161,218
Military Medical Research And Development	W81XWH2210338	12.420	39,274	119,438
Military Medical Research And Development	W81XWH2210572	12.420	5,081	51,026
Military Medical Research And Development	W81XWH2211040	12.420	7,674	65,808
Pass-through Fdn for Atlanta Veterans Educ and Res	W81XWH-08-02-0062	12.420	—	(271)
Pass-through Georgia Institute of Technology	W81XWH-18-1-0669	12.420	—	363,574
Pass-through Georgia Institute of Technology	W81XWH-20-1-0649	12.420	—	103,270
Pass-through Public Health Institute	S352LSPJLMP8.	12.420	—	219,346
Pass-through University of Arizona	W81XWH-17-1-0443	12.420	—	44,724
Pass-through University of Georgia	W81XWH2210261	12.420	—	58,133
Pass-through University of Maryland, Baltimore	066469933	12.420	—	9,991
Pass-through University of Michigan	W81XWH2010336	12.420	—	58,466
Pass-through Wayne State University	W81XWH-19-1-0794	12.420	—	41,785
Total AL No. 12.420			301,831	3,026,842
Basic Scientific Research:				
Pass-through Mclean Hospital	W911NF-17-2-0086	12.431	—	477
Total AL No. 12.431			—	477
Basic, Applied, and Advanced Research in Science and Engineering:				
Pass-through University of Maryland, Baltimore	FA95502210259	12.630	—	30,973
Pass-through University of Washington	W911NF1910291	12.630	—	29,123
Total AL No. 12.630			—	60,096
Uniformed Services University Medical Research Projects:				
Pass-through Duke University	HT9404-13-0032	12.750	—	(29)
Pass-through Henry M. Jackson Foundation	HU0001-17-2-0023	12.750	—	117,558
Pass-through Henry M. Jackson Foundation	HU0001220029	12.750	—	563,356
Pass-through Henry M. Jackson Foundation	HU00012220018	12.750	—	1,656,499
Total AL No. 12.750			—	2,337,384
Air Force Defense Research Sciences Program	FA9550-18-1-0420	12.800	1,245,367	1,441,453
Air Force Defense Research Sciences Program	FA9550-20-1-0372	12.800	—	154,433
Air Force Defense Research Sciences Program	FA9550-20-1-0411	12.800	—	56,036
Pass-through Georgia State University	FA95501510373	12.800	—	3,972
Total AL No. 12.800			1,245,367	1,655,894
Research and Technology Development:				
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	1,259,755
Pass-through Johns Hopkins University	2019-190516000005	12.910	—	184,631
Pass-through University of California San Francisco	HR0011-19-2-0007	12.910	—	47,140
Total AL No. 12.910			—	1,491,526

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Contract	0011751760	12.CTR	\$ —	255,068
Contract	W81XWH	12.CTR	—	7,176
Contract	W81XWH1810505	12.CTR	—	2,024
Contract	W81XWH1910281	12.CTR	—	215,150
Contract	W81XWH1910353	12.CTR	—	94,870
Contract	W81XWH2110213	12.CTR	—	162,187
Contract	W81XWH2210922	12.CTR	—	82,915
Contract	W81XWH22D0013	12.CTR	—	82,069
Pass-through Adv Tech Intl Med Cbrn Defense Consort	2020-467	12.CTR	715,470	2,811,888
Pass-through Coalition For National Trauma Research	W81XWH15-9-001	12.CTR	—	13,178
Pass-through Georgia Institute of Technology	N6600122C4012	12.CTR	—	368,866
Pass-through Henry M Jackson Foundation	AWD001593 (416052-6A)	12.CTR	—	37,639
Pass-through University of Dayton	FA8651-20-F-1024	12.CTR	—	111,782
Pass-through University of North Carolina Chapel Hill	W81XWH22C0122	12.CTR	—	150,750
Pass-through Weill Cornell Medical College	15060932	12.CTR	—	258
Total AL No. 12.CTR			715,470	4,395,820
U.S. Department of Defense Total			2,356,607	13,025,420
U.S. Department of the Interior:				
Great Lakes Restoration	F22AC02246	15.662	11,550	38,691
Total AL No. 15.662			11,550	38,691
U.S. Department of the Interior Total			11,550	38,691
U.S. Department of Justice:				
National Institute of Justice Research, Evaluation, and Development Project Grants:				
Pass-through George Mason University	2019-R2-CX-0005	16.560	—	2,982
Total AL No. 16.560			—	2,982
U.S. Department of Justice Total			—	2,982
U.S. Department of State:				
Academic Exchange Programs – Hubert H. Humphrey Fellowship Program:				
Pass-through Institute of International Education	SECAGD21CA3001	19.010	—	51,731
Total AL No. 19.010			—	51,731
Contract:				
Pass-through Health Through Walls	SHAPE/HW09202002	19.CTR	—	9,155
Total AL No. 19.CTR			—	9,155
U.S. Department of State Total			—	60,886
U.S. Department of Transportation:				
National Priority Safety Programs:				
Pass-through Governors Office of Highway Safety	69A375193000405BGAH	20.616	—	48,116
Pass-through Governors Office of Highway Safety	69A3752030000405BGAH	20.616	—	209,800
Total AL No. 20.616			—	257,916
Contract	693J922D000025	20.CTR	5,377	610,906
Contract	DTNH2217D00068	20.CTR	97,896	153,388
Contract	DTNH2217F00160	20.CTR	42,404	56,742
Pass-through University of Michigan	DTNH2215D00017/693J918F000234	20.CTR	—	12,569
Total AL No. 20.CTR			145,677	833,605
U.S. Department of Transportation Total			145,677	1,091,521
National Aeronautics and Space Administration:				
Science	80NSSC19K0191	43.001	13,204	131,920
Science	80NSSC21K0507	43.001	7,537	168,314
Science	80NSSC22K0292	43.001	—	9,361
Science	80NSSC22K1659	43.001	—	101,536
Pass-through California Institute of Technology	1588347	43.001	—	176,301
Pass-through University of Georgia	80NSSC20K0360	43.001	—	41,993
Pass-through University of Georgia	80NSSC22K1167	43.001	—	61,357
Total AL No. 43.001			20,741	690,782
Aeronautics				
Pass-through California Institute of Technology	NMO710860	43.002	—	93,999
Total AL No. 43.002			—	93,999
Exploration	80NSSC188K1116	43.003	—	201,686
Exploration	80NSSC21K0251	43.003	—	44,143
Total AL No. 43.003			—	245,829
National Aeronautics and Space Administration Total			20,741	1,030,610
National Endowment for the Humanities:				
Promotion of the Humanities Division of Preservation and Access	HAA-281011-21	45.149	—	33,554
Promotion of the Humanities Division of Preservation and Access	PW- 277494-21	45.149	7,764	122,563
Total AL No. 45.149			7,764	156,117
Promotion of the Humanities Research	RQ-260871-18	45.161	—	6,562
Promotion of the Humanities Research	RZ-271209-20	45.161	—	12,342
Total AL No. 45.161			—	18,904
Promotion of the Humanities Professional Development	AV-279598-21	45.163	—	6,903
Total AL No. 45.163			—	6,903
National Endowment for the Humanities Total			7,764	181,924
National Science Foundation:				
Engineering	1741691	47.041	47,333	43,299
Engineering	1762211	47.041	—	21,104
Engineering	1804198	47.041	—	9,728
Engineering	1926387	47.041	—	96,288
Engineering	2002815	47.041	—	113,610
Engineering	2005786	47.041	—	156,463
Engineering	2044657	47.041	—	65,928
Engineering	2231857	47.041	—	56,134
Engineering	2306371	47.041	—	3,604
Engineering	2326931	47.041	—	29,445
Engineering	2127509	47.041	—	126,377
Pass-through Amer Society For Engineering Education	UA-2019-0921	47.041	—	26,381
Pass-through Center for the Advancement of Science In	1749677	47.041	10,281	17,501
Pass-through Georgia Institute of Technology	EEC-1648035	47.041	—	73,937
Pass-through Georgia Institute of Technology	1928481	47.041	—	46,524
Pass-through Indiana University			—	—
Total AL No. 47.041			57,614	886,323

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mathematical And Physical Sciences	1555048	47.049	\$ —	(4,455)
Mathematical And Physical Sciences	1605418	47.049	—	(2,567)
Mathematical And Physical Sciences	1654485	47.049	—	13,142
Mathematical And Physical Sciences	1700982	47.049	1,101,870	1,723,245
Mathematical And Physical Sciences	1751636	47.049	—	84,466
Mathematical And Physical Sciences	1755698	47.049	—	2,082
Mathematical And Physical Sciences	1764385	47.049	—	26,035
Mathematical And Physical Sciences	1808771	47.049	—	4,217
Mathematical And Physical Sciences	1809566	47.049	—	1,934
Mathematical And Physical Sciences	1900532	47.049	—	68,584
Mathematical And Physical Sciences	1902260	47.049	—	648
Mathematical And Physical Sciences	1904885	47.049	—	4,057
Mathematical And Physical Sciences	1905782	47.049	—	126,312
Mathematical And Physical Sciences	1905809	47.049	—	141,769
Mathematical And Physical Sciences	1905947	47.049	—	70,725
Mathematical And Physical Sciences	1951682	47.049	—	25,456
Mathematical And Physical Sciences	1956154	47.049	—	102,399
Mathematical And Physical Sciences	2003157	47.049	—	50,537
Mathematical And Physical Sciences	2003692	47.049	—	3,754
Mathematical And Physical Sciences	2003962	47.049	—	62,589
Mathematical And Physical Sciences	2003987	47.049	—	541
Mathematical And Physical Sciences	2004090	47.049	—	151,288
Mathematical And Physical Sciences	2004126	47.049	—	133,535
Mathematical And Physical Sciences	2004846	47.049	—	78,484
Mathematical And Physical Sciences	2010524	47.049	—	204,573
Mathematical And Physical Sciences	2012686	47.049	—	66,035
Mathematical And Physical Sciences	2014173	47.049	—	141,211
Mathematical And Physical Sciences	2015540	47.049	—	62,985
Mathematical And Physical Sciences	2022641	47.049	—	46,737
Mathematical And Physical Sciences	2038019	47.049	—	146,354
Mathematical And Physical Sciences	2038118	47.049	—	200,826
Mathematical And Physical Sciences	2051019	47.049	—	135,173
Mathematical And Physical Sciences	2055579	47.049	—	188,874
Mathematical And Physical Sciences	2103515	47.049	—	72,285
Mathematical And Physical Sciences	2106290	47.049	—	155,227
Mathematical And Physical Sciences	2108821	47.049	—	165,054
Mathematical And Physical Sciences	2108774	47.049	—	208,747
Mathematical And Physical Sciences	2113350	47.049	—	(1,619)
Mathematical And Physical Sciences	2143815	47.049	—	161,143
Mathematical And Physical Sciences	2146260	47.049	—	137,288
Mathematical And Physical Sciences	2152661	47.049	—	28,656
Mathematical And Physical Sciences	2205266	47.049	—	53,861
Mathematical And Physical Sciences	2206187	47.049	—	79,960
Mathematical And Physical Sciences	2208294	47.049	—	156,137
Mathematical And Physical Sciences	2208412	47.049	—	58,362
Mathematical And Physical Sciences	2242508	47.049	—	90,582
Mathematical And Physical Sciences	2245192	47.049	—	20,237
Mathematical And Physical Sciences	2246659	47.049	—	22,861
Mathematical And Physical Sciences	2247013	47.049	—	20,588
Mathematical And Physical Sciences	2300347	47.049	—	47,105
Mathematical And Physical Sciences	2302356	47.049	—	24,668
Mathematical And Physical Sciences	2308017	47.049	—	49,181
Mathematical And Physical Sciences	2326893	47.049	—	31,944
Mathematical And Physical Sciences	2329296	47.049	—	23,205
Mathematical And Physical Sciences	CHE 1145227	47.049	—	(1,343)
Mathematical And Physical Sciences	CHE 1352040	47.049	—	(869)
Mathematical And Physical Sciences	DMS 1208874	47.049	—	(1,348)
Pass-through Georgia Institute of Technology	1806833	47.049	—	52,194
Total AL No. 47.049			1,101,870	5,715,499
Geosciences:				
Pass-through Georgia State University	2228192	47.050	—	26,464
Pass-through Rutgers University	2108984	47.050	—	42,559
Total AL No. 47.050			—	69,023
Computer And Information Science And Engineering	1636933	47.070	—	(1,680)
Computer And Information Science And Engineering	1835364	47.070	—	14,361
Computer And Information Science And Engineering	1838200	47.070	—	14,607
Computer And Information Science And Engineering	1907711	47.070	—	(1,339)
Computer And Information Science And Engineering	1952192	47.070	—	294
Computer And Information Science And Engineering	2003720	47.070	—	59,308
Computer And Information Science And Engineering	2103592	47.070	—	77,643
Computer And Information Science And Engineering	2106359	47.070	—	114,063
Computer And Information Science And Engineering	2106446	47.070	68,053	130,826
Computer And Information Science And Engineering	2110926	47.070	116,608	115,421
Computer And Information Science And Engineering	2124104	47.070	—	202,723
Computer And Information Science And Engineering	2125530	47.070	156,122	300,701
Computer And Information Science And Engineering	2145411	47.070	—	129,159
Computer And Information Science And Engineering	2232829	47.070	—	39,975
Computer And Information Science And Engineering	2302968	47.070	—	48,413
Computer And Information Science And Engineering	2303655	47.070	—	37,021
Computer And Information Science And Engineering	2303678	47.070	—	91,655
Computer And Information Science And Engineering	2310114	47.070	—	41,253
Computer And Information Science And Engineering	2127309	47.070	—	128,458
Pass-through Computing Research Association				
Pass-through Duke University	ISS-2211526	47.070	—	37,865
Pass-through Georgia Institute of Technology	1915504	47.070	—	56,527
Pass-through Georgia Institute of Technology	2205152	47.070	—	46,392
Pass-through University of Arizona	IIS-1838745	47.070	—	(8,253)
Pass-through University of Virginia	2041952	47.070	—	49,916
Total AL No. 47.070			340,783	1,725,309
Biological Sciences	1624104	47.074	—	38,920
Biological Sciences	1750553	47.074	—	102,354
Biological Sciences	1754595	47.074	—	136,184
Biological Sciences	1755002	47.074	—	5,011
Biological Sciences	1755418	47.074	—	71,522
Biological Sciences	1844803	47.074	7,200	19,424
Biological Sciences	1919953	47.074	—	7,237
Biological Sciences	1922720	47.074	—	195,300
Biological Sciences	1927411	47.074	—	79,292
Biological Sciences	1931697	47.074	—	147,586
Biological Sciences	2032610	47.074	—	18,611
Biological Sciences	2050009	47.074	—	168,901
Biological Sciences	2106137	47.074	—	127,618
Biological Sciences	2202255	47.074	—	137,456
Biological Sciences	2207028	47.074	—	819
Biological Sciences	2208659	47.074	—	119,542
Biological Sciences	2209996	47.074	—	47,187
Biological Sciences	2239526	47.074	—	63,864
Biological Sciences	2243665	47.074	—	37,972
Biological Sciences	2310626	47.074	—	56,541
Biological Sciences	2330206	47.074	—	36,096

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Biological Sciences	MCB 1350829	47.074	\$ —	10
Pass-through Case Western Reserve University	DBI-2015317	47.074	—	140,364
Pass-through George Mason University	2109647	47.074	—	26,930
Pass-through University of California Riverside	2119820	47.074	—	199,051
Pass-through University of Texas Austin	2227399	47.074	—	147,508
Total AL No. 47.074			7,200	2,131,300
Social, Behavioral, And Economic Sciences	1756853	47.075	—	9,854
Social, Behavioral, And Economic Sciences	1822677	47.075	—	(4,963)
Social, Behavioral, And Economic Sciences	1853185	47.075	—	23,782
Social, Behavioral, And Economic Sciences	1920081	47.075	—	2,150
Social, Behavioral, And Economic Sciences	1926075	47.075	—	55,457
Social, Behavioral, And Economic Sciences	1945046	47.075	—	171,755
Social, Behavioral, And Economic Sciences	1946767	47.075	—	200,384
Social, Behavioral, And Economic Sciences	1946768	47.075	—	6,726
Social, Behavioral, And Economic Sciences	1947845	47.075	—	768
Social, Behavioral, And Economic Sciences	1952882	47.075	—	87,083
Social, Behavioral, And Economic Sciences	2017425	47.075	—	799
Social, Behavioral, And Economic Sciences	2037376	47.075	—	1,171
Social, Behavioral, And Economic Sciences	2049460	47.075	—	16,241
Social, Behavioral, And Economic Sciences	2051553	47.075	—	224,984
Social, Behavioral, And Economic Sciences	2116355	47.075	—	14,158
Social, Behavioral, And Economic Sciences	2120917	47.075	—	8,731
Social, Behavioral, And Economic Sciences	2127373	47.075	—	81,379
Social, Behavioral, And Economic Sciences	2127913	47.075	—	89,975
Social, Behavioral, And Economic Sciences	2147325	47.075	—	18,354
Social, Behavioral, And Economic Sciences	2214387	47.075	—	18,570
Social, Behavioral, And Economic Sciences	2214544	47.075	—	1,330
Social, Behavioral, And Economic Sciences	2218094	47.075	—	54,618
Social, Behavioral, And Economic Sciences	2219815	47.075	—	80,870
Social, Behavioral, And Economic Sciences	2244460	47.075	—	748
Social, Behavioral, And Economic Sciences	2314858	47.075	—	1,265
Pass-through Case Western Reserve University	2129072	47.075	—	58,692
Pass-through University of Colorado	2149191	47.075	—	11,686
Total AL No. 47.075			—	1,236,867
Education And Human Resources	1821533	47.076	—	132,536
Education And Human Resources	1937971	47.076	—	1,627,451
Education And Human Resources	2010333	47.076	—	43,021
Total AL No. 47.076			—	1,803,008
Polar Programs	2025795	47.078	—	130,589
Total AL No. 47.078			—	130,589
Office of International Science and Engineering	1827201	47.079	—	105,031
Total AL No. 47.079			—	105,031
NSF Technology, Innovation, and Partnerships:				
Pass-through University of Missouri Columbia	2303003	47.084	—	92,627
Total AL No. 47.084			—	92,627
National Science Foundation Total			1,507,467	13,895,576
U.S. Department of Veterans Affairs:				
Contract:				
Pass-through University of California San Francisco	TEIN2272-01	64.CTR	—	14,778
Total AL No. 64.CTR			—	14,778
U.S. Department of Veterans Affairs Total			—	14,778
U.S. Environmental Protection Agency:				
Science To Achieve Results (STAR) Research Program	84019801	66.509	10,000	227,812
Science To Achieve Results (STAR) Research Program	84042901	66.509	—	56,578
Science To Achieve Results (STAR) Research Program	84048501	66.509	135,137	288,855
Total AL No. 66.509			145,137	573,245
Office of Research and Development Consolidated Research/Training/Fellowships:				
Pass-through Silent Spring Institute	84043001	66.511	—	58,518
Total AL No. 66.511			—	58,518
Solid Waste Management Assistance Grants	02D01621	66.808	—	29,431
Total AL No. 66.808			—	29,431
Environmental Education Grants	01D14720	66.951	8,951	25,609
Environmental Education Grants	02D34022	66.951	—	14,584
Total AL No. 66.951			8,951	40,193
Contract:				
Pass-through Health Effects Institute	CR-83998101	66.CTR	198,259	267,585
Total AL No. 66.CTR			198,259	267,585
U.S. Environmental Protection Agency Total			352,347	968,972
U.S. Department of Energy:				
Office Of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	54,838
Office Of Science Financial Assistance Program	DEFG0207ER15906	81.049	—	358,412
Office Of Science Financial Assistance Program	DE-FG02-07ER15906	81.049	—	28,119
Office Of Science Financial Assistance Program	DE-SC0008798	81.049	—	5,623
Office Of Science Financial Assistance Program	DE-SC0016004 MOD 0002	81.049	—	4,427
Office Of Science Financial Assistance Program	DE-SC0018976	81.049	—	1,848
Office Of Science Financial Assistance Program	DESC0019374	81.049	593,185	822,336
Office Of Science Financial Assistance Program	DE-SC0020101	81.049	—	10,047
Office Of Science Financial Assistance Program	DE-SC0020101/0004	81.049	—	12,021
Office Of Science Financial Assistance Program	DE-SC0020996	81.049	—	88,714
Office Of Science Financial Assistance Program	DE-SC0022314	81.049	22,934	156,396
Office Of Science Financial Assistance Program	DE-SC0023327	81.049	—	79,668
Office Of Science Financial Assistance Program	DE-SC008798	81.049	—	217,827
Pass-through University of Arizona	0023411	81.049	—	112,836
Pass-through University of North Carolina Chapel Hill	DE-SC0021173	81.049	—	253,991
Total AL No. 81.049			616,119	2,203,103
Contract	89233218CNA000001	81.CTR	—	26,030
Total AL No. 81.CTR			—	26,030
U.S. Department of Energy Total			616,119	2,229,133

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Education:				
Overseas Programs – Doctoral Dissertation Research Abroad	P022A210020	84.022	\$ —	16,900
Overseas Programs – Doctoral Dissertation Research Abroad	P022A220003	84.022	—	5,250
Total AL No. 84.002			—	22,150
Research in Special Education:				
Pass-through Florida State University	R324A180193	84.324	—	48,529
Pass-through University of California Davis	R324A210288	84.324	—	55,644
Total AL No. 84.324			—	104,173
Contract	DE-AC05-76RL01830	84.CTR	—	1,521
Total AL No. 84.CTR			—	1,521
U.S. Department of Education Total			—	127,844
U.S. Department of Health and Human Services:				
Chronic Diseases: Research, Control, and Prevention	U01DP006488	93.068	—	672,559
Chronic Diseases: Research, Control, and Prevention	U18DP006747	93.068	672	80,929
Total AL No. 93.068			672	753,488
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000057	93.073	—	516,643
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000098	93.073	17,353	314,142
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU84DD000020	93.073	—	259,621
Pass-through University of Iowa	U01DD001223	93.073	—	5,717
Total AL No. 93.073			17,353	1,096,123
Blood Disorder Program: Prevention, Surveillance, and Research:				
Pass-through Georgia State University	NU58DD0000021	93.080	—	5,358
Pass-through Georgia State University	NU58DD000003	93.080	12,577	44,465
Pass-through Georgia State University	NU58DD000021	93.080	—	16,880
Pass-through Hemophilia of Georgia	NU27DD000020-02-00	93.080	—	1,540
Pass-through Hemophilia of Georgia	NU27DD000020-03-00	93.080	—	27,189
Total AL No. 93.080			12,577	95,432
COVID-19 – Prevention Of Disease, Disability, And Death By Infectious Diseases	U54CK000601	93.084	15,194	1,246,556
Prevention Of Disease, Disability, And Death By Infectious Diseases	U01FS005244	93.084	10,435	330,815
Pass-through Children's Hospital of Philadelphia	U54CK000610	93.084	—	6,353
Pass-through Georgia Dept of Public Health	NU50CK000626	93.084	—	6,858
Pass-through Rush University Medical Center	U54CK000607	93.084	—	5,695
Pass-through State University of New York Albany	NU38PS004650	93.084	—	664,153
Pass-through Yale University	U01CK000572	93.084	—	136,980
Total AL No. 93.084			25,629	2,397,410
Food and Drug Administration Research	R01FD005746	93.103	30,922	118,372
Pass-through Critical Path Institute (C-Path)	U18FD005320	93.103	—	459,272
Pass-through Yale University	U01FD005938	93.103	—	37,644
Total AL No. 93.103			30,922	615,288
Maternal And Child Health Federal Consolidated Programs	T76MC28446	93.110	43,037	470,497
Pass-through Organization of Teratology Information S	UG4MC27861	93.110	—	48,648
Total AL No. 93.110			43,037	519,145
Environmental Health	D43ES030927	93.113	42,068	75,276
Environmental Health	F31ES031845	93.113	—	46,679
Environmental Health	F32ES031827	93.113	—	55,350
Environmental Health	F32ES033908	93.113	—	35,537
Environmental Health	F32ES034241	93.113	—	66,962
Environmental Health	K00ES033033	93.113	—	81,872
Environmental Health	K12ES035593	93.113	25,699	194,877
Environmental Health	P2CES033430	93.113	162,932	634,750
Environmental Health	P30ES019776	93.113	141,034	1,807,803
Environmental Health	P30RD019776	93.113	—	(1,165)
Environmental Health	R01ES025775	93.113	—	399,956
Environmental Health	R01ES026082	93.113	95,315	101,812
Environmental Health	R01ES027859	93.113	—	329,662
Environmental Health	R01ES027892	93.113	120,836	154,903
Environmental Health	R01ES028346	93.113	326,441	535,939
Environmental Health	R01ES029212	93.113	271,415	448,013
Environmental Health	R01ES031980	93.113	117,583	468,761
Environmental Health	R01ES032009	93.113	308,392	597,651
Environmental Health	R01ES032140	93.113	195,094	703,777
Environmental Health	R01ES032440	93.113	—	302,506
Environmental Health	R01ES032446	93.113	66,977	310,652
Environmental Health	R01ES032831	93.113	—	59,521
Environmental Health	R01ES033241	93.113	91,237	260,294
Environmental Health	R01ES033530	93.113	749,482	1,285,290
Environmental Health	R01ES033603	93.113	—	526,660
Environmental Health	R01ES034175	93.113	162,957	511,115
Environmental Health	R03ES035164	93.113	—	7,292
Environmental Health	R21ES022795	93.113	—	1,018
Environmental Health	R21ES028903	93.113	—	(80)
Environmental Health	R21ES031824	93.113	—	68,469
Environmental Health	R21ES032117	93.113	—	148,007
Environmental Health	R21ES032344	93.113	92,810	173,052
Environmental Health	R21ES032606	93.113	85,295	150,899
Environmental Health	R21ES034130	93.113	12,865	171,513
Environmental Health	R21ES034139	93.113	—	86,047
Environmental Health	R21ES034190	93.113	—	57,431
Environmental Health	R24ES028507	93.113	160,318	185,095
Environmental Health	R24ES028528	93.113	36,520	175,433
Environmental Health	R24ES029490	93.113	—	272,984
Environmental Health	R56ES033530	93.113	159,255	394,545
Environmental Health	T32ES012870	93.113	—	522,026
Environmental Health	U24ES028507	93.113	87,603	204,258
Pass-through Alaska Community Action on Toxics	R01ES019620	93.113	—	13,133
Pass-through Brown University	R01ES032836	93.113	—	27,928
Pass-through Colorado State University	R01ES029995	93.113	—	5,353
Pass-through Columbia University	R01ES030945	93.113	—	58,705
Pass-through Johns Hopkins University	R01ES030414	93.113	—	61,186
Pass-through Mount Sinai School of Medicine	R01ES033688	93.113	—	12,995
Pass-through Rutgers University	R01ES032144	93.113	—	57,347
Pass-through University of Alabama Birmingham	U54ES030246	93.113	—	14,999
Pass-through University of Arizona	R01ES032392	93.113	—	62,668
Pass-through University of Kentucky	R01ES032176	93.113	—	155,771
Pass-through University of Louisville	R01ES032189	93.113	—	299,795
Pass-through University of Michigan	R01ES032157	93.113	—	21,810
Pass-through University of Rochester	R21ES033750	93.113	—	5,878
Pass-through University of Southern California	R01ES029944	93.113	—	21,846
Pass-through University of Southern California	R01ES030364	93.113	—	27,922
Pass-through University of Southern California	R01ES032247	93.113	—	121,557
Pass-through Wayne State University	R01ES031584	93.113	—	33,711
Total AL No. 93.113			3,512,128	13,704,946
Preventive Medicine Residency	D33HP31663	93.117	—	385,361
Total AL No. 93.117			—	385,361

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Oral Diseases And Disorders Research	F31DE030704	93.121	\$ —	(11,392)
Oral Diseases And Disorders Research	F31DE032588	93.121	—	47,262
Oral Diseases And Disorders Research	F32DE032260	93.121	—	62,983
Oral Diseases And Disorders Research	R00DE026810	93.121	—	291,956
Oral Diseases And Disorders Research	R01DE025837	93.121	—	(5,423)
Oral Diseases And Disorders Research	R01DE026333	93.121	105,827	86,720
Oral Diseases And Disorders Research	R01DE026941	93.121	25,752	2,454
Oral Diseases And Disorders Research	R01DE028342	93.121	31,002	348,347
Oral Diseases And Disorders Research	R01DE028351	93.121	50,795	502,023
Oral Diseases And Disorders Research	R01DE028905	93.121	307,244	673,983
Oral Diseases And Disorders Research	R01DE030342	93.121	169,515	378,484
Oral Diseases And Disorders Research	R01DE031271	93.121	12,993	352,680
Oral Diseases And Disorders Research	R01DE032243	93.121	22,431	366,235
Oral Diseases And Disorders Research	R03DE027103	93.121	—	(703)
Oral Diseases And Disorders Research	R03DE026387	93.121	—	(55)
Oral Diseases And Disorders Research	R03DE031118	93.121	—	78,980
Oral Diseases And Disorders Research	R03DE032084	93.121	17,897	101,538
Oral Diseases And Disorders Research	R21DE029592	93.121	—	145,902
Oral Diseases And Disorders Research	R21DE029698	93.121	—	66,729
Oral Diseases And Disorders Research	R21DE030632	93.121	—	209,518
Oral Diseases And Disorders Research	R56DE031771	93.121	—	84,008
Pass-through Children's Hospital of Philadelphia	R01DE027983	93.121	—	46,477
Pass-through Children's Hospital of Philadelphia	R01DE032332	93.121	—	8,888
Pass-through Florida International University	R03DE030259	93.121	—	604
Pass-through University of Pittsburgh	R01DE032319	93.121	—	13,766
Pass-through University of Washington	R01DE027362	93.121	—	59,442
Total AL No. 93.121			743,456	3,911,206
COVID-19 – Centers For Research And Demonstration For Health Promotion And Disease Prevention	U48DP066377	93.135	540,801	3,273,257
Centers For Research And Demonstration For Health Promotion And Disease Prevention:				
Pass-through Morehouse School of Medicine	U48DP066411	93.135	—	32,237
Total AL No. 93.135			540,801	3,305,494
Injury Prevention And Control Research And State And Community Based Programs	R01CE003104	93.136	—	92,511
Injury Prevention And Control Research And State And Community Based Programs	R01CE003509	93.136	87,751	432,412
Injury Prevention And Control Research And State And Community Based Programs	R49CE003072	93.136	65,345	791,901
Injury Prevention And Control Research And State And Community Based Programs	U01CE002939	93.136	10,662	281,262
Total AL No. 93.136			163,758	1,598,086
Community Programs to Improve Minority Health Grant Program:				
Pass-through Georgia State University	CPIMP221348	93.137	—	32,813
Total AL No. 93.137			—	32,813
NIEHS Hazardous Waste Worker Health and Safety Training:				
Pass-through Nova Southeastern University	U45ES019350	93.142	—	17,280
Total AL No. 93.142			—	17,280
NIEHS Superfund Hazardous Substances Basic Research and Education:				
Pass-through Michigan State University	P42ES004911	93.143	—	25,487
Total AL No. 93.143			—	25,487
Health Program for Toxic Substances and Disease Registry:				
Pass-through American Academy of Pediatrics	5 NU61TS000296-04-00	93.161	—	227,318
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	20,705	30,274
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	9,913	64,339
Total AL No. 93.161			30,618	321,931
Human Genome Research:				
Pass-through Morehouse School of Medicine	RM1HG012334	93.172	—	28,866
Pass-through University of Chicago	RM1HG008935	93.172	—	156,254
Total AL No. 93.172			—	185,120
Research Related To Deafness And Communication Disorders	R01DC008343	93.173	—	268,442
Research Related To Deafness And Communication Disorders	R01DC014021	93.173	105,761	667,622
Research Related To Deafness And Communication Disorders	R01DC014496	93.173	—	(592)
Research Related To Deafness And Communication Disorders	R01DC020749	93.173	—	252,059
Research Related To Deafness And Communication Disorders	R21DC010197	93.173	—	119,310
Pass-through Harvard University	R21DC019567	93.173	—	79,981
Pass-through Massachusetts General Hospital	R01DC020247	93.173	—	12,180
Pass-through Medical University of South Carolina	R21DC019749	93.173	—	23,405
Pass-through Medical University of South Carolina	U01DC017521	93.173	—	60,971
Pass-through University of Kansas	R01DC020418	93.173	19,213	218,375
Pass-through University of South Carolina	P50DC014664	93.173	—	35,740
Pass-through University of South Florida	R01DC009029	93.173	—	30,846
Total AL No. 93.173			124,974	1,766,439
COVID-19 – Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	—	33,305
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001117	93.185	—	221,781
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	—	84,045
Pass-through Georgia Institute of Technology	NU2RGH001919	93.185	—	10,806
Pass-through Yale University	U011PO1110	93.185	—	51,842
Total AL No. 93.185			—	401,779
Telehealth Programs	H2ARH39957	93.211	—	315,278
Pass-through University of Arizona	U1U42527	93.211	—	103,026
Total AL No. 93.211			—	418,304
Research and Training in Complementary and Integrative Health	F31AT011988	93.213	—	44,177
Research and Training in Complementary and Integrative Health	F31AT012140	93.213	—	45,533
Research and Training in Complementary and Integrative Health	K01AT010488	93.213	—	164,903
Research and Training in Complementary and Integrative Health	K23AT009713	93.213	—	57,429
Research and Training in Complementary and Integrative Health	K24AT009893	93.213	—	197,409
Research and Training in Complementary and Integrative Health	R01AT011267	93.213	314,280	902,556
Research and Training in Complementary and Integrative Health	R01AT011990	93.213	333,492	599,303
Research and Training in Complementary and Integrative Health	R21AT011105	93.213	—	12,425
Research and Training in Complementary and Integrative Health	R33AT010457	93.213	45,953	376,454
Research and Training in Complementary and Integrative Health	R61AT012421	93.213	65,737	381,034
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	34,005
Total AL No. 93.213			759,462	2,815,228
Research On Healthcare Costs, Quality And Outcomes	R01HS026081	93.226	118,893	192,694
Research On Healthcare Costs, Quality And Outcomes	R01HS026232	93.226	115,273	223,927
Research On Healthcare Costs, Quality And Outcomes	R03HS027689	93.226	—	12,988
Research On Healthcare Costs, Quality And Outcomes	R03HS029245	93.226	—	40,202
Research On Healthcare Costs, Quality And Outcomes	R18HS026877	93.226	—	4,766
Research On Healthcare Costs, Quality And Outcomes	R36HS029137	93.226	—	23,303
Pass-through University of Georgia	R01HS029009	93.226	—	15,813
Pass-through University of Georgia	R21HS028485	93.226	—	19,252
Pass-through University of Pittsburgh	U18HS028380	93.226	2,913	14,527
Pass-through University of Wisconsin-Madison	R01HS026724	93.226	—	62,630
Total AL No. 93.226			237,079	610,102

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
National Center On Sleep Disorders Research	K01HL138211	93.233	\$ —	22,779
National Center On Sleep Disorders Research	R01HL147212	93.233	—	335,872
National Center On Sleep Disorders Research	R01HL157954	93.233	—	548,527
National Center On Sleep Disorders Research	R01HL162712	93.233	—	283,350
Pass-through Beth Israel Deaconess Medical Center	R01HL161253	93.233	—	112,142
Pass-through New York University	R01HL160324	93.233	—	20,153
Total AL No. 93.233				1,322,823
Mental Health Research Grants	F30MH117878	93.242	—	53,821
Mental Health Research Grants	F31MH126623	93.242	—	47,382
Mental Health Research Grants	F31MH127911	93.242	—	57,192
Mental Health Research Grants	F31MH127915	93.242	—	48,959
Mental Health Research Grants	F31MH130274	93.242	—	43,872
Mental Health Research Grants	F32MH124273	93.242	—	7,859
Mental Health Research Grants	F32MH134528	93.242	—	9,896
Mental Health Research Grants	K01MH121653	93.242	—	199,454
Mental Health Research Grants	K01MH126308	93.242	—	145,094
Mental Health Research Grants	K01MH133970	93.242	—	9,690
Mental Health Research Grants	K23MH114037	93.242	—	138,545
Mental Health Research Grants	K23MH114771	93.242	44,463	152,201
Mental Health Research Grants	K23MH123816	93.242	—	193,654
Mental Health Research Grants	K23MH130651	93.242	—	50,562
Mental Health Research Grants	P50MH100023	93.242	178,307	1,728,248
Mental Health Research Grants	P50MH100029	93.242	352,250	1,205,226
Mental Health Research Grants	R00MH102355	93.242	—	(374)
Mental Health Research Grants	R00MH119319	93.242	—	173,812
Mental Health Research Grants	R01MH069852	93.242	—	17,982
Mental Health Research Grants	R01MH072908	93.242	—	9,992
Mental Health Research Grants	R01MH082833	93.242	—	117,726
Mental Health Research Grants	R01MH105561	93.242	219,648	494,520
Mental Health Research Grants	R01MH107033	93.242	—	39,632
Mental Health Research Grants	R01MH108605	93.242	—	26,917
Mental Health Research Grants	R01MH108826	93.242	208,766	574,293
Mental Health Research Grants	R01MH109026	93.242	—	61,332
Mental Health Research Grants	R01MH110701	93.242	—	(835)
Mental Health Research Grants	R01MH111416	93.242	—	172
Mental Health Research Grants	R01MH112076	93.242	—	(375)
Mental Health Research Grants	R01MH112788	93.242	—	255,817
Mental Health Research Grants	R01MH114692	93.242	206,566	730,658
Mental Health Research Grants	R01MH115174	93.242	105,302	689,098
Mental Health Research Grants	R01MH115831	93.242	—	262,029
Mental Health Research Grants	R01MH116695	93.242	—	435,273
Mental Health Research Grants	R01MH117009	93.242	63,639	915,028
Mental Health Research Grants	R01MH117103	93.242	—	501,759
Mental Health Research Grants	R01MH117122	93.242	39,050	496,657
Mental Health Research Grants	R01MH117315	93.242	—	774,237
Mental Health Research Grants	R01MH118285	93.242	1,277	386,279
Mental Health Research Grants	R01MH118534	93.242	51,248	287,723
Mental Health Research Grants	R01MH118771	93.242	—	520,328
Mental Health Research Grants	R01MH118982	93.242	218,737	516,111
Mental Health Research Grants	R01MH119251	93.242	—	218,202
Mental Health Research Grants	R01MH120197	93.242	—	778,549
Mental Health Research Grants	R01MH120262	93.242	—	394,899
Mental Health Research Grants	R01MH121363	93.242	16,947	519,947
Mental Health Research Grants	R01MH121622	93.242	—	101,261
Mental Health Research Grants	R01MH121962	93.242	—	707,188
Mental Health Research Grants	R01MH122341	93.242	—	1,096,734
Mental Health Research Grants	R01MH123352	93.242	—	12,605
Mental Health Research Grants	R01MH125457	93.242	51,786	1,038,510
Mental Health Research Grants	R01MH125956	93.242	—	885,323
Mental Health Research Grants	R01MH126083	93.242	14,446	522,110
Mental Health Research Grants	R01MH126195	93.242	8,946	821,332
Mental Health Research Grants	R01MH126985	93.242	—	530,721
Mental Health Research Grants	R01MH128045	93.242	131,998	680,206
Mental Health Research Grants	R01MH128130	93.242	143,761	468,373
Mental Health Research Grants	R01MH128158	93.242	—	422,205
Mental Health Research Grants	R01MH128244	93.242	—	539,573
Mental Health Research Grants	R01MH128705	93.242	—	743,287
Mental Health Research Grants	R01MH128872	93.242	—	218,637
Mental Health Research Grants	R01MH129855	93.242	100,129	671,227
Mental Health Research Grants	R01MH130755	93.242	—	72,967
Mental Health Research Grants	R01MH131434	93.242	—	88,013
Mental Health Research Grants	R01MH131910	93.242	—	143,062
Mental Health Research Grants	R01MH132059	93.242	—	59,104
Mental Health Research Grants	R01MH132470	93.242	—	73,617
Mental Health Research Grants	R01MH134267	93.242	—	2,429
Mental Health Research Grants	R21MH114151	93.242	—	(2,524)
Mental Health Research Grants	R21MH117338	93.242	—	(1,864)
Mental Health Research Grants	R21MH118092	93.242	—	(22)
Mental Health Research Grants	R21MH120414	93.242	—	149,134
Mental Health Research Grants	R21MH121891	93.242	—	(426)
Mental Health Research Grants	R21MH124200	93.242	48,118	225,058
Mental Health Research Grants	R21MH127404	93.242	—	83,772
Mental Health Research Grants	R21MH132012	93.242	—	155,400
Mental Health Research Grants	R25MH101079	93.242	—	238,635
Mental Health Research Grants	R33MH124200	93.242	—	8,951
Mental Health Research Grants	R34MH116805	93.242	119,739	165,727
Mental Health Research Grants	R34MH119007	93.242	—	97,059
Mental Health Research Grants	R34MH124638	93.242	—	172,340
Mental Health Research Grants	R34MH128048	93.242	187,253	395,649
Mental Health Research Grants	R34MH129187	93.242	32,332	221,316
Mental Health Research Grants	R34MH132497	93.242	—	176,794
Mental Health Research Grants	R36MH127827	93.242	—	29,252
Mental Health Research Grants	R56MH129019	93.242	16,707	218,775
Mental Health Research Grants	R61MH121625	93.242	—	355,994
Mental Health Research Grants	RF1MH119622	93.242	—	42,415
Mental Health Research Grants	U01MH116441	93.242	664,020	849,668
Mental Health Research Grants	U19MH069056	93.242	—	1,250
Pass-through Brown University	R01MH117960	93.242	—	54,206
Pass-through Carnegie Mellon University	R01MH129725	93.242	—	83,683
Pass-through Childrens Hospital of Los Angeles	R01MH120133	93.242	—	11,213
Pass-through Columbia University	R01MH104606	93.242	—	49,750
Pass-through Creighton University	R01MH116003	93.242	—	101,332
Pass-through Duke University	R01MH111671	93.242	—	2,500
Pass-through Georgia Institute of Technology	R01MH119189	93.242	—	784
Pass-through Georgia Institute of Technology	R21MH122825	93.242	—	797
Pass-through Johns Hopkins University	R01MH110358	93.242	—	115,920
Pass-through Johns Hopkins University	R01MH129656	93.242	—	211,078
Pass-through Johns Hopkins University	R01MH132150	93.242	—	136,931
Pass-through Massachusetts General Hospital	R21MH132947	93.242	—	8,771

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Massachusetts General Hospital	R34MH122362	93.242	\$ —	23,842
Pass-through Mckean Hospital	R01MH117292	93.242	—	241,173
Pass-through Md Anderson	R01MH120299	93.242	—	139,323
Pass-through Rhode Island Hospital	R01MH125796	93.242	—	307,608
Pass-through Rutgers University	R01MH126449	93.242	—	22,909
Pass-through Stanford University	R01MH123486	93.242	—	6,588
Pass-through State University of New York Stony Brook	R01MH120293	93.242	—	12,634
Pass-through University of Alabama Birmingham	R34MH128072	93.242	—	57,941
Pass-through University of Arizona	R01MH121706	93.242	—	6,050
Pass-through University of California Los Angeles	R01MH100027	93.242	—	122,632
Pass-through University of California Los Angeles	R01MH118514	93.242	—	146,938
Pass-through University of California Los Angeles	R01MH118973	93.242	—	32,212
Pass-through University of California San Diego	R01MH123641	93.242	—	43,805
Pass-through University of California San Diego	R01MH124590	93.242	—	136,357
Pass-through University of California San Francisco	P30MH062246	93.242	—	63,210
Pass-through University of California San Francisco	R01MH123396	93.242	—	100,512
Pass-through University of Cape Town	U01MH115484	93.242	—	(256)
Pass-through University of Georgia	R01MH116039	93.242	—	25,806
Pass-through University of Georgia	R01MH120092	93.242	—	72,379
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	158,348
Pass-through University of Louisiana at Lafayette	R01MH125395	93.242	—	136,689
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	313,458
Pass-through University of Maryland, Baltimore	R21MH121120	93.242	—	94,969
Pass-through University of Michigan	R01MH115765	93.242	—	43,879
Pass-through University of Michigan	R01MH123388	93.242	—	79,651
Pass-through University of Michigan	R01MH125857	93.242	—	49,095
Pass-through University of Michigan	R01MH126693	93.242	—	26,241
Pass-through University of North Carolina Chapel Hill	U01MH110925	93.242	—	73,656
Pass-through University of Pennsylvania	R01MH114847	93.242	—	135,062
Pass-through University of Pittsburgh	R01MH115922	93.242	—	10,384
Pass-through University of Pittsburgh	R01MH116943	93.242	—	8,513
Pass-through University of Pittsburgh	R01MH118270	93.242	—	20,210
Pass-through University of Pittsburgh	R01MH121619	93.242	—	18,684
Pass-through University of Pittsburgh	R01MH125816	93.242	—	42,118
Pass-through University of Pittsburgh	R21MH120511	93.242	—	(26)
Pass-through University of Rochester	R01MH045573	93.242	—	44,739
Pass-through University of South Carolina	R01MH127081	93.242	—	5,846
Pass-through University of Washington Saint Louis	R01MH123723	93.242	—	63,440
Pass-through Vanderbilt University Medical Center	R61MH123029	93.242	—	114,592
Pass-through Washington University	R01MH120194	93.242	—	62,708
Pass-through Washington University	R01MH125820	93.242	—	13,655
Pass-through Wayne State University	R33MH111935	93.242	—	119,355
Pass-through Yale University	R01MH125205	93.242	—	157,070
Pass-through Yale University	U01MH124639	93.242	—	90,227
Total AL No. 93.242			3,225,435	32,090,991
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	86,530	1,061,457
Pass-through American Psychiatric Association	H79SM080818	93.243	—	208,253
Total AL No. 93.243			86,530	1,269,710
Advanced Nursing Education Workforce Grant Program	T1433112	93.247	507,961	674,191
Advanced Nursing Education Workforce Grant Program	T9642058	93.247	—	334,876
Total AL No. 93.247			507,961	1,009,067
Children's Hospitals Graduate Medical Education Payment Program	F32HS029592	93.255	—	9,932
Total AL No. 93.255			—	9,932
Occupational Safety And Health Program	R01OH011782	93.262	—	491,372
Total AL No. 93.262			—	491,372
COVID-19 – Alcohol Research Programs	U01AA029345	93.273	67,033	517,765
Alcohol Research Programs	F31AA029000	93.273	—	44,777
Alcohol Research Programs	F31AA029938	93.273	—	35,678
Alcohol Research Programs	K01AA028258	93.273	—	107,203
Alcohol Research Programs	K03AA024512	93.273	—	153,258
Alcohol Research Programs	R01AA022601	93.273	—	292
Alcohol Research Programs	R01AA025854	93.273	26,343	13,283
Alcohol Research Programs	R01AA025857	93.273	—	(4,666)
Alcohol Research Programs	R01AA026086	93.273	—	281,950
Alcohol Research Programs	R01AA027020	93.273	—	449,887
Alcohol Research Programs	R01AA027396	93.273	—	321,898
Alcohol Research Programs	R01AA028527	93.273	—	226,042
Alcohol Research Programs	R01AA029690	93.273	—	103,806
Alcohol Research Programs	R03AA027335	93.273	—	(403)
Alcohol Research Programs	R03AA027662	93.273	—	4,340
Alcohol Research Programs	R21AA028606	93.273	—	220,433
Alcohol Research Programs	U01AA026108	93.273	186,737	367,632
Pass-through Boston Medical Center	P01AA029541	93.273	—	17,202
Pass-through Columbia University	R01AA030529	93.273	—	77,729
Pass-through Duke University	R01AA029819	93.273	—	13,818
Pass-through Fdtn for Atlanta Veterans Educ and Res	M20029	93.273	—	22
Pass-through Fdtn for Atlanta Veterans Educ and Res	M21026	93.273	—	5,875
Pass-through University of California San Diego	R01AA026579	93.273	—	43,088
Pass-through University of California San Diego	R01AA027785	93.273	—	69,036
Pass-through University of Colorado	R24AA019661	93.273	—	15,882
Total AL No. 93.273			280,113	3,085,827
COVID-19 – Drug Abuse and Addiction Research Programs	U01DA056000	93.279	92,067	507,031
Drug Abuse and Addiction Research Programs	DP1DA042103	93.279	115,061	349,628
Drug Abuse and Addiction Research Programs	F31DA051184	93.279	—	8,711
Drug Abuse and Addiction Research Programs	F31DA053005	93.279	—	32,079
Drug Abuse and Addiction Research Programs	F31DA055447	93.279	—	52,983
Drug Abuse and Addiction Research Programs	F31DA059435	93.279	—	17,431
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	127,820
Drug Abuse and Addiction Research Programs	K01DA053438	93.279	—	168,333
Drug Abuse and Addiction Research Programs	K01DA053985	93.279	—	143,950
Drug Abuse and Addiction Research Programs	K23DA057415	93.279	—	144,889
Drug Abuse and Addiction Research Programs	R01DA042712	93.279	43,855	132,267
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	52,512	127,417
Drug Abuse and Addiction Research Programs	R01DA043263	93.279	46,760	178,576
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	289,404
Drug Abuse and Addiction Research Programs	R01DA045612	93.279	117,061	436,536
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	203,207	636,488
Drug Abuse and Addiction Research Programs	R01DA046619	93.279	54,700	57,625
Drug Abuse and Addiction Research Programs	R01DA046257	93.279	50,719	470,461
Drug Abuse and Addiction Research Programs	R01DA051302	93.279	—	163,335
Drug Abuse and Addiction Research Programs	R01DA052909	93.279	62,308	813,857
Drug Abuse and Addiction Research Programs	R01DA056770	93.279	8,785	670,074
Drug Abuse and Addiction Research Programs	R01DA057599	93.279	5,622	321,972
Drug Abuse and Addiction Research Programs	R01DA058065	93.279	—	25,474

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Drug Abuse and Addiction Research Programs	R21DA033478	93.279	\$	(352)
Drug Abuse and Addiction Research Programs	RD04056235A	93.279	92,054	554,330
Drug Abuse and Addiction Research Programs	RF1DA055667	93.279	220,497	483,784
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	233,967
Drug Abuse and Addiction Research Programs	U01DA055360	93.279	—	1,242,864
Drug Abuse and Addiction Research Programs	UG3DA0448502	93.279	13,778	90,833
Drug Abuse and Addiction Research Programs	UH3DA050234	93.279	393,290	1,134,497
Pass-through Friends Research Institute	R01DA056888	93.279	—	38,876
Pass-through Jackson Laboratory	R01DA037927	93.279	—	9,409
Pass-through Johns Hopkins University	R33DA047022	93.279	—	228,192
Pass-through Miriam Hospital	R01DA044504	93.279	—	188,077
Pass-through Miriam Hospital	R25DA037190	93.279	—	4,477
Pass-through Northwestern University	R01DA055502	93.279	—	116,521
Pass-through Oregon Health and Science University	R01DA046229	93.279	—	246,193
Pass-through Pennsylvania State University	R01DA047396	93.279	—	1,047
Pass-through University of California San Diego	U24D055325	93.279	—	24,129
Pass-through University of California San Diego	U24DA055325	93.279	—	120,317
Pass-through University of California San Francisco	R61DA047024	93.279	—	19,009
Pass-through University of Kentucky	R01DA055872	93.279	—	18,687
Pass-through University of Kentucky	UH3DA044798	93.279	—	166,968
Pass-through University of Miami	UG1DA013720	93.279	—	60,900
Pass-through Wake Forest University	R01DA052214	93.279	—	49,979
Pass-through Yale University	UG1DA015831	93.279	—	312,038
Pass-through Magee-Womens Research Institute and Foundation	R25DA043880	93.279	—	10,919
Total AL No. 93.279			1,572,276	11,231,702
Centers for Disease Control and Prevention Investigations and Technical Assistance	U01DP006488	93.283	—	244,731
Pass-through Fdtn for Atlanta Veterans Educ and Res	NU50CK000485	93.283	—	7,185,167
Total AL No. 93.283			—	7,429,898
COVID-19 – Discovery And Applied Research For Technological Innovations To Improve Human Health	U54EB027690	93.286	3,482,327	18,288,121
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027147	93.286	46,691	431,031
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027774	93.286	194,827	333,416
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB028350	93.286	146,500	334,271
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029320	93.286	36,772	607,467
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029857	93.286	15,851	301,012
Discovery And Applied Research For Technological Innovations To Improve Human Health	R13EB034924	93.286	—	10,300
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB028519	93.286	203	152,856
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB029622	93.286	27,239	189,360
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB031545	93.286	43,127	131,231
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB033994	93.286	—	20,185
Discovery And Applied Research For Technological Innovations To Improve Human Health	R56EB033332	93.286	—	372,975
Pass-through Beth Israel Deaconess Medical Center	R01EB030362	93.286	—	42,111
Pass-through Georgia Institute of Technology	R01E029331	93.286	—	19,884
Pass-through Georgia Institute of Technology	R01EB023808	93.286	—	(670)
Pass-through Georgia Institute of Technology	R01EB028916	93.286	—	13,768
Pass-through Georgia Institute of Technology	R01EB031101	93.286	—	225,193
Pass-through Georgia Institute of Technology	R03EB029099	93.286	—	7,383
Pass-through Georgia Institute of Technology	R21EB031535	93.286	—	52,522
Pass-through Georgia Institute of Technology	T32EB021962	93.286	—	12,874
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	138,499
Pass-through Georgia Institute of Technology	U54EB027690	93.286	—	24,247
Pass-through Massachusetts General Hospital	R01EB027122	93.286	—	90,621
Pass-through University of Maryland, Baltimore	R01EB032680	93.286	—	147,709
Pass-through University of Maryland, Baltimore	REB028324B	93.286	—	69,887
Pass-through University of Pittsburgh	R01EB028248	93.286	—	27,917
Pass-through Wayne State University	R01EB026453	93.286	—	34,328
Total AL No. 93.286			3,993,537	22,077,798
Minority Health And Health Disparities Research	F31MD017935	93.307	—	47,769
Minority Health And Health Disparities Research	F31MD018957	93.307	—	2,262
Minority Health And Health Disparities Research	K01MD016170	93.307	—	125,708
Minority Health And Health Disparities Research	K23MD015088	93.307	—	112,821
Minority Health And Health Disparities Research	R01MD009064	93.307	—	14
Minority Health And Health Disparities Research	R01MD011682	93.307	—	139,205
Minority Health And Health Disparities Research	R01MD013320	93.307	257,443	583,488
Minority Health And Health Disparities Research	R01MD015204	93.307	203,585	379,104
Minority Health And Health Disparities Research	R01MD016031	93.307	—	973,640
Minority Health And Health Disparities Research	R01MD017046	93.307	29,537	297,071
Minority Health And Health Disparities Research	R21MD017943	93.307	—	145,529
Minority Health And Health Disparities Research	R21MD010811	93.307	—	(52,360)
Pass-through Brown University	R01MD017080	93.307	—	216,072
Pass-through Georgetown University	R01MD017071	93.307	—	146,695
Pass-through Medical University of South Carolina	R01MD015395	93.307	—	8,660
Pass-through Morehouse School of Medicine	U54MD007602	93.307	—	70,364
Pass-through University of Illinois at Chicago	R21MD015813	93.307	—	13,191
Pass-through University of Michigan	R01MD016244	93.307	—	39,513
Pass-through University of Minnesota	R01MD013801	93.307	—	119,597
Pass-through University of Pennsylvania	R01MD013558	93.307	—	76,416
Pass-through University of Pennsylvania	U01MD011274	93.307	—	70,897
Pass-through University of Southern California	R01MD011698	93.307	—	156,810
Pass-through University of Utah	R21MD014281	93.307	—	8,069
Pass-through Yale University	R01MD016386	93.307	—	67,626
Total AL No. 93.307			490,565	3,748,562
COVID-19 – Trans-Nih Research Support	P30DK111024	93.310	423,912	1,668,267
COVID-19 – Trans-Nih Research Support	U01DK132737	93.310	360,579	573,610
COVID-19 – Trans-Nih Research Support	U01MD018313	93.310	44,916	214,727
Trans-Nih Research Support	DP2GM149749	93.310	—	119,549
Trans-Nih Research Support	DP5OD023100	93.310	—	144,618
Trans-Nih Research Support	K01OD023039	93.310	—	(12,658)
Trans-Nih Research Support	OT2OD030535	93.310	275,114	570,429
Trans-Nih Research Support	R01CA271304	93.310	—	373,174
Trans-Nih Research Support	R03HD108261	93.310	—	151,541
Trans-Nih Research Support	R21GM122632	93.310	—	(195)
Trans-Nih Research Support	U24DK112341	93.310	149,933	851,342
Trans-Nih Research Support	U2CES026560	93.310	—	(2,813)
Trans-Nih Research Support	U2CES030163	93.310	1,839	19,714
Trans-Nih Research Support	UH3OD023318	93.310	22,732	2,015,341
Trans-Nih Research Support	UH3TR002855	93.310	—	250,706
Pass-through Aim-Ahead	OT2OD032581	93.310	—	334,471
Pass-through Albert Einstein College of Medicine	UH3OD023320	93.310	—	22,638
Pass-through Duke University	U24MD016258	93.310	—	184,518
Pass-through Duke University	U2COD023375	93.310	—	1,096
Pass-through Georgia Institute of Technology	UG3TR002855	93.310	—	39,186
Pass-through Mount Sinai School of Medicine	DP5OD031876	93.310	—	119,099
Pass-through National Alliance for Hispanic Health	OT2OD02577	93.310	—	35,244
Pass-through New York University	UH3OD023305	93.310	—	160,451
Pass-through Research Foundation for Mental Hygiene	UH3OD023328	93.310	—	36,706
Pass-through Research Triangle Institute	7R03HD106123-02	93.310	—	32,420
Pass-through State University of New York Stony Brook	OT2H161847	93.310	—	83,401
Pass-through University of California San Francisco	R33HD105618	93.310	—	123,558
Pass-through University of California San Francisco	R61HD105618	93.310	—	65,021
Pass-through University of Illinois Urbana Champaign	R21HD106125	93.310	—	4,358
Pass-through University of Miami	OT2OD026551	93.310	—	83,038
Pass-through University of Miami	OT2OD026551	93.310	—	2,545,566
Pass-through University of Michigan	U54CA280805	93.310	—	16,772

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of North Carolina	UH3OD023348	93.310	\$ —	13,797
Pass-through Vanderbilt University Medical Center	UH3OD023282	93.310	—	16,852
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	—	116,707
Pass-through Women & Infants Hospital of Rhode Island	UHOD023347	93.310	—	117,426
Total AL No. 93.310			1,279,025	11,089,677
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	471,185	618,459
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	—	95,423
Total AL No. 93.318			471,185	713,882
National Center For Advancing Translational Sciences	KL2TR002381	93.350	434,368	1,616,776
National Center For Advancing Translational Sciences	R03TR003669	93.350	—	44,049
National Center For Advancing Translational Sciences	R03TR004022	93.350	—	83,755
National Center For Advancing Translational Sciences	R03TR004312	93.350	—	1,570
National Center For Advancing Translational Sciences	TL1TR002382	93.350	26,548	409,022
National Center For Advancing Translational Sciences	UL1TR002378	93.350	2,976,770	8,941,484
Pass-through Oregon Health and Science University	U01TR002631	93.350	—	39,004
Pass-through University of Michigan	R01TR004244	93.350	—	14,971
Pass-through University of North Carolina Chapel Hill	U01TR003629	93.350	—	46,828
Pass-through University of North Carolina Chapel Hill	U01TR003715	93.350	—	50,338
Total AL No. 93.350			3,437,686	11,247,797
Research Infrastructure Programs	P51OD011132	93.351	—	11,081,703
Research Infrastructure Programs	R13OD034052	93.351	—	19,532
Research Infrastructure Programs	R24OD030035	93.351	149,764	924,022
Research Infrastructure Programs	R25GM129213	93.351	—	540
Research Infrastructure Programs	S10OD028503	93.351	—	90,000
Research Infrastructure Programs	S10OD032320	93.351	—	308,440
Research Infrastructure Programs	U42OD011023	93.351	—	2,039,966
Pass-through Oregon Health and Science University	R24OD021324	93.351	—	34,716
Total AL No. 93.351			149,764	14,498,919
Construction Support	C06OD030081	93.352	—	552,272
Total AL No. 93.352			—	552,272
21st Century Cures Act – Beau Biden Cancer Moonshot:				
Pass-through Dana Farber Cancer Institute	U01CA243688	93.353	—	71,044
Pass-through Dana Farber Cancer Institute	U2CA233243	93.353	—	1,012
Pass-through University of Alabama Birmingham	U01CA246587	93.353	26,933	140,715
Pass-through University of Michigan	U01CA254822	93.353	—	94,519
Pass-through Vanderbilt University Medical Center	U2CCA23291	93.353	—	83,727
Total AL No. 93.353			26,933	388,993
Nurse Education, Practice Quality and Retention Grants	T1O47312	93.359	—	653,583
Nurse Education, Practice Quality and Retention Grants	U4E42423	93.359	—	166,044
Nurse Education, Practice Quality and Retention Grants	UK147321	93.359	326,417	809,818
Nurse Education, Practice Quality and Retention Grants	UK1HP31697	93.359	—	111,955
Nurse Education, Practice Quality and Retention Grants	US647225	93.359	—	247,515
Total AL No. 93.359			326,417	1,988,915
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	IDSEP190055	93.360	10,222	48,482
Total AL No. 93.360			10,222	48,482
Nursing Research	F31NR014611	93.361	—	(13,370)
Nursing Research	F31NR020575	93.361	—	43,872
Nursing Research	K01NR016971	93.361	—	(432)
Nursing Research	K01NR019651	93.361	—	138,255
Nursing Research	K23NR020037	93.361	20,775	165,761
Nursing Research	K23NR020208	93.361	—	180,320
Nursing Research	K23NR020356	93.361	—	148,005
Nursing Research	K24NR018866	93.361	—	161,993
Nursing Research	P30NR018090	93.361	—	434,867
Nursing Research	R00NR017897	93.361	34,178	283,042
Nursing Research	R01NR015783	93.361	—	(3,031)
Nursing Research	R01NR017018	93.361	—	196,972
Nursing Research	R01NR017939	93.361	180,973	544,128
Nursing Research	R01NR018666	93.361	241,380	636,867
Nursing Research	R01NR019083	93.361	44,605	808,963
Nursing Research	R01NR019254	93.361	—	379,029
Nursing Research	R01NR020154	93.361	—	387,159
Nursing Research	R01NR020188	93.361	93,564	443,974
Nursing Research	R01NR020334	93.361	—	329,404
Nursing Research	R01NR020756	93.361	—	311,458
Nursing Research	R21NR018015	93.361	—	(436)
Nursing Research	R21NR019872	93.361	—	150,531
Nursing Research	R56NR019482	93.361	—	32,949
Nursing Research	T32NR012715	93.361	—	445,967
Pass-through Indiana University	R21NR017777	93.361	—	104,616
Pass-through Johns Hopkins University	R01NR020437	93.361	—	575,604
Pass-through State University of New York	R01NR018979	93.361	—	96,164
Total AL No. 93.361			615,475	6,982,631
National and State Tobacco Control Program	R01HL155711	93.387	31,251	713,265
Total AL No. 93.387			31,251	713,265
Cancer Cause And Prevention Research	F99CA264407	93.393	—	41,244
Cancer Cause And Prevention Research	R00CA204601	93.393	—	83,555
Cancer Cause And Prevention Research	R01CA095318	93.393	—	(431)
Cancer Cause And Prevention Research	R01CA178999	93.393	—	356,342
Cancer Cause And Prevention Research	R01CA207260	93.393	6,554	158,059
Cancer Cause And Prevention Research	R01CA207467	93.393	—	(18)
Cancer Cause And Prevention Research	R01CA211574	93.393	319,543	473,103
Cancer Cause And Prevention Research	R01CA216579	93.393	23,823	282,944
Cancer Cause And Prevention Research	R01CA218155	93.393	34,961	282,334
Cancer Cause And Prevention Research	R01CA218389	93.393	151,110	643,818
Cancer Cause And Prevention Research	R01CA227918	93.393	—	28,482
Cancer Cause And Prevention Research	R01CA230268	93.393	—	363,866
Cancer Cause And Prevention Research	R01CA234538	93.393	13,299	540,316
Cancer Cause And Prevention Research	R01CA235721	93.393	63,499	714,227
Cancer Cause And Prevention Research	R01CA236871	93.393	—	277,405
Cancer Cause And Prevention Research	R01CA237318	93.393	621,872	1,073,919
Cancer Cause And Prevention Research	R01CA245063	93.393	232,966	743,919
Cancer Cause And Prevention Research	R01CA250110	93.393	52,384	274,672
Cancer Cause And Prevention Research	R01CA254403	93.393	—	438,559
Cancer Cause And Prevention Research	R01CA259192	93.393	—	656,116
Cancer Cause And Prevention Research	R01CA266574	93.393	—	289,017
Cancer Cause And Prevention Research	R01CA268024	93.393	98,728	334,578
Cancer Cause And Prevention Research	R03CA259665	93.393	23,867	57,574
Cancer Cause And Prevention Research	R03CA267456	93.393	10,734	116,611
Cancer Cause And Prevention Research	R21CA238356	93.393	234	44,738
Cancer Cause And Prevention Research	R21CA273773	93.393	—	111,259
Cancer Cause And Prevention Research	R37CA234119	93.393	251,123	556,641
Cancer Cause And Prevention Research	R37CA276317	93.393	—	7,086
Cancer Cause And Prevention Research	U01CA217875	93.393	—	217,623
Cancer Cause And Prevention Research	U01CA240581	93.393	31,270	541,788
Cancer Cause And Prevention Research	U01CA289181	93.393	—	339,398

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Cause And Prevention Research	U01CA275113	93.393	\$ 232,813	412,795
Pass-through Baylor College of Medicine	R01CA263000	93.393	—	82,314
Pass-through Duke University	R21CA274665	93.393	—	8,159
Pass-through Duke University	R37CA233777	93.393	—	19,728
Pass-through Georgia State University	R01CA248551	93.393	—	120,900
Pass-through Georgia State University	R01CA261887	93.393	—	24,844
Pass-through M D Anderson Cancer Center	R01CA261750	93.393	—	48,699
Pass-through Mayo Clinic	R01CA246288	93.393	—	38,566
Pass-through Mayo Clinic	U01CA195568	93.393	—	147,722
Pass-through Mayo Clinic Arizona	U01CA269264	93.393	—	37,761
Pass-through Md Anderson	R01CA207467	93.393	—	106,106
Pass-through Md Anderson	R01CA255322	93.393	—	157,202
Pass-through Moffitt Cancer Center	R01CA275974	93.393	—	29,111
Pass-through North Carolina State University	UG3CA265942	93.393	—	284,328
Pass-through Ohio State University	R01CA266402	93.393	—	21,792
Pass-through Public Health Institute	R01CA264519	93.393	—	234,025
Pass-through Seattle Children's Research Institute	R01CA269574	93.393	—	5,921
Pass-through Stanford University	R01CA234538	93.393	—	13,470
Pass-through State University of New York Stony Brook	R01CA235720	93.393	—	6,793
Pass-through State University of New York Stony Brook	UG3CA225021	93.393	—	88,851
Pass-through Texas Agricultural and Mechanical Univ	R01CA257559	93.393	—	7,307
Pass-through University of Alabama Birmingham	R01CA248439	93.393	8,750	29,362
Pass-through University of Alabama Birmingham	R01CA262039	93.393	—	190,148
Pass-through University of Arizona	R01CA264047	93.393	—	49,299
Pass-through University of California Irvine	R01CA262312	93.393	—	134,842
Pass-through University of California Irvine	R01CA272680	93.393	—	17,208
Pass-through University of Florida	R01CA268014	93.393	—	13,375
Pass-through University of Iowa	R01CA259048	93.393	—	65,311
Pass-through University of Kansas Medical Center	R01CA2181047	93.393	—	161,582
Pass-through University of Michigan	R01CA237046	93.393	—	24,760
Pass-through University of Michigan	R37CA251464	93.393	—	88,718
Pass-through University of Southern California	U19CA214253	93.393	—	509,543
Pass-through University of Utah	R01CA200854	93.393	—	18,813
Pass-through University of Utah	R01CA237404	93.393	—	9,647
Pass-through University of Washington Saint Louis	R01CA235773	93.393	—	42,616
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	37,810
Pass-through Vanderbilt University Medical Center	UG3CA265846	93.393	—	18,320
Total AL No. 93.393			2,177,580	13,366,492
COVID-19 – Cancer Detection And Diagnosis Research	U54CA260563	93.394	—	2,483,681
Cancer Detection And Diagnosis Research	R01CA169188	93.394	—	2,406
Cancer Detection And Diagnosis Research	R01CA203388	93.394	—	99,046
Cancer Detection And Diagnosis Research	R01CA249992	93.394	—	360,386
Cancer Detection And Diagnosis Research	R01CA257612	93.394	106,235	430,957
Cancer Detection And Diagnosis Research	R01CA261251	93.394	30,943	423,329
Cancer Detection And Diagnosis Research	R01CA26828	93.394	61,459	587,297
Cancer Detection And Diagnosis Research	R01CA272991	93.394	—	63,496
Cancer Detection And Diagnosis Research	R21CA256280	93.394	9,120	81,576
Cancer Detection And Diagnosis Research	R21CA256375	93.394	—	69,802
Cancer Detection And Diagnosis Research	R21CA256605	93.394	32,651	59,940
Cancer Detection And Diagnosis Research	R21CA259935	93.394	—	84,563
Cancer Detection And Diagnosis Research	U01CA113913	93.394	—	129,799
Cancer Detection And Diagnosis Research	U01CA264039	93.394	220,100	608,732
Pass-through Children's Hospital of Philadelphia	R01CA248501	93.394	—	15,993
Pass-through Fred Hutchinson Cancer Center	U01CA224255	93.394	—	78,319
Pass-through Georgia Institute of Technology	R37CA239039	93.394	—	3,737
Pass-through Memorial Sloan Kettering Cancer Center	U24CA264369	93.394	—	80,435
Pass-through Northwestern University	R01CA240639	93.394	—	84,215
Pass-through Ohio State University	R01CA237133	93.394	—	23,529
Pass-through Rhode Island Hospital	U24CA265879	93.394	—	19,379
Pass-through Rice University	R21CA255894	93.394	—	19,031
Pass-through State Univ of New York Downstate Med Ctr	R01CA2496701A	93.394	—	20,568
Pass-through Thomas Jefferson University	R01CA236857	93.394	—	49,327
Pass-through Thomas Jefferson University	UG3CA247605	93.394	—	57,546
Pass-through Univ of Arkansas for Medical Services	U24CA215109	93.394	—	21,628
Pass-through University of Michigan	R01CA208236	93.394	—	91,252
Pass-through University of South Florida	R01CA240319	93.394	6,896	32,752
Pass-through University of Washington Seattle	R01CA268207	93.394	—	136,082
Pass-through University of Wisconsin-Madison	R01CA264017	93.394	—	2,121
Total AL No. 93.394			467,404	6,221,524
Cancer Treatment Research	P01CA257906	93.395	—	2,118,339
Cancer Treatment Research	R00CA222493	93.395	—	143,460
Cancer Treatment Research	R01CA193828	93.395	—	413
Cancer Treatment Research	R01CA203928	93.395	—	84,420
Cancer Treatment Research	R01CA207768	93.395	—	33,018
Cancer Treatment Research	R01CA209253	93.395	10,879	84,853
Cancer Treatment Research	R01CA208328	93.395	—	4,144
Cancer Treatment Research	R01CA215718	93.395	—	180,244
Cancer Treatment Research	R01CA223220	93.395	—	414,448
Cancer Treatment Research	R01CA226992	93.395	—	615,014
Cancer Treatment Research	R01CA228406	93.395	—	254,740
Cancer Treatment Research	R01CA228414	93.395	80,358	132,239
Cancer Treatment Research	R01CA238471	93.395	—	358,200
Cancer Treatment Research	R01CA245386	93.395	—	366,066
Cancer Treatment Research	R01CA255257	93.395	—	401,691
Cancer Treatment Research	R01CA257861	93.395	—	389,406
Cancer Treatment Research	R01CA262123	93.395	—	149,907
Cancer Treatment Research	R01CA267694	93.395	—	830,570
Cancer Treatment Research	R01CA277686	93.395	—	158,106
Cancer Treatment Research	R03CA248039	93.395	—	4,968
Cancer Treatment Research	R21CA255831	93.395	—	27,186
Cancer Treatment Research	R21CA256456	93.395	—	212,506
Cancer Treatment Research	R21CA266088	93.395	—	118,117
Cancer Treatment Research	R21CA267365	93.395	—	268,325
Cancer Treatment Research	R21CA267612	93.395	—	188,714
Cancer Treatment Research	R21CA267914	93.395	—	60,520
Cancer Treatment Research	R21CA277103	93.395	—	140,159
Cancer Treatment Research	R37CA255459	93.395	—	391,199
Cancer Treatment Research	R50CA233168	93.395	—	142,999
Cancer Treatment Research	UG1CA233247	93.395	—	751,301
Cancer Treatment Research	UG1CA233259	93.395	615,177	722,699
Pass-through Baylor College of Medicine	R21CA260331	93.395	—	3,519
Pass-through Childrens Healthcare of Atlanta	GR-1000658	93.395	—	23,498
Pass-through Childrens Healthcare of Atlanta	U10CA180886	93.395	—	159,187
Pass-through Childrens Healthcare of Atlanta	UM1CA228823	93.395	—	7,908
Pass-through City of Hope	R01CA194742	93.395	—	148,443

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Clark Atlanta University	R01CA256058	93.395	\$ —	41,167
Pass-through Ecoq-Acrti Medical Research Foundation	U10CA180820	93.395	—	39,577
Pass-through Indiana University	R01CA235632	93.395	14,972	18,164
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	51,073
Pass-through Medical University of South Carolina	P01CA203628	93.395	—	(8,222)
Pass-through Nrg Oncology Foundation, Inc.	U10CA180868	93.395	—	7,585
Pass-through St. Jude Childrens Research Hospital	UM1CA081457	93.395	75,433	142,424
Pass-through University of Chicago	R37CA272755	93.395	—	76,596
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	196,866
Pass-through University of North Carolina Chapel Hill	R01CA259077	93.395	—	148,281
Pass-through University of Pennsylvania	R21CA238108	93.395	—	191,308
Pass-through University of Rochester	R01CA214890	93.395	—	4,100
Pass-through Vanderbilt University Medical Center	R21CA226562	93.395	—	(18,051)
Pass-through Washington University	R01CA258681	93.395	—	11,180
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA240447	93.395	—	325,169
Total AL No. 93.395			796,819	11,317,743
Cancer Biology Research	P30CA138292	93.396	—	1,594,639
Cancer Biology Research	R01CA175316	93.396	—	347,873
Cancer Biology Research	R01CA202948	93.396	—	74,830
Cancer Biology Research	R01CA203928	93.396	—	34,307
Cancer Biology Research	R01CA208514	93.396	—	192
Cancer Biology Research	R01CA236359	93.396	—	489,045
Cancer Biology Research	R01CA247367	93.396	—	646,030
Cancer Biology Research	R01CA250422	93.396	—	369,872
Cancer Biology Research	R01CA251393	93.396	71,201	614,075
Cancer Biology Research	R01CA258765	93.396	8,494	315,443
Cancer Biology Research	R01CA258857	93.396	84,552	454,111
Cancer Biology Research	R01CA268613	93.396	—	414,505
Cancer Biology Research	R01CA275193	93.396	—	71,154
Cancer Biology Research	R01CA275199	93.396	—	33,808
Cancer Biology Research	R01CA275964	93.396	—	203,883
Cancer Biology Research	R21CA274620	93.396	—	158,426
Cancer Biology Research	R21CA280584	93.396	—	11,532
Cancer Biology Research	R35CA197603	93.396	—	636,555
Cancer Biology Research	R01CA265345	93.396	—	143,981
Pass-through Georgia Institute of Technology	R01CA266052	93.396	—	137,677
Pass-through Georgia Institute of Technology	R21CA240214	93.396	—	17,996
Pass-through Georgia Institute of Technology	U01CA214354	93.396	—	(10,457)
Pass-through Georgia Institute of Technology	U01CA250040	93.396	—	382,704
Pass-through Georgia State University	R33CA235319	93.396	—	42,430
Pass-through Indiana University	R01CA121044	93.396	—	31,900
Pass-through Univ of Texas Health Sciences Ctr	R01CA239227	93.396	—	3,795
Pass-through University of Alabama Birmingham	U01CA223976	93.396	—	12,499
Pass-through University of North Carolina Chapel Hill	R01CA244361	93.396	—	13,283
Pass-through University of North Carolina Chapel Hill	R01CA248359	93.396	—	10,019
Pass-through University of Rochester	R01CA250531	93.396	—	19,046
Total AL No. 93.396			164,247	7,275,154
Cancer Centers Support Grants	P30CA138292	93.397	—	918,399
Cancer Centers Support Grants	P50CA217691	93.397	250,205	2,278,648
Pass-through Case Western Reserve University	RES600415	93.397	—	142,564
Pass-through Cleveland Clinic Foundation	U54CA274513	93.397	—	338,513
Pass-through Mayo Clinic	P50CA116201	93.397	—	64,608
Pass-through Morehouse School of Medicine	U54CA118638	93.397	—	10,506
Total AL No. 93.397			250,205	3,753,238
Cancer Research Manpower	F30CA243250	93.398	—	32,268
Cancer Research Manpower	F31CA239563	93.398	—	27,773
Cancer Research Manpower	F31CA243472	93.398	—	258
Cancer Research Manpower	F31CA243502	93.398	—	14,461
Cancer Research Manpower	F31CA247564	93.398	—	41,973
Cancer Research Manpower	F31CA254207	93.398	—	46,310
Cancer Research Manpower	F31CA265249	93.398	—	44,137
Cancer Research Manpower	F31CA268737	93.398	—	38,312
Cancer Research Manpower	F31CA271764	93.398	—	19,642
Cancer Research Manpower	F32CA257436	93.398	—	83,673
Cancer Research Manpower	F99CA274690	93.398	—	48,801
Cancer Research Manpower	K07CA211956	93.398	—	158,288
Cancer Research Manpower	K08CA248962	93.398	—	191,651
Cancer Research Manpower	K08CA267055	93.398	—	195,755
Cancer Research Manpower	K12CA237806	93.398	—	537,020
Cancer Research Manpower	K22CA266739	93.398	—	101,978
Cancer Research Manpower	K99CA267674	93.398	—	93,057
Cancer Research Manpower	R25CA265864	93.398	—	123,420
Total AL No. 93.398			—	1,798,757
Cancer Control	UG1CA275400	93.399	65,415	158,267
Pass-through Nrg Oncology Foundation, Inc.	UG1CA189867	93.399	—	186,009
Total AL No. 93.399			65,415	344,276
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health:				
Pass-through CDC Foundation	5005	93.421	—	119,084
Pass-through University of Washington	NU38OT000286	93.421	—	3,082
Total AL No. 93.421			—	122,166
Every Student Succeeds Act/Preschool Development Grants:				
Pass-through Georgia Department of Early Care and Learning	90TP0070	93.434	6,732	20,950
Total AL No. 93.434			6,732	20,950
CDC Undergraduate Public Health Scholars Program (CUPS): A Public Health Experience to Expose Undergraduates Interested in Minority Health to Public Health and the Public Health Professions:				
Pass-through Kennedy Krieger Institute	NU50CD300866	93.456	—	23,263
Total AL No. 93.456			—	23,263
COVID-19 – Affordable Care Act (Aca) Public Health Training Centers Program	T2946687	93.516	16,200	436,028
COVID-19 – Affordable Care Act (Aca) Public Health Training Centers Program	T5246760	93.516	—	59,432
Affordable Care Act (Aca) Public Health Training Centers Program	UB631680	93.516	204,401	1,124,949
Total AL No. 93.516			220,601	1,620,409
University Centers for Excellence in Developmental Disabilities Education, Research, and Service:				
Pass-through University of Georgia	90DDC10002	93.632	—	133,751
Total AL No. 93.632			—	133,751
Trans-NIH Recovery Act Research Support:				
Pass-through Wistar Institute	P01AI082282	93.701	—	178
Total AL No. 93.701			—	178
COVID-19 – Mental and Behavioral Health Education and Training Grants	U3N45397	93.732	—	998,529
Total AL No. 93.732			—	998,529
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities:				
Pass-through Georgia Dept of Public Health	U3REP150546	93.817	54,176	500,628
Total AL No. 93.817			54,176	500,628

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Health Careers Opportunity Program	1D18HP32120-01-00	93.822	\$ 1,500	545,320
Total AL No. 93.822			1,500	545,320
COVID-19 – National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	6,241,313
COVID-19 – National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	269,998	579,494
National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	307,151
National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	3,801,644	6,668,632
National Ebola Training and Education Center (NETEC)	U3REP170552	93.825	532,429	652,377
Total AL No. 93.825			4,604,071	14,448,967
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing: Pass-through University of Florida	R01NS112291	93.835	—	380,231
Total AL No. 93.835			—	380,231
Cardiovascular Diseases Research	F31HL143900	93.837	—	(108)
Cardiovascular Diseases Research	F31HL145974	93.837	—	(789)
Cardiovascular Diseases Research	F31HL149285	93.837	—	2,894
Cardiovascular Diseases Research	F31HL156426	93.837	—	72
Cardiovascular Diseases Research	F31HL156495	93.837	—	44,710
Cardiovascular Diseases Research	F31HL158155	93.837	—	33,632
Cardiovascular Diseases Research	F32HL167625	93.837	—	49,936
Cardiovascular Diseases Research	K01HL155235	93.837	—	123,262
Cardiovascular Diseases Research	K23HL127251	93.837	—	1,191
Cardiovascular Diseases Research	K23HL143164	93.837	—	139,998
Cardiovascular Diseases Research	K23HL152903	93.837	—	134,263
Cardiovascular Diseases Research	K24HL148521	93.837	—	107,561
Cardiovascular Diseases Research	K24HL163696	93.837	—	129,345
Cardiovascular Diseases Research	K99HL161355	93.837	—	80,444
Cardiovascular Diseases Research	OT2HL155038-02	93.837	—	30,274
Cardiovascular Diseases Research	P01HL095070	93.837	—	19
Cardiovascular Diseases Research	P01HL154996	93.837	1,174,119	2,274,586
Cardiovascular Diseases Research	R00HL127295	93.837	—	(5,114)
Cardiovascular Diseases Research	R00HL143211	93.837	—	74,440
Cardiovascular Diseases Research	R00HL144824	93.837	11,620	239,833
Cardiovascular Diseases Research	R01HL109413	93.837	—	980,413
Cardiovascular Diseases Research	R01HL119798	93.837	37,821	376,624
Cardiovascular Diseases Research	R01HL122392	93.837	159,929	812,703
Cardiovascular Diseases Research	R01HL125442	93.837	36,415	49,732
Cardiovascular Diseases Research	R01HL125761	93.837	—	35,697
Cardiovascular Diseases Research	R01HL130471	93.837	—	(1,793)
Cardiovascular Diseases Research	R01HL130915	93.837	—	(65)
Cardiovascular Diseases Research	R01HL133667	93.837	—	252,841
Cardiovascular Diseases Research	R01HL135145	93.837	—	29
Cardiovascular Diseases Research	R01HL135183	93.837	10,163	467,367
Cardiovascular Diseases Research	R01HL136345	93.837	—	202,903
Cardiovascular Diseases Research	R01HL136915	93.837	—	37,826
Cardiovascular Diseases Research	R01HL137338	93.837	250,869	499,277
Cardiovascular Diseases Research	R01HL139867	93.837	—	10,402
Cardiovascular Diseases Research	R01HL140223	93.837	—	385,730
Cardiovascular Diseases Research	R01HL141406	93.837	—	10,404
Cardiovascular Diseases Research	R01HL142782	93.837	—	154,458
Cardiovascular Diseases Research	R01HL143348	93.837	102,243	772,090
Cardiovascular Diseases Research	R01HL143350	93.837	37,430	14,086
Cardiovascular Diseases Research	R01HL144741	93.837	117,077	166,450
Cardiovascular Diseases Research	R01HL145644	93.837	151,143	386,325
Cardiovascular Diseases Research	R01HL146147	93.837	369,786	771,463
Cardiovascular Diseases Research	R01HL150005	93.837	—	447,413
Cardiovascular Diseases Research	R01HL150887	93.837	19,310	255,941
Cardiovascular Diseases Research	R01HL155537	93.837	361,175	675,723
Cardiovascular Diseases Research	R01HL155549	93.837	62,615	620,274
Cardiovascular Diseases Research	R01HL156008	93.837	—	437,809
Cardiovascular Diseases Research	R01HL157242	93.837	—	345,854
Cardiovascular Diseases Research	R01HL157311	93.837	—	688,662
Cardiovascular Diseases Research	R01HL157323	93.837	219,534	387,851
Cardiovascular Diseases Research	R01HL158141	93.837	62,601	951,462
Cardiovascular Diseases Research	R01HL158571	93.837	33,550	757,691
Cardiovascular Diseases Research	R01HL160589	93.837	—	352,849
Cardiovascular Diseases Research	R01HL160693	93.837	—	410,129
Cardiovascular Diseases Research	R01HL161366	93.837	1,569	159,463
Cardiovascular Diseases Research	R01HL163998	93.837	—	93,420
Cardiovascular Diseases Research	R01HL164806	93.837	—	75,157
Cardiovascular Diseases Research	R01HL165252	93.837	—	544,721
Cardiovascular Diseases Research	R01HL166004	93.837	—	612,325
Cardiovascular Diseases Research	R01HL166233	93.837	—	199,680
Cardiovascular Diseases Research	R01HL166817	93.837	—	43,682
Cardiovascular Diseases Research	R01HL168383	93.837	—	326,160
Cardiovascular Diseases Research	R01HL168994	93.837	—	14,102
Cardiovascular Diseases Research	R03HL146874	93.837	(4,008)	(6,252)
Cardiovascular Diseases Research	R03HL146879	93.837	—	(7,082)
Cardiovascular Diseases Research	R03HL155253	93.837	—	52,732
Cardiovascular Diseases Research	R03HL156476	93.837	—	136,258
Cardiovascular Diseases Research	R21HL156184	93.837	—	180,301
Cardiovascular Diseases Research	R33HL154116	93.837	—	369,905
Cardiovascular Diseases Research	R56HL167243	93.837	—	12,625
Cardiovascular Diseases Research	R56HL164737	93.837	—	82,143
Cardiovascular Diseases Research	R61HL154116A	93.837	—	(10,092)
Cardiovascular Diseases Research	T32HL007745	93.837	—	603,144
Cardiovascular Diseases Research	T32HL130025	93.837	—	690,241
Cardiovascular Diseases Research	T32HL166146	93.837	—	5,523
Cardiovascular Diseases Research	U01HL146241	93.837	110,033	3,101,931
Cardiovascular Diseases Research	U54HL141981	93.837	293,602	1,405,428
Cardiovascular Diseases Research	UG41HL135682	93.837	180,397	307,017
Pass-through Albert Einstein College of Medicine	R01HL159062	93.837	—	45,514
Pass-through Beth Israel Deaconess Medical Center	R01HL086741	93.837	—	223,139
Pass-through Beth Israel Deaconess Medical Center	R01HL161697	93.837	—	73,794
Pass-through Boston University	U01HL146382	93.837	—	17,528
Pass-through Case Western Reserve University	R01HL158071	93.837	—	225,987
Pass-through Georgia Institute of Technology	R01HL135505	93.837	—	20,761
Pass-through Georgia Institute of Technology	R01HL140325	93.837	—	272,475
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	114,391
Pass-through Georgia State University	R01HL142005	93.837	—	2,215
Pass-through State University of New York	R25HL105446	93.837	—	1,852
Pass-through Univ of Texas Hlth Sci Ctr At San Antoni	R21HL157810	93.837	—	14,691
Pass-through University of Alabama Birmingham	R01HL131017	93.837	—	293,981
Pass-through University of California Berkeley	R01HL157820	93.837	—	103,312
Pass-through University of California Los Angeles	R01HL118650	93.837	—	18,862
Pass-through University of California Los Angeles	R01HL160850	93.837	—	32,589
Pass-through University of California San Francisco	R01HL155226	93.837	—	25,929
Pass-through University of Miami	R25HL105444	93.837	—	3,868
Pass-through University of Minnesota	R01HL141288	93.837	—	7,328

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Pennsylvania	R01HL151277	93.837	\$ —	269,299
Pass-through University of Pittsburgh	UH3HL153847	93.837	—	1,716
Pass-through University of Texas Houston	K01HL149982	93.837	—	24,710
Pass-through University of Texas San Antonio	U01HL146382	93.837	—	30,861
Pass-through University of Virginia	R01HL137112	93.837	—	(842)
Pass-through University of Washington	R01HL153136	93.837	—	19,724
Pass-through Washington University	R01HL156991	93.837	—	33,562
Pass-through Research Institute at Nationwide Children's Hospital	R01HL145032	93.837	—	9,645
Pass-through Research Institute at Nationwide Children's Hospital	UG3HL161338	93.837	—	200,549
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL118491	93.837	—	22,035
Pass-through Ann & Robert H. Lurie Children's Hospital	UH3HL148318	93.837	—	3,936
Total AL No. 93.837			3,798,993	27,251,802
Lung Diseases Research	F31HL156639	93.838	—	18,086
Lung Diseases Research	F31HL164049	93.838	—	9,446
Lung Diseases Research	F31HL163914	93.838	—	6,786
Lung Diseases Research	F32HL151133	93.838	—	(320)
Lung Diseases Research	K23HL151897	93.838	—	207,462
Lung Diseases Research	K99HL151965	93.838	—	(635)
Lung Diseases Research	R00HL151965	93.838	—	246,712
Lung Diseases Research	R01HL113548	93.838	—	224,353
Lung Diseases Research	R01HL136414	93.838	587,859	916,663
Lung Diseases Research	R01HL139876	93.838	334,994	976,223
Lung Diseases Research	R01HL144478	93.838	—	169,920
Lung Diseases Research	R01HL148171	93.838	1,755	120,329
Lung Diseases Research	R01HL150658	93.838	—	193,066
Lung Diseases Research	R01HL152210	93.838	—	451,803
Lung Diseases Research	R01HL158747	93.838	—	59,473
Lung Diseases Research	R01HL158979	93.838	87,169	597,592
Lung Diseases Research	R01HL159058	93.838	—	762,482
Lung Diseases Research	R01HL166455	93.838	—	205,220
Lung Diseases Research	R35HL150803	93.838	—	736,792
Lung Diseases Research	R56HL150658	93.838	—	58
Lung Diseases Research	R56HL152167	93.838	—	2,882
Lung Diseases Research	T32HL116271	93.838	—	415,975
Lung Diseases Research	UM1HL134590	93.838	178,850	165,870
Pass-through Cincinnati Childrens Hospital	R34HL158586	93.838	—	10,571
Pass-through Medical College of Georgia	R01HL138410	93.838	—	6,169
Pass-through Morehouse School of Medicine	OT2HL158287	93.838	—	190,467
Pass-through New York University	OT2HL161847-01	93.838	—	19,750
Pass-through University of Arizona	U01HL130045	93.838	—	45,079
Pass-through University of Arizona	UG3HL147016	93.838	6,536	39,414
Pass-through University of Florida	OT2HL161847	93.838	—	219,043
Pass-through University of Georgia	R01HL136707	93.838	—	8,897
Pass-through University of Michigan	R01HL162661	93.838	—	18,695
Total AL No. 93.838			1,197,163	7,064,323
COVID-19 – Blood Diseases And Resources Research	R01HL138656	93.839	—	8,261
Blood Diseases And Resources Research	F31HL149357	93.839	—	10,349
Blood Diseases And Resources Research	F31HL158223	93.839	—	50,658
Blood Diseases And Resources Research	F31HL160210	93.839	—	46,805
Blood Diseases And Resources Research	K08HL141635	93.839	—	142,354
Blood Diseases And Resources Research	K08HL151965	93.839	—	232,720
Blood Diseases And Resources Research	K23HL133457	93.839	20,201	48,757
Blood Diseases And Resources Research	K23HL140142	93.839	13,081	158,377
Blood Diseases And Resources Research	K23HL146904	93.839	—	168,311
Blood Diseases And Resources Research	K25HL141636	93.839	—	148,971
Blood Diseases And Resources Research	K99HL150595	93.839	—	167,891
Blood Diseases And Resources Research	K99HL150626	93.839	—	280,788
Blood Diseases And Resources Research	P01HL086773	93.839	—	(2,886)
Blood Diseases And Resources Research	R01HL082808	93.839	28,946	328,523
Blood Diseases And Resources Research	R01HL129141	93.839	—	267,806
Blood Diseases And Resources Research	R01HL130995	93.839	—	370,344
Blood Diseases And Resources Research	R01HL137128	93.839	4,389	(13,133)
Blood Diseases And Resources Research	R01HL138656	93.839	19,819	22,447
Blood Diseases And Resources Research	R01HL138714	93.839	5,245	5,580
Blood Diseases And Resources Research	R01HL140589	93.839	232,349	327,776
Blood Diseases And Resources Research	R01HL141335	93.839	—	376,924
Blood Diseases And Resources Research	R01HL143794	93.839	169,333	396,555
Blood Diseases And Resources Research	R01HL146668	93.839	473,573	627,424

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Blood Diseases And Resources Research	R01HL152074	93.839	\$ —	339,165
Blood Diseases And Resources Research	R01HL152131	93.839	—	254,428
Blood Diseases And Resources Research	R01HL152322	93.839	6,853	487,934
Blood Diseases And Resources Research	R01HL155330	93.839	—	358,838
Blood Diseases And Resources Research	R01HL159213	93.839	42,046	354,474
Blood Diseases And Resources Research	R01HL162725	93.839	—	372,680
Blood Diseases And Resources Research	R01HL164583	93.839	88,152	342,771
Blood Diseases And Resources Research	R03HL162694	93.839	—	75,882
Blood Diseases And Resources Research	R03HL164333	93.839	4,937	62,184
Blood Diseases And Resources Research	R35HL145000	93.839	—	737,187
Blood Diseases And Resources Research	R35HL166654	93.839	—	403,237
Blood Diseases And Resources Research	R61HL163743	93.839	—	167,395
Blood Diseases And Resources Research	T32HL069769	93.839	—	144,543
Blood Diseases And Resources Research	T32HL139443	93.839	—	256,590
Blood Diseases And Resources Research	U01HL117721	93.839	—	59
Blood Diseases And Resources Research	U01HL139483	93.839	—	485,875
Blood Diseases And Resources Research	UG3HL148560	93.839	—	(41)
Blood Diseases And Resources Research	UH3HL148560	93.839	664,869	1,136,835
Pass-through Boston Children's Hospital	P01HL046925	93.839	—	26,862
Pass-through Boston Children's Hospital	UH3HL157564	93.839	—	16,125
Pass-through Brigham and Womens Hospital	P01HL132819	93.839	—	2,105
Pass-through Case Western Reserve University	R56HL165946	93.839	—	43,138
Pass-through Fred Hutchinson Cancer Center	R34HL142322	93.839	—	9,354
Pass-through New York University	UG3HL155798	93.839	—	7,651
Pass-through Rice University	R01HL152314	93.839	—	173,906
Pass-through University of Florida	UG1HL069301	93.839	—	60,323
Pass-through University of Maryland	UH3HL143192	93.839	—	41,964
Pass-through University of Pittsburgh	UG3HL143192	93.839	—	9,649
Pass-through University of Washington	UG3HL165064	93.839	—	90,568
Pass-through Wake Forest University	R01HL161290	93.839	—	63,633
Pass-through Wake Forest University	R01HL166462	93.839	—	4,370
Pass-through Yale University	R21HL165306	93.839	—	17,486
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL136480	93.839	19,772	43,651
Pass-through Augusta University Research Institute Inc	RHL106365	93.839	232	435
Total AL No. 93.839			1,793,797	10,762,858
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL152368	93.840	—	257,101
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	R33HL138657	93.840	—	283,587
Pass-through Seattle Biomedical Research Institute	U01HL142103	93.840	—	3,526
Pass-through University of Maryland, Baltimore	HL163514-01	93.840	—	39,892
Pass-through University of Washington	R01HL137808	93.840	—	111,370
Pass-through University of Witwatersrand	UG3HL156388	93.840	—	251,592
Total AL No. 93.840			—	947,068
Arthritis, Musculoskeletal And Skin Diseases Research	F31AR081697	93.846	—	16,644
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR075888	93.846	—	158,660
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR080245	93.846	—	162,975
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR048615	93.846	—	273,843
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR059364	93.846	—	2,062
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR061987	93.846	—	51,094
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR068157	93.846	—	(1,599)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR070091	93.846	—	(8,701)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR070736	93.846	—	224,463
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR071397	93.846	—	409,966
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR073874	93.846	56,794	392,746
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076089	93.846	—	175,478
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076153	93.846	83,825	305,757
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076427	93.846	37,438	510,201
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR077926	93.846	—	357,715
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078892	93.846	83,718	216,305
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078908	93.846	74,058	406,505
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR079298	93.846	60,948	703,118
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080169	93.846	—	140,833
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080750	93.846	300,285	700,971
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR071529	93.846	—	13,441
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR078463	93.846	—	200,474
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR080869	93.846	—	14,195
Arthritis, Musculoskeletal And Skin Diseases Research	U01AR067997	93.846	—	228,788
Pass-through Brigham and Womens Hospital	R21AR077768	93.846	—	39,005
Pass-through Cincinnati Childrens Hospital	R01AR070474	93.846	—	20,984
Pass-through Georgia Institute of Technology	R01AR071026	93.846	—	17,927
Pass-through Georgia State University	R01AR080154	93.846	—	40,905
Pass-through Louisiana State University	R01AR073277	93.846	—	49,526
Pass-through Mayo Clinic Rochester	R01AR055563	93.846	—	183,177
Pass-through Ohio University	R01AR077248	93.846	—	60,117
Pass-through State University of New York Buffalo	R01AR078785	93.846	—	28,041
Pass-through University of California Los Angeles	R01AR081794	93.846	—	17,277
Pass-through University of Florida	UC2AR082196	93.846	—	24,060
Pass-through University of Washington	R34AR080279	93.846	—	26,344
Total AL No. 93.846			697,066	6,163,297
COVID-19 - Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	9,363	9,363
Diabetes, Digestive, and Kidney Diseases Extramural Research	DF3DK108245	93.847	(24,964)	(24,965)
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK134204	93.847	—	12,394
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK122745	93.847	—	32,635
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126435	93.847	—	98
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126467	93.847	—	(15,884)
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK134199	93.847	—	51,109
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK135379	93.847	—	18,906
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK136254	93.847	—	16,644
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK137590	93.847	—	4,524
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK127848	93.847	—	61,250
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK131726	93.847	—	27,866
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK109025	93.847	—	15,730
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK128384	93.847	—	175,004
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK113241	93.847	—	46,317
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	5,924	173,515
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	156,495
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	159,680
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK123384	93.847	—	43,437
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	183,969
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK131317	93.847	—	142,313
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23MH129694	93.847	—	144,413
Diabetes, Digestive, and Kidney Diseases Extramural Research	K24DK096574	93.847	—	(778)
Diabetes, Digestive, and Kidney Diseases Extramural Research	K25DK135913	93.847	—	65,756
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	232,341	967,741
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK125013	93.847	162,533	684,538
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	184,464
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK047987	93.847	—	1,556
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK054514	93.847	—	1,872
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK055679	93.847	—	(40)
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	10,061	88,482
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	365,555	942,874
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK107719	93.847	—	21

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK108070	93.847	\$ 7,852	155,830
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK110409	93.847	—	116,605
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK112946	93.847	—	46
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	7,280	176,370
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	12,502
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115937	93.847	34,102	169,639
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK116799	93.847	—	397,404
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119229	93.847	—	429,948
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119793	93.847	—	176,329
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK120814	93.847	294,751	615,722
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK122701	93.847	—	310,168
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK124821	93.847	83,535	594,304
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	113,711	542,487
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125246	93.847	—	778,391
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125647	93.847	18,462	363,799
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125701	93.847	—	328,259
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125936	93.847	101,461	339,858
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK127083	93.847	303,522	320,154
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128061	93.847	—	334,245
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128902	93.847	—	288,537
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK129950	93.847	—	653,779
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK132653	93.847	—	479,512
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133523	93.847	—	429,189
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133650	93.847	57,859	301,491
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK134509	93.847	—	69,943
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK135815	93.847	—	78,178
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK129627	93.847	—	105,691
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK137007	93.847	—	4,196
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK122229	93.847	63,492	109,245
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK123616	93.847	1,602	155,539
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK128731	93.847	—	127,821
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	103,236
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK098231	93.847	—	(3,471)
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK115213	93.847	—	153,955
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	77,549
Diabetes, Digestive, and Kidney Diseases Extramural Research	TL1DK136047	93.847	—	78,234
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	613,847	961,719
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK116099	93.847	62,200	235,276
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK134191	93.847	16,642	512,011
Diabetes, Digestive, and Kidney Diseases Extramural Research	U2CDK129501	93.847	4,842	257,730
Pass-through Adventhealth Research Institute	R01DK112700	93.847	—	6,816
Pass-through Baylor College of Medicine	R01DK124395	93.847	—	48,633
Pass-through Brigham and Womens Hospital	R01DK056626	93.847	—	100,542
Pass-through Columbia University	R01DK123285	93.847	—	9,626
Pass-through Connecticut Childrens Medical Center	U34DK126638	93.847	—	16,266
Pass-through Cornell University	R01DK103046	93.847	—	118,321
Pass-through Drexel University	R01DK124388	93.847	—	18,998
Pass-through Duke University	R01DK118431	93.847	—	54,758
Pass-through Georgia State University	R01DK099071	93.847	—	23,676
Pass-through Georgia State University	R01DK126080	93.847	—	6,692
Pass-through Johns Hopkins University	R01DK110375	93.847	—	1,881
Pass-through Mayo Clinic	RC2DK118619	93.847	—	20,367
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	15,280
Pass-through New York University	R01DL110048	93.847	—	17,899
Pass-through Northern California Inst of Res and Edu	R01DK109823	93.847	—	2,821
Pass-through Sanford Health	R01DK131020	93.847	—	6,197
Pass-through University of Alabama Birmingham	R01DK115473	93.847	—	32,351
Pass-through University of Alabama Birmingham	R01DK128457	93.847	—	12,153
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	93,087
Pass-through University of California San Francisco	R01DK132271	93.847	—	15,705
Pass-through University of Florida	R01DK133465	93.847	—	97,022
Pass-through University of Kansas Medical Center	R01DK099611	93.847	—	17,180
Pass-through University of Kansas Medical Center	R01DK113111	93.847	—	121
Pass-through University of Kentucky	R01DK095662	93.847	—	1,979
Pass-through University of Michigan	U01DK133090	93.847	—	38,675
Pass-through University of South Florida	U01DK106993	93.847	—	132,100
Pass-through University of Virginia	RDK132369	93.847	—	98,165
Pass-through Vanderbilt University Medical Center	R01DK135938	93.847	—	3,325
Pass-through Virginia Commonwealth University	U01DK061731	93.847	—	48,344
Pass-through Yale University	R01DK121326	93.847	—	19,549
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	—	63,072
Pass-through Ann & Robert H. Lurie Children's Hospital	U01DK127995	93.847	8,201	16,154
Total AL No. 93.847			2,554,174	16,870,464
Extramural Research Programs In The Neurosciences And Neurological Disorders	DP2NS127291	93.853	6,835	478,844
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS027704	93.853	—	206,006
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS13530	93.853	—	27,580
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS115479	93.853	—	25,509
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS117086	93.853	—	47,946
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS117129	93.853	—	41,322
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS124269	93.853	—	56,137
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS125984	93.853	—	18,119
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127419	93.853	—	27,421
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127530	93.853	—	43,763
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127537	93.853	—	13,321
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127545	93.853	—	51,848
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127574	93.853	—	8,065
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS131020	93.853	—	21,265
Extramural Research Programs In The Neurosciences And Neurological Disorders	F32HD105458	93.853	—	67,673
Extramural Research Programs In The Neurosciences And Neurological Disorders	F9NS029188	93.853	—	94,524
Extramural Research Programs In The Neurosciences And Neurological Disorders	K0NS108539	93.853	—	75,962
Extramural Research Programs In The Neurosciences And Neurological Disorders	K01NS124912	93.853	—	288,054
Extramural Research Programs In The Neurosciences And Neurological Disorders	K0NS099474	93.853	—	(8,220)
Extramural Research Programs In The Neurosciences And Neurological Disorders	K0NS105929	93.853	—	66
Extramural Research Programs In The Neurosciences And Neurological Disorders	K2NS083748	93.853	—	(92)
Extramural Research Programs In The Neurosciences And Neurological Disorders	K2NS097576	93.853	—	4,494
Extramural Research Programs In The Neurosciences And Neurological Disorders	K2NS105944	93.853	—	112,283
Extramural Research Programs In The Neurosciences And Neurological Disorders	K2NS119964	93.853	—	171,867
Extramural Research Programs In The Neurosciences And Neurological Disorders	P50NS098685	93.853	—	(892)
Extramural Research Programs In The Neurosciences And Neurological Disorders	P50NS123103	93.853	106,532	2,600,049
Extramural Research Programs In The Neurosciences And Neurological Disorders	R00NS119739	93.853	—	60,479
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS036232	93.853	—	173,415
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS037112	93.853	—	436,821
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS045982	93.853	56,148	552,083
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS047357	93.853	—	670,870
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS051630	93.853	—	11,230
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS065992	93.853	—	388,320
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS078095	93.853	—	344,365
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS083654	93.853	—	160,852
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS084844	93.853	—	292,972
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS088748	93.853	142,441	615,771
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS089694	93.853	—	(1,003)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS090677	93.853	—	13
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS091201	93.853	—	149,354
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS092343	93.853	—	221,586

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Stanford University	U01NS038455	93.853	\$ —	108,270
Pass-through University of Akron	R1NS109957	93.853	—	1,861
Pass-through University of California Los Angeles	R01NS112799	93.853	—	40,346
Pass-through University of California Los Angeles	RF1NS130691	93.853	—	158,426
Pass-through University of California San Diego	R01NS124585	93.853	—	273,578
Pass-through University of Cincinnati	U01NS086872	93.853	—	61,863
Pass-through University of Georgia	R01NS099596	93.853	—	11,182
Pass-through University of Pennsylvania	U01NS113198	93.853	—	188,268
Pass-through University of Pittsburgh	R21NS111053	93.853	—	13,786
Pass-through University of South Carolina	R01NS117821	93.853	—	89,262
Pass-through University of Southern California	R01NS115845	93.853	—	45,362
Pass-through University of Wisconsin-Madison	R01NS108756	93.853	—	235,488
Pass-through Virginia Commonwealth University	U24NS100673	93.853	—	16,053
Pass-through Weill Cornell Medical College	R01NS093002	93.853	—	58,821
Pass-through Weill Cornell Medical College	R01NS115963	93.853	—	45,703
Total AL No. 93.853			4,790,231	39,669,674
COVID-19 – Allergy, Immunology And Transplantation Research	P01AI125180	93.855	—	(37)
COVID-19 – Allergy, Immunology And Transplantation Research	P51OD011132	93.855	31,874	141,584
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI143875	93.855	16,349	327,526
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI148378	93.855	—	41,974
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI161570	93.855	210,514	548,180
COVID-19 – Allergy, Immunology And Transplantation Research	F31AI161953	93.855	62,610	116,996
COVID-19 – Allergy, Immunology And Transplantation Research	U19A057266	93.855	244,211	791,274
COVID-19 – Allergy, Immunology And Transplantation Research	U19A090023	93.855	—	2,074,605
COVID-19 – Allergy, Immunology And Transplantation Research	U19A110483	93.855	7,678,220	11,068,872
COVID-19 – Allergy, Immunology And Transplantation Research	U19A171403	93.855	6,571,361	11,901,299
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	—	7,142,615
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148684	93.855	11,635,624	13,959,837
COVID-19 – Allergy, Immunology And Transplantation Research	F30AI152342	93.855	—	27,977
Allergy, Immunology And Transplantation Research	F31AI147589	93.855	—	8,358
Allergy, Immunology And Transplantation Research	F31AI147611	93.855	—	43,733
Allergy, Immunology And Transplantation Research	F31AI150114	93.855	—	23,166
Allergy, Immunology And Transplantation Research	F31AI154792	93.855	—	39,372
Allergy, Immunology And Transplantation Research	F31AI157884	93.855	—	34,222
Allergy, Immunology And Transplantation Research	F31AI161911	93.855	—	57,331
Allergy, Immunology And Transplantation Research	F31AI167527	93.855	—	44,223
Allergy, Immunology And Transplantation Research	F31AI172335	93.855	—	6,991
Allergy, Immunology And Transplantation Research	F31AI172377	93.855	—	1,720
Allergy, Immunology And Transplantation Research	F31AI172618	93.855	—	50,950
Allergy, Immunology And Transplantation Research	F31AI174951	93.855	—	27,919
Allergy, Immunology And Transplantation Research	F31AI179158	93.855	—	2,947
Allergy, Immunology And Transplantation Research	F31AI179421	93.855	—	4,524
Allergy, Immunology And Transplantation Research	F32AI161857	93.855	—	61,998
Allergy, Immunology And Transplantation Research	HHSN2722013000231	93.855	—	84,083
Allergy, Immunology And Transplantation Research	K01AI130326	93.855	—	85,500
Allergy, Immunology And Transplantation Research	K01AI166093	93.855	—	112,893
Allergy, Immunology And Transplantation Research	K08AI139348	93.855	—	75,734
Allergy, Immunology And Transplantation Research	K08AI166837	93.855	—	145,318
Allergy, Immunology And Transplantation Research	K23AI134182	93.855	—	201,501
Allergy, Immunology And Transplantation Research	K23AI143479	93.855	2,835	125,514
Allergy, Immunology And Transplantation Research	K23AI144036	93.855	2,120	130,459
Allergy, Immunology And Transplantation Research	K23AI144040	93.855	—	156,179
Allergy, Immunology And Transplantation Research	K24AI114444	93.855	—	208,084
Allergy, Immunology And Transplantation Research	K24AI165099	93.855	—	18,870
Allergy, Immunology And Transplantation Research	K99AI153736	93.855	—	(1,598)
Allergy, Immunology And Transplantation Research	P01AI125180	93.855	514,414	2,607,377
Allergy, Immunology And Transplantation Research	P01AI178376	93.855	—	24,891
Allergy, Immunology And Transplantation Research	P30A050409	93.855	792,373	4,908,928
Allergy, Immunology And Transplantation Research	P30AI168386	93.855	39,797	1,101,369
Allergy, Immunology And Transplantation Research	R00AI138860	93.855	—	185,883
Allergy, Immunology And Transplantation Research	R00AI151891	93.855	—	200,644
Allergy, Immunology And Transplantation Research	R01AI021150	93.855	222,261	394,055
Allergy, Immunology And Transplantation Research	R01AI030048	93.855	—	236,748
Allergy, Immunology And Transplantation Research	R01AI047498	93.855	—	(2,722)
Allergy, Immunology And Transplantation Research	R01AI051231	93.855	309,566	925,012
Allergy, Immunology And Transplantation Research	R01AI053668	93.855	83,024	589,191
Allergy, Immunology And Transplantation Research	R01AI064462	93.855	—	272,979
Allergy, Immunology And Transplantation Research	R01AI065429	93.855	—	(98)
Allergy, Immunology And Transplantation Research	R01AI088025	93.855	39,373	684,626
Allergy, Immunology And Transplantation Research	R01AI1072435	93.855	—	88,937
Allergy, Immunology And Transplantation Research	R01AI107960	93.855	221,151	665,787
Allergy, Immunology And Transplantation Research	R01AI110680	93.855	—	2,057
Allergy, Immunology And Transplantation Research	R01AI110701	93.855	—	12
Allergy, Immunology And Transplantation Research	R01AI113021	93.855	25,023	513,083
Allergy, Immunology And Transplantation Research	R01AI116933	93.855	—	635,997
Allergy, Immunology And Transplantation Research	R01AI120860	93.855	180,713	528,918
Allergy, Immunology And Transplantation Research	R01AI121315	93.855	—	18,616
Allergy, Immunology And Transplantation Research	R01AI123383	93.855	—	602,382
Allergy, Immunology And Transplantation Research	R01AI123733	93.855	—	31,353
Allergy, Immunology And Transplantation Research	R01AI125064	93.855	—	816,485
Allergy, Immunology And Transplantation Research	R01AI125202	93.855	81,741	267,500
Allergy, Immunology And Transplantation Research	R01AI127799	93.855	108,587	149,029
Allergy, Immunology And Transplantation Research	R01AI128799	93.855	—	20,978
Allergy, Immunology And Transplantation Research	R01AI128837	93.855	451,269	459,953
Allergy, Immunology And Transplantation Research	R01AI129862	93.855	232,146	590,563
Allergy, Immunology And Transplantation Research	R01AI130163	93.855	196,918	206,072
Allergy, Immunology And Transplantation Research	R01AI132786	93.855	87,084	587,547
Allergy, Immunology And Transplantation Research	R01AI132953	93.855	—	513,276
Allergy, Immunology And Transplantation Research	R01AI133706	93.855	—	269,589
Allergy, Immunology And Transplantation Research	R01AI134244	93.855	—	3,672
Allergy, Immunology And Transplantation Research	R01AI135806	93.855	—	314,480
Allergy, Immunology And Transplantation Research	R01AI136533	93.855	117,763	987,326
Allergy, Immunology And Transplantation Research	R01AI136581	93.855	—	267,194
Allergy, Immunology And Transplantation Research	R01AI137127	93.855	—	430,267
Allergy, Immunology And Transplantation Research	R01AI138646	93.855	264,620	650,153
Allergy, Immunology And Transplantation Research	R01AI138783	93.855	273,110	542,597
Allergy, Immunology And Transplantation Research	R01AI139063	93.855	—	178,733
Allergy, Immunology And Transplantation Research	R01AI139406	93.855	81,284	829,767
Allergy, Immunology And Transplantation Research	R01AI139761	93.855	243,051	517,235
Allergy, Immunology And Transplantation Research	R01AI141327	93.855	125,990	321,513
Allergy, Immunology And Transplantation Research	R01AI141883	93.855	—	453,880
Allergy, Immunology And Transplantation Research	R01AI143414	93.855	—	185,235
Allergy, Immunology And Transplantation Research	R01AI143875	93.855	284,463	546,149
Allergy, Immunology And Transplantation Research	R01AI144067	93.855	—	355,994

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R01AI145231	93.855	\$	834,586
Allergy, Immunology And Transplantation Research	R01AI145640	93.855	89,500	1,243,030
Allergy, Immunology And Transplantation Research	R01AI146017	93.855	273,945	569,184
Allergy, Immunology And Transplantation Research	R01AI146260	93.855	—	456,288
Allergy, Immunology And Transplantation Research	R01AI147609	93.855	210,197	541,789
Allergy, Immunology And Transplantation Research	R01AI148377	93.855	—	808,041
Allergy, Immunology And Transplantation Research	R01AI148378	93.855	—	491,905
Allergy, Immunology And Transplantation Research	R01AI148382	93.855	646,136	1,172,231
Allergy, Immunology And Transplantation Research	R01AI148471	93.855	45,853	465,803
Allergy, Immunology And Transplantation Research	R01AI148661	93.855	92,648	791,132
Allergy, Immunology And Transplantation Research	R01AI149297	93.855	101,608	591,733
Allergy, Immunology And Transplantation Research	R01AI149486	93.855	—	1,080,626
Allergy, Immunology And Transplantation Research	R01AI149527	93.855	—	285,112
Allergy, Immunology And Transplantation Research	R01AI149724	93.855	—	567,224
Allergy, Immunology And Transplantation Research	R01AI150453	93.855	—	595,985
Allergy, Immunology And Transplantation Research	R01AI150774	93.855	77,500	276,142
Allergy, Immunology And Transplantation Research	R01AI152516	93.855	—	409,342
Allergy, Immunology And Transplantation Research	R01AI152766	93.855	—	245,901
Allergy, Immunology And Transplantation Research	R01AI153071	93.855	—	260,510
Allergy, Immunology And Transplantation Research	R01AI153102	93.855	—	492,815
Allergy, Immunology And Transplantation Research	R01AI153152	93.855	205,565	708,862
Allergy, Immunology And Transplantation Research	R01AI154894	93.855	140,460	742,020
Allergy, Immunology And Transplantation Research	R01AI155007	93.855	171,091	609,134
Allergy, Immunology And Transplantation Research	R01AI155023	93.855	137,830	937,807
Allergy, Immunology And Transplantation Research	R01AI156052	93.855	—	497,099
Allergy, Immunology And Transplantation Research	R01AI158484	93.855	—	27,674
Allergy, Immunology And Transplantation Research	R01AI161570	93.855	—	20,954
Allergy, Immunology And Transplantation Research	R01AI162267	93.855	16,356	666,335
Allergy, Immunology And Transplantation Research	R01AI162633	93.855	—	433,171
Allergy, Immunology And Transplantation Research	R01AI164716	93.855	—	776,586
Allergy, Immunology And Transplantation Research	R01AI165644	93.855	—	496,322
Allergy, Immunology And Transplantation Research	R01AI166305	93.855	373,499	792,772
Allergy, Immunology And Transplantation Research	R01AI166988	93.855	328,839	811,014
Allergy, Immunology And Transplantation Research	R01AI167356	93.855	135,718	688,224
Allergy, Immunology And Transplantation Research	R01AI167724	93.855	—	950,705
Allergy, Immunology And Transplantation Research	R01AI172254	93.855	—	494,108
Allergy, Immunology And Transplantation Research	R01AI172452	93.855	—	254,540
Allergy, Immunology And Transplantation Research	R01AI172740	93.855	53,118	584,495
Allergy, Immunology And Transplantation Research	R01AI173946	93.855	27,759	118,819
Allergy, Immunology And Transplantation Research	R01AI174933	93.855	—	348,722
Allergy, Immunology And Transplantation Research	R01AI175428	93.855	2,941	138,181
Allergy, Immunology And Transplantation Research	R01AI179476	93.855	—	17,636
Allergy, Immunology And Transplantation Research	R01AI47839	93.855	362,303	975,360
Allergy, Immunology And Transplantation Research	R13AI167425	93.855	—	12,000
Allergy, Immunology And Transplantation Research	R21AI122192	93.855	—	(3,410)
Allergy, Immunology And Transplantation Research	R21AI135711	93.855	—	(1,698)
Allergy, Immunology And Transplantation Research	R21AI146443	93.855	—	7,770
Allergy, Immunology And Transplantation Research	R21AI146503	93.855	—	728
Allergy, Immunology And Transplantation Research	R21AI148847	93.855	—	67,263
Allergy, Immunology And Transplantation Research	R21AI152031	93.855	—	75,544
Allergy, Immunology And Transplantation Research	R21AI154232	93.855	—	(97)
Allergy, Immunology And Transplantation Research	R21AI154352	93.855	—	1,379
Allergy, Immunology And Transplantation Research	R21AI155142	93.855	—	146,108
Allergy, Immunology And Transplantation Research	R21AI155221	93.855	—	229,671
Allergy, Immunology And Transplantation Research	R21AI156161	93.855	65,292	134,452
Allergy, Immunology And Transplantation Research	R21AI156376	93.855	69,339	303,962
Allergy, Immunology And Transplantation Research	R21AI157730	93.855	—	68,093
Allergy, Immunology And Transplantation Research	R21AI157911	93.855	—	175,312
Allergy, Immunology And Transplantation Research	R21AI159765	93.855	—	253,222
Allergy, Immunology And Transplantation Research	R21AI161521	93.855	—	156,650
Allergy, Immunology And Transplantation Research	R21AI163427	93.855	12,762	175,690
Allergy, Immunology And Transplantation Research	R21AI164733	93.855	68,982	232,594
Allergy, Immunology And Transplantation Research	R21AI167032	93.855	—	102,770
Allergy, Immunology And Transplantation Research	R21AI171501	93.855	—	180,806
Allergy, Immunology And Transplantation Research	R21AI173471	93.855	—	13,692
Allergy, Immunology And Transplantation Research	R21AI174000	93.855	18,599	33,953
Allergy, Immunology And Transplantation Research	R21AI175869	93.855	—	144,692
Allergy, Immunology And Transplantation Research	R21AI176458	93.855	3,810	53,388
Allergy, Immunology And Transplantation Research	R21AI176683	93.855	—	36,266
Allergy, Immunology And Transplantation Research	R21AI176944	93.855	—	9,810
Allergy, Immunology And Transplantation Research	R21AI176946	93.855	—	11,266
Allergy, Immunology And Transplantation Research	R21AI178702	93.855	—	24,987
Allergy, Immunology And Transplantation Research	R21AI38079	93.855	127,732	124,397
Allergy, Immunology And Transplantation Research	R24AI162317	93.855	398,663	752,269
Allergy, Immunology And Transplantation Research	R33AI121684	93.855	—	(55)
Allergy, Immunology And Transplantation Research	R37AI021150	93.855	—	(99)
Allergy, Immunology And Transplantation Research	R37AI076119	93.855	113,636	489,869
Allergy, Immunology And Transplantation Research	R37AI11278	93.855	75,253	735,267
Allergy, Immunology And Transplantation Research	R37AI141258	93.855	81,375	896,304
Allergy, Immunology And Transplantation Research	R37AI157862	93.855	—	1,333,707
Allergy, Immunology And Transplantation Research	R58AI140299	93.855	—	218,412
Allergy, Immunology And Transplantation Research	R56AI150401	93.855	—	233,331
Allergy, Immunology And Transplantation Research	R56AI154895	93.855	—	5,288
Allergy, Immunology And Transplantation Research	R56AI165149	93.855	—	519,816
Allergy, Immunology And Transplantation Research	R56AI172452	93.855	—	57,008
Allergy, Immunology And Transplantation Research	T32AI070081	93.855	—	148,861
Allergy, Immunology And Transplantation Research	T32AI074492	93.855	—	286,160
Allergy, Immunology And Transplantation Research	T32AI106699	93.855	—	225,125
Allergy, Immunology And Transplantation Research	T32AI138952	93.855	—	200,637
Allergy, Immunology And Transplantation Research	T32AI157855	93.855	—	477,720
Allergy, Immunology And Transplantation Research	U01AI077821	93.855	—	(446)
Allergy, Immunology And Transplantation Research	U01AI131295	93.855	774,758	981,997
Allergy, Immunology And Transplantation Research	U01AI131566	93.855	—	30,315
Allergy, Immunology And Transplantation Research	U01AI138909	93.855	—	918,006
Allergy, Immunology And Transplantation Research	U01AI141993	93.855	48,011	601,521
Allergy, Immunology And Transplantation Research	U01AI148069	93.855	708,895	1,438,790
Allergy, Immunology And Transplantation Research	U01AI150747	93.855	635,868	1,271,562
Allergy, Immunology And Transplantation Research	U19 AI051731	93.855	1,514,654	1,718,917
Allergy, Immunology And Transplantation Research	U19AI051731	93.855	360,677	358,424
Allergy, Immunology And Transplantation Research	U19AI057266	93.855	1,816,029	3,821,269
Allergy, Immunology And Transplantation Research	U19AI090023	93.855	312,918	827,725
Allergy, Immunology And Transplantation Research	U19AI110483	93.855	3,685,562	5,211,866
Allergy, Immunology And Transplantation Research	U19AI11121	93.855	405,453	455,373
Allergy, Immunology And Transplantation Research	U19AI158080	93.855	351,542	1,929,276
Allergy, Immunology And Transplantation Research	U19AI159819	93.855	282,290	1,694,721
Allergy, Immunology And Transplantation Research	U24AI120134	93.855	67,491	764,188
Allergy, Immunology And Transplantation Research	UG3AI176853	93.855	—	212,146
Allergy, Immunology And Transplantation Research	UH3AI122320	93.855	599	86,453
Allergy, Immunology And Transplantation Research	UM1AI069418	93.855	1,227,919	3,566,885
Allergy, Immunology And Transplantation Research	UM1AI124436	93.855	87,979	2,640,923
Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	15,924	1,256,313
Allergy, Immunology And Transplantation Research	UM1AI164562	93.855	1,329,051	4,772,890

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	UM1AI169662	93.855	\$ 1,149,261	2,403,838
Pass-through Albert Einstein College of Medicine	R01HL149921	93.855	—	102,296
Pass-through Benaroya Research Institute at Virginia	UM1AI109565	93.855	—	311,081
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	501
Pass-through Boston Children's Hospital	U24AI152179	93.855	—	232,088
Pass-through Brigham and Womens Hospital	R01AI138801	93.855	—	27,435
Pass-through Case Western Reserve University	A1072219-11	93.855	—	86,127
Pass-through Cincinnati Childrens Hospital	R01AI148276	93.855	—	17,480
Pass-through Cincinnati Childrens Hospital	U01AI144673	93.855	—	913,830
Pass-through Columbia University	R01AI169938	93.855	—	91,856
Pass-through Dana Farber Cancer Institute	R33AI129017	93.855	—	291,981
Pass-through Drexel University	U19AI128910	93.855	—	11,450
Pass-through Duke Clinical Research Institute	UM1AI104681	93.855	—	132,325
Pass-through Duke University	P01AI131276	93.855	—	11,090
Pass-through Duke University	R01AI143457	93.855	—	161,854
Pass-through Duke University	R01AI175411	93.855	—	10,893
Pass-through Duke University	UM1AI104681	93.855	—	28,006
Pass-through FHI 360 LLC	A1068619	93.855	(4,794)	(4,794)
Pass-through FHI 360 LLC	P018001927	93.855	83,906	94,031
Pass-through FHI 360 LLC	P019002009	93.855	—	7,226
Pass-through FHI 360 LLC	UM1AI068619	93.855	132,685	247,652
Pass-through Fred Hutchinson Cancer Center	UM1AI068614	93.855	—	223,874
Pass-through Fred Hutchinson Cancer Center	UM1AI068635	93.855	—	98,533
Pass-through Fred Hutchinson Cancer Center	UM1AI1068635	93.855	—	46,705
Pass-through George Washington University	P30AI117970	93.855	—	28,632
Pass-through Georgia Institute of Technology	R01AI153116	93.855	—	80,281
Pass-through Georgia Institute of Technology	R21AI166639	93.855	—	19,413
Pass-through Georgia State University	R01AI071002	93.855	—	132,982
Pass-through Georgia State University	R01AI1414222	93.855	—	182,101
Pass-through Georgia State University	R01AI153400	93.855	—	168,355
Pass-through Georgia State University	R01AI154656	93.855	—	36,397
Pass-through Harvard Pilgrim Health Care Institute	R01AI174862	93.855	—	17,738
Pass-through Harvard University	P01AI056299	93.855	—	336,811
Pass-through Henry M Jackson Foundation	U19AI144180	93.855	—	84,513
Pass-through Immune Tolerance Network	UM1AI109665	93.855	—	417,934
Pass-through J. Craig Venter institute	R01AI170111	93.855	—	69,854
Pass-through Johns Hopkins University	R01AI172092	93.855	—	25,943
Pass-through Johns Hopkins University	U01AI069918	93.855	—	118,153
Pass-through Johns Hopkins University	U01AI138897	93.855	—	45,072
Pass-through Johns Hopkins University	UH3AI133669	93.855	—	60,000
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	28,573
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	39,352
Pass-through Johns Hopkins University	UM1AI164566	93.855	—	1,402,445
Pass-through Johns Hopkins University	UM2AI130836	93.855	160,204	208,309
Pass-through La Jolla Institute for Allergy	R01AI125068	93.855	—	(16,133)
Pass-through La Jolla Institute for Allergy	R37AI125068	93.855	—	560,366
Pass-through La Jolla Institute for Allergy	U01AI167892	93.855	—	39,125
Pass-through La Jolla Institute for Allergy	U19AI142742	93.855	—	26,775
Pass-through La Jolla Institute For Immunology	U01AI167892	93.855	—	100,933
Pass-through La Jolla Institute For Immunology	U19AI142790	93.855	—	105,283
Pass-through Massachusetts General Hospital	R01AI042006	93.855	—	21,708
Pass-through Massachusetts General Hospital	R01AI176533	93.855	—	12,191
Pass-through Massachusetts General Hospital	R21AI171732	93.855	—	91,401
Pass-through Massachusetts General Hospital	R37AI106878	93.855	—	30,043
Pass-through Massachusetts Institute of Technology	R61AI161297	93.855	—	36,562
Pass-through Mayo Clinic Rochester	R01AI121054	93.855	—	52,892
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	170,163
Pass-through Memorial Sloan Kettering Cancer Center	R01AI087644	93.855	—	37,006
Pass-through Mount Sinai School of Medicine	P01AI097092	93.855	—	410,777
Pass-through Mount Sinai School of Medicine	U19AI135972	93.855	—	113,432
Pass-through Ohio State University	R01AI127863	93.855	—	30,198
Pass-through Pennsylvania State University	R01AI158706	93.855	—	98,304
Pass-through Population Council	R01AI150360	93.855	—	91,615
Pass-through Regents of the University of California	R01AI125842	93.855	—	85,313
Pass-through Regents of the University of California	UM1AI068636	93.855	—	10,611
Pass-through Rutgers University	R21AI171755	93.855	—	5,215
Pass-through Scripps Research Institute	P01AI157299	93.855	—	660,911
Pass-through Scripps Research Institute	R01AI145629	93.855	—	68,454
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	338,546
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	3,298,753
Pass-through Scripps Research Institute	UM1AI164561	93.855	—	3,135,141
Pass-through Seattle Childrens Hospital	R01AI165351	93.855	—	3,418
Pass-through Seattle Childrens Hospital	U54AI170855	93.855	—	149,933
Pass-through Seattle Children's Research Institute	R01AI134419	93.855	—	(15,380)
Pass-through Seattle Children's Research Institute	U54AI170855	93.855	—	465,234
Pass-through St. Jude Childrens Research Hospital	U01AI144616	93.855	—	386,230
Pass-through Stanford University	U19AI159840	93.855	—	126,434
Pass-through Stanford University	U19AI167903	93.855	—	159,651
Pass-through Stanford University	U19AI171421	93.855	—	730,978
Pass-through Tufts University	R01AI137424	93.855	—	94,112
Pass-through University of Alabama Birmingham	R01AI153365	93.855	—	47,495
Pass-through University of Alabama Birmingham	U19AI142737	93.855	—	134,001
Pass-through University of Alabama Birmingham	U19AI142759	93.855	—	304,312
Pass-through University of Alabama Birmingham	U54AI150225	93.855	(210)	(9,859)
Pass-through University of Calgary	R01AI165327	93.855	2,860	33,508
Pass-through University of California Berkeley	R01AI148127	93.855	—	52,605
Pass-through University of California Berkeley	U01AI151788	93.855	—	113,415
Pass-through University of California Irvine	R01AI175312	93.855	—	10,368
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	53,483
Pass-through University of California Los Angeles	UM1AI106701	93.855	—	365,440
Pass-through University of California San Diego	R01AI173689	93.855	—	3,858
Pass-through University of California San Diego	R21AI171385	93.855	—	18,075
Pass-through University of California San Francisco	R01AI143464	93.855	—	101,542
Pass-through University of California San Francisco	R01AI151075	93.855	—	252,806
Pass-through University of California San Francisco	R01AI152161	93.855	—	110,869
Pass-through University of California San Francisco	R01AI158527	93.855	—	81,017
Pass-through University of California San Francisco	R01AI165706	93.855	—	101,655
Pass-through University of Colorado Denver	R01AI162665	93.855	—	224,842
Pass-through University of Georgia	R01AI125738	93.855	—	80,860
Pass-through University of Georgia	R01AI148667	93.855	—	33,120
Pass-through University of Georgia	R01AI173084	93.855	—	67,216
Pass-through University of Georgia	R21AI154343	93.855	—	29,925
Pass-through University of Kentucky	R01AI141889	93.855	—	92,317
Pass-through University of Louisiana at Lafayette	R01AI139288	93.855	—	34,150
Pass-through University of Maryland, Baltimore	R01AI138797	93.855	—	739,233
Pass-through University of Minnesota	U01AI132904	93.855	—	125,608
Pass-through University of North Carolina	K23AI159073	93.855	—	3,732
Pass-through University of North Carolina	UM1AI126619	93.855	—	(652)
Pass-through University of North Carolina Chapel Hill	R01AI136990	93.855	—	52
Pass-through University of North Carolina Chapel Hill	R01AI153007	93.855	—	175,094
Pass-through University of North Carolina Chapel Hill	UA110625C	93.855	—	28,325
Pass-through University of North Carolina Chapel Hill	UM1AI164567	93.855	—	1,265,480
Pass-through University of Pennsylvania	P01AI131338	93.855	—	4,587
Pass-through University of Pennsylvania	R01AI139188	93.855	—	159,322
Pass-through University of Pennsylvania	R01AI147487	93.855	—	41,384
Pass-through University of Pennsylvania	R01AI158452-01A1	93.855	—	23,669

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Pennsylvania	U19AI131130	93.855	\$ —	107,066
Pass-through University of South Florida	R01AI153830	93.855	—	14,003
Pass-through University of Texas Medical Branch	R01AI143653	93.855	—	33,209
Pass-through University of Texas Southwestern	R01AI141101	93.855	—	90,811
Pass-through University of Utah	R01AI147641	93.855	—	26,591
Pass-through University of Utah	R01AI169835	93.855	—	17,438
Pass-through University of Virginia	R01AI154242	93.855	—	19,195
Pass-through University of Washington	R01AI137679	93.855	—	31,616
Pass-through University of Washington	R01AI142647	93.855	—	354,045
Pass-through University of Washington	R61AI149665	93.855	—	(496)
Pass-through University of Wisconsin-Madison	R01AI148707	93.855	—	94,700
Pass-through Vanderbilt University Medical Center	P30AI110527	93.855	—	16,727
Pass-through Vanderbilt University Medical Center	R01AI170172	93.855	—	1,281
Pass-through Vanderbilt University Medical Center	U19AI095227	93.855	—	34,575
Pass-through Washington State University	U01AI151799	93.855	—	179,206
Pass-through Washington University	R56AI147623	93.855	—	11,638
Pass-through Weill Cornell Medical College	P01AI131276	93.855	—	270,296
Pass-through Wistar Institute	U19AI109646	93.855	—	(82,917)
Pass-through Yale University	R01AI112970	93.855	—	71,309
Pass-through Yale University	R01AI161399	93.855	—	110,374
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096882	93.855	—	39,881
Pass-through Research Institute at Nationwide Children's Hospital	R01AI126890	93.855	—	(5,005)
Pass-through Research Institute at Nationwide Children's Hospital	R01AI151175	93.855	—	99,316
Total AL No. 93.855			51,106,480	170,978,030
Microbiology And Infectious Diseases Research	R01GM099142	93.856	—	425,261
Total AL No. 93.856			—	425,261
Biomedical Research and Research Training	F31GM134649	93.859	—	29,926
Biomedical Research and Research Training	F31GM143891	93.859	—	46,503
Biomedical Research and Research Training	F32GM140778	93.859	—	51,243
Biomedical Research and Research Training	K12GM000680	93.859	77,529	744,596
Biomedical Research and Research Training	K23GM128221	93.859	—	191,619
Biomedical Research and Research Training	K23GM137182	93.859	43,721	284,665
Biomedical Research and Research Training	K23GM144867	93.859	—	145,146
Biomedical Research and Research Training	K99GM143517	93.859	—	103,219
Biomedical Research and Research Training	R00GM129460	93.859	—	194,457
Biomedical Research and Research Training	R01GM053640	93.859	—	331,840
Biomedical Research and Research Training	R01GM072808	93.859	—	46,385
Biomedical Research and Research Training	R01GM083889	93.859	—	114,045
Biomedical Research and Research Training	R01GM093278	93.859	—	433,307
Biomedical Research and Research Training	R01GM100151	93.859	—	132
Biomedical Research and Research Training	R01GM104323	93.859	—	(47,026)
Biomedical Research and Research Training	R01GM113243	93.859	27,166	181,993
Biomedical Research and Research Training	R01GM116065	93.859	—	24,689
Biomedical Research and Research Training	R01GM116991	93.859	—	75
Biomedical Research and Research Training	R01GM121967	93.859	—	170
Biomedical Research and Research Training	R01GM122083	93.859	5,024	2,360
Biomedical Research and Research Training	R01GM123136	93.859	99,709	107,565
Biomedical Research and Research Training	R01GM124280	93.859	43,021	356,335
Biomedical Research and Research Training	R01GM124472	93.859	—	(832)
Biomedical Research and Research Training	R01GM129495	93.859	—	281,978
Biomedical Research and Research Training	R01GM130950	93.859	—	368,502
Biomedical Research and Research Training	R01GM131099	93.859	268,442	344,765
Biomedical Research and Research Training	R01GM132598	93.859	—	497,459
Biomedical Research and Research Training	R01GM132985	93.859	—	269,430
Biomedical Research and Research Training	R01GM134245	93.859	—	284,120
Biomedical Research and Research Training	R01GM136880	93.859	—	315,965
Biomedical Research and Research Training	R01GM137011	93.859	—	298,781
Biomedical Research and Research Training	R01GM138544	93.859	—	311,955
Biomedical Research and Research Training	R01GM139842	93.859	129,802	189,593
Biomedical Research and Research Training	R01GM139967	93.859	203,265	531,439
Biomedical Research and Research Training	R01GM140632	93.859	268,977	441,570
Biomedical Research and Research Training	R01GM140657	93.859	—	(12,504)
Biomedical Research and Research Training	R01GM141074	93.859	—	298,206
Biomedical Research and Research Training	R01GM141392	93.859	102,150	215,832
Biomedical Research and Research Training	R01GM142113	93.859	—	318,998
Biomedical Research and Research Training	R01GM144729	93.859	—	227,971
Biomedical Research and Research Training	R01GM148075	93.859	—	11,950
Biomedical Research and Research Training	R21GM127971	93.859	—	(1,131)
Biomedical Research and Research Training	R21GM134564	93.859	20,971	38,404
Biomedical Research and Research Training	R21GM148931	93.859	—	59,161
Biomedical Research and Research Training	R25GM125598	93.859	—	400,502
Biomedical Research and Research Training	R25GM146271	93.859	—	128,293
Biomedical Research and Research Training	R35GM119426	93.859	—	358,750
Biomedical Research and Research Training	R35GM122549	93.859	—	58,035
Biomedical Research and Research Training	R35GM122568	93.859	—	691,070
Biomedical Research and Research Training	R35GM122591	93.859	—	(16)
Biomedical Research and Research Training	R35GM128570	93.859	—	381,820
Biomedical Research and Research Training	R35GM133509	93.859	—	368,393
Biomedical Research and Research Training	R35GM133719	93.859	—	527,736
Biomedical Research and Research Training	R35GM139407	93.859	—	337,198
Biomedical Research and Research Training	R35GM139123	93.859	—	436,595
Biomedical Research and Research Training	R35GM138313	93.859	16,358	458,199
Biomedical Research and Research Training	R35GM139408	93.859	—	416,093
Biomedical Research and Research Training	R35GM142503	93.859	—	601,384
Biomedical Research and Research Training	R35GM142724	93.859	—	488,762
Biomedical Research and Research Training	R35GM143050	93.859	—	648,543
Biomedical Research and Research Training	R35GM147557	93.859	—	207,701
Biomedical Research and Research Training	R35GM147558	93.859	—	451,443
Biomedical Research and Research Training	R35GM148217	93.859	—	176,397
Biomedical Research and Research Training	R35GM148416	93.859	—	233,912
Biomedical Research and Research Training	R35GM149296	93.859	—	118,864
Biomedical Research and Research Training	R35GM150587	93.859	—	16,472
Biomedical Research and Research Training	R35GM150760	93.859	—	19,608
Biomedical Research and Research Training	R35GM150920	93.859	—	810
Biomedical Research and Research Training	T32GM008169	93.859	—	3,870
Biomedical Research and Research Training	T32GM008490	93.859	—	487,578
Biomedical Research and Research Training	T32GM008602	93.859	—	27,386
Biomedical Research and Research Training	T32GM095442	93.859	—	290,036
Biomedical Research and Research Training	T32GM135060	93.859	—	311,055
Biomedical Research and Research Training	T32GM142617	93.859	—	1,367,309
Biomedical Research and Research Training	T32GM148391	93.859	—	22,196
Pass-through Georgia Institute of Technology	R01AI148740	93.859	—	106,048
Pass-through Johns Hopkins University	R01GM147162	93.859	—	74,233
Pass-through North Carolina State University	R25GM130528	93.859	—	60,552
Pass-through Ohio State University	R01GM30135	93.859	—	38,399
Pass-through Pennsylvania State University	R01GM121650	93.859	—	27,567
Pass-through Seattle Children's Research Institute	U54AI150472	93.859	—	17,185
Pass-through Texas Agricultural and Mechanical Univ	R01AI145640	93.859	—	110,493
Total AL No. 93.859			1,306,135	19,085,027

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Emerging Infectious Sentinel Networks: Pass-through International Society of Travel Medicine	1U01CK000632-01-00	93.860	\$ —	24,026
Total AL No. 93.860				24,026
Child Health And Human Development Extramural Research	75N94022P00789	93.865	—	16,996
Child Health And Human Development Extramural Research	F31HD096815	93.865	—	210
Child Health And Human Development Extramural Research	F31HD100145	93.865	—	23,798
Child Health And Human Development Extramural Research	F31HD105452	93.865	—	43,872
Child Health And Human Development Extramural Research	F31HD109748	93.865	—	45,207
Child Health And Human Development Extramural Research	F31HD107988	93.865	—	55,036
Child Health And Human Development Extramural Research	F31HD108974	93.865	—	17,923
Child Health And Human Development Extramural Research	F31HD108988	93.865	—	63,081
Child Health And Human Development Extramural Research	F32HD100176	93.865	—	76,030
Child Health And Human Development Extramural Research	F32HD108927	93.865	—	80,082
Child Health And Human Development Extramural Research	F32HD112173	93.865	—	14,220
Child Health And Human Development Extramural Research	K01HD100588	93.865	—	136,249
Child Health And Human Development Extramural Research	K01HD107294	93.865	—	128,765
Child Health And Human Development Extramural Research	K12HD072245	93.865	—	424,725
Child Health And Human Development Extramural Research	K12HD085850	93.865	—	717,747
Child Health And Human Development Extramural Research	K23HD078153	93.865	—	89
Child Health And Human Development Extramural Research	K99HD104991	93.865	—	126,523
Child Health And Human Development Extramural Research	P01HD112217	93.865	—	117,026
Child Health And Human Development Extramural Research	P50HD104458	93.865	762,988	2,063,607
Child Health And Human Development Extramural Research	R00HD092625	93.865	—	3,911
Child Health And Human Development Extramural Research	R00HD093858	93.865	—	40,568
Child Health And Human Development Extramural Research	R00HD096322	93.865	—	218,990
Child Health And Human Development Extramural Research	R00HD097290	93.865	—	290,697
Child Health And Human Development Extramural Research	R00HD104896	93.865	—	254,054
Child Health And Human Development Extramural Research	R01HD046922	93.865	—	20,947
Child Health And Human Development Extramural Research	R01HD081120	93.865	89,740	581,399
Child Health And Human Development Extramural Research	R01HD082373	93.865	—	343,671
Child Health And Human Development Extramural Research	R01HD090642	93.865	279,312	528,804
Child Health And Human Development Extramural Research	R01HD090925	93.865	—	62,598
Child Health And Human Development Extramural Research	R01HD092580	93.865	150,922	223,258
Child Health And Human Development Extramural Research	R01HD092595	93.865	193,864	282,570
Child Health And Human Development Extramural Research	R01HD093602	93.865	—	40,528
Child Health And Human Development Extramural Research	R01HD093706	93.865	70,444	253,231
Child Health And Human Development Extramural Research	R01HD094716	93.865	—	18,299
Child Health And Human Development Extramural Research	R01HD095741	93.865	15,220	388,145
Child Health And Human Development Extramural Research	R01HD095975	93.865	—	571,288
Child Health And Human Development Extramural Research	R01HD097175	93.865	435,267	570,411
Child Health And Human Development Extramural Research	R01HD099224	93.865	—	198,624
Child Health And Human Development Extramural Research	R01HD099480	93.865	521,729	712,802
Child Health And Human Development Extramural Research	R01HD101600	93.865	344,808	571,854
Child Health And Human Development Extramural Research	R01HD102534	93.865	444,235	700,444
Child Health And Human Development Extramural Research	R01HD108310	93.865	—	21,145
Child Health And Human Development Extramural Research	R01HD109005	93.865	24,266	257,531
Child Health And Human Development Extramural Research	R01HD109126	93.865	15,811	549,914
Child Health And Human Development Extramural Research	R01HD110480	93.865	24,355	337,998
Child Health And Human Development Extramural Research	R03HD102513	93.865	—	17,146
Child Health And Human Development Extramural Research	R21HD097491	93.865	—	109,843
Child Health And Human Development Extramural Research	R21HD100820	93.865	99,442	78,533
Child Health And Human Development Extramural Research	R21HD103030	93.865	—	64,938
Child Health And Human Development Extramural Research	R21HD107409	93.865	1,255	97,374
Child Health And Human Development Extramural Research	R21HD109723	93.865	—	8,124
Child Health And Human Development Extramural Research	R21HD110847	93.865	—	52,874
Child Health And Human Development Extramural Research	R33HD099745	93.865	260,775	403,594
Child Health And Human Development Extramural Research	T32HD071845	93.865	—	224,845
Child Health And Human Development Extramural Research	UG1HD027851	93.865	—	263,359
Cr-Pass-through Baylor College of Medicine	PSDH104463	93.865	—	538,721
Cr-Pass-through Bradley Hospital	R01HD095837	93.865	—	93,276
Cr-Pass-through Brown University	R01HD108048	93.865	—	10,176
Cr-Pass-through Case Western Reserve University	R01HD092351	93.865	—	36,294
Cr-Pass-through Childrens Hospital of Los Angeles	R01HD101641	93.865	—	3,413
Cr-Pass-through Childrens Hospital of Los Angeles	R21HD107983	93.865	—	19,328
Cr-Pass-through Children's Hospital of Philadelphia	R01HD101528	93.865	—	20,041
Cr-Pass-through Cincinnati Childrens Hospital	PL1HD101059	93.865	—	18,686
Cr-Pass-through City University of New York	R01HD102429	93.865	—	159,857
Cr-Pass-through Florida State University	UM2HD111102	93.865	—	706
Cr-Pass-through Georgia State University	R21HD109879	93.865	—	4,000
Cr-Pass-through Global Health Uganda Ltd	R01HD096559	93.865	—	11,018
Cr-Pass-through Harvard University	R01HD102342	93.865	—	39,748
Cr-Pass-through Michigan State University	R01HD096033	93.865	—	18,538
Cr-Pass-through Morehouse School of Medicine	R01HD097843	93.865	—	43,156
Cr-Pass-through Mount Sinai School of Medicine	R01HD099231	93.865	—	43,446
Cr-Pass-through Northwestern University	R01HD099344	93.865	—	15,294
Cr-Pass-through Ohio State University	R01HD091274	93.865	—	53,001
Cr-Pass-through Population Council	P50HD106793	93.865	—	63,690
Cr-Pass-through Rush University Medical Center	R01HD107522	93.865	—	203,277
Cr-Pass-through Shepherd Center	F31HD101151	93.865	—	16,760
Cr-Pass-through Univ of Massachusetts Medical School	R01HD109293	93.865	—	30,785
Cr-Pass-through University of California Davis	R01HD102571	93.865	—	1,483
Cr-Pass-through University of California San Francisco	P01HD106414	93.865	—	48,047
Cr-Pass-through University of California San Francisco	R61HD105618	93.865	5,227	142,148
Cr-Pass-through University of Colorado	R01HD105939	93.865	—	26,119
Cr-Pass-through University of Connecticut	R01HD106617	93.865	—	19,207
Cr-Pass-through University of Miami	R01HD101352	93.865	—	685,721
Cr-Pass-through University of Michigan	R01HD097107	93.865	—	10,010
Cr-Pass-through University of Minnesota	R01HD103634	93.865	—	12,128
Cr-Pass-through University of North Carolina	U19HD98981	93.865	—	130,549
Cr-Pass-through University of North Carolina Chapel Hill	R01HD094009	93.865	—	60,166
Cr-Pass-through University of North Carolina Chapel Hill	U19HD08981	93.865	—	162,427
Cr-Pass-through University of North Carolina Chapel Hill	U24HD08980	93.865	—	954
Cr-Pass-through University of Pittsburgh	P2CHD101895	93.865	—	10,358
Cr-Pass-through University of Pittsburgh	R01HD102313	93.865	—	105,018
Cr-Pass-through University of South Carolina	R01HD108444	93.865	—	106,857
Cr-Pass-through Wake Forest University	R01HD099231	93.865	—	375,191
Cr-Pass-through Wayne State University	R01HD099178	93.865	—	173,852
Cr-Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	873,847
Total AL No. 93.865			3,766,260	18,102,843
Aging Research	F31AG067623	93.866	—	32,746
Aging Research	F31AG069502	93.866	—	46,161
Aging Research	F31AG071319	93.866	—	44,804
Aging Research	F31AG072907	93.866	—	33,557
Aging Research	F31AG074665	93.866	—	46,494
Aging Research	F31AG076289	93.866	—	43,872
Aging Research	F31AG076332	93.866	—	8,851
Aging Research	F31AG079597	93.866	—	12,120
Aging Research	F31AG079670	93.866	—	46,483
Aging Research	F31AG081046	93.866	—	25,380
Aging Research	F31AG081129	93.866	—	26,384
Aging Research	F32AG064862	93.866	—	(390)
Aging Research	K01AG078497	93.866	—	35,819

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	K08AG068604	93.866	\$ —	148,028
Aging Research	K23AG065452	93.866	—	142,124
Aging Research	K23AG065505	93.866	—	143,288
Aging Research	K23AG066931	93.866	—	159,657
Aging Research	K23AG070378	93.866	—	215,800
Aging Research	K23AG073516	93.866	—	142,418
Aging Research	K23AG076977	93.866	—	125,405
Aging Research	P30AG064200	93.866	176,317	771,017
Aging Research	P30AG066511	93.866	158,200	3,315,449
Aging Research	P50AG025688	93.866	—	(15,367)
Aging Research	R01AG049752	93.866	360,800	377,273
Aging Research	R01AG054991	93.866	—	(200,367)
Aging Research	R01AG055634	93.866	—	245,561
Aging Research	R01AG056533	93.866	165,124	591,239
Aging Research	R01AG057714	93.866	21,537	216,467
Aging Research	R01AG058704	93.866	192,875	319,761
Aging Research	R01AG061175	93.866	—	493,046
Aging Research	R01AG061179	93.866	8,077	217,729
Aging Research	R01AG061971	93.866	34,262	235,587
Aging Research	R01AG062577	93.866	14,891	238,999
Aging Research	R01AG062581	93.866	—	527,625
Aging Research	R01AG062691	93.866	—	776,185
Aging Research	R01AG064464	93.866	—	317,301
Aging Research	R01AG065177	93.866	—	430,237
Aging Research	R01AG065611	93.866	260,300	887,600
Aging Research	R01AG066203	93.866	238,855	583,586
Aging Research	R01AG066956	93.866	514,057	970,368
Aging Research	R01AG067736	93.866	—	315,455
Aging Research	R01AG068247	93.866	—	449,532
Aging Research	R01AG070060	93.866	64,400	702,871
Aging Research	R01AG070704	93.866	85,882	1,380,114
Aging Research	R01AG070861	93.866	—	35
Aging Research	R01AG070937	93.866	10,136	6,175,450
Aging Research	R01AG072120	93.866	57,750	885,317
Aging Research	R01AG072603	93.866	62,348	619,122
Aging Research	R01AG072756	93.866	—	541,751
Aging Research	R01AG074019	93.866	138,968	310,341
Aging Research	R01AG074357	93.866	174,573	744,431
Aging Research	R01AG075444	93.866	—	539,976
Aging Research	R01AG075820	93.866	163,854	1,125,732
Aging Research	R01AG075827	93.866	—	608,376
Aging Research	R01AG076373	93.866	—	818,990
Aging Research	R01AG078248	93.866	—	460,400
Aging Research	R01AG078937	93.866	—	647,330
Aging Research	R01AG079170	93.866	—	205,620
Aging Research	R01AG079836	93.866	—	986
Aging Research	R01AG079956	93.866	—	319,126
Aging Research	R01AG079990	93.866	—	27,319
Aging Research	R01AG072309	93.866	41,914	376,298
Aging Research	R03AG067207	93.866	—	49,881
Aging Research	R13AG071267	93.866	—	50,000
Aging Research	R21AG054903	93.866	—	(2,534)
Aging Research	R21AG064405	93.866	—	61,135
Aging Research	R21AG065815	93.866	—	199,266
Aging Research	R21AG065977	93.866	—	67,279
Aging Research	R21AG067473	93.866	—	261,357
Aging Research	R21AG072142	93.866	—	147,731
Aging Research	R21AG072767	93.866	—	169,406
Aging Research	R21AG074218	93.866	—	201,443
Aging Research	R21AG075247	93.866	—	136,753
Aging Research	R21AG078058	93.866	—	204,626
Aging Research	R21AG080262	93.866	—	159,842
Aging Research	R21AG082333	93.866	—	27,877
Aging Research	R24AG066599	93.866	295,885	561,791
Aging Research	R34AG058835	93.866	117,247	142,354
Aging Research	R36AG075455	93.866	—	24,614
Aging Research	R56AG070861	93.866	—	(34,892)
Aging Research	R56AG074886	93.866	15,894	155,170
Aging Research	R61AG080606	93.866	—	129,490
Aging Research	RF1AG051633	93.866	—	(953)
Aging Research	RF1AG057470	93.866	—	(103)
Aging Research	RF1AG057965	93.866	153,761	860,115
Aging Research	RF1AG060285	93.866	28,167	342,174
Aging Research	RF1AG064942	93.866	—	29,641
Aging Research	RF1AG065262	93.866	64,000	263,020
Aging Research	RF1AG069114	93.866	57,517	711,885
Aging Research	RF1AG069253	93.866	—	336,799
Aging Research	RF1AG071170	93.866	—	727,929
Aging Research	RF1AG071587	93.866	—	454,352
Aging Research	RF1AG073428	93.866	63,607	396,225
Aging Research	RF1AG079199	93.866	82,089	374,302
Aging Research	RF1AG079256	93.866	112,259	888,945
Aging Research	RF1AG079269	93.866	273,062	614,759
Aging Research	RF1AG079318	93.866	—	545,962
Aging Research	RF1AG081401	93.866	—	42,808
Aging Research	U01AG052460	93.866	—	15,252
Aging Research	U01AG061357	93.866	243,619	1,343,275
Aging Research	U54AG062334	93.866	266,251	2,013,731
Aging Research	U54AG065167	93.866	6,207,515	8,286,019
Pass-through Beth Israel Deaconess Medical Center	R01AG068141	93.866	—	54,472
Pass-through Beth Israel Deaconess Medical Center	RF2AG062181	93.866	—	273,127
Pass-through Brown University	U54AG063546	93.866	—	55,162
Pass-through Case Western Reserve University	R01AG067607	93.866	—	87,325
Pass-through Columbia University	R01AG062624	93.866	—	2,335
Pass-through Florida International University	R13AG069360	93.866	—	50,918
Pass-through Georgia Institute of Technology	RF1AG078736	93.866	—	43,780
Pass-through Georgia State University	R01AG062310	93.866	—	45,398
Pass-through Georgia State University	R01AG080093	93.866	—	7,856
Pass-through Harvard University	R21AG073744	93.866	—	104,899
Pass-through Indiana University	U54AG054345	93.866	—	208,606
Pass-through Jackson Laboratory	R01AG075818	93.866	—	33,579
Pass-through M D Anderson Cancer Center	R01AG067419	93.866	—	70,262
Pass-through M D Anderson Cancer Center	R01AG071174	93.866	—	81,252
Pass-through Mayo Clinic	U01AG046139	93.866	—	502,354
Pass-through Mclean Hospital	R01AG061100	93.866	—	782,352
Pass-through Northwestern University	U19AG073153	93.866	—	112,105
Pass-through Northwestern University	U2CAG057441	93.866	—	13,055
Pass-through Northwestern University	U2CAG060426	93.866	—	50,714
Pass-through Ohio State University	R21AG068851	93.866	—	13,609
Pass-through Oregon Health and Science University	R01AG067546	93.866	—	12,576
Pass-through Rush University Medical Center	R01AG015819	93.866	—	184,976
Pass-through State University of New York Stony Brook	R01AG067590	93.866	—	61,143
Pass-through Tulane University	R01AG077497	93.866	—	31,323
Pass-through Univ of Texas Health Sciences Ctr	R01AG059993	93.866	—	13,710
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	204,355

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Arizona	U19AG065169	93.866	\$ —	452,803
Pass-through University of California Berkeley	R01AG077001	93.866	—	33,932
Pass-through University of California San Diego	R01AG062387	93.866	—	273,149
Pass-through University of Connecticut	U54AG063546	93.866	—	7,037
Pass-through University of Florida	R01AG064786	93.866	—	673,965
Pass-through University of Florida	RF1AG064914	93.866	—	79,670
Pass-through University of Florida	RF1AG074569	93.866	—	493,257
Pass-through University of Iowa	R21AG065980	93.866	—	15,000
Pass-through University of Louisville	R43AG07059A	93.866	—	62,118
Pass-through University of Nebraska Medical Center	R01AG069609	93.866	—	311,351
Pass-through University of New Mexico	R01AG049395	93.866	—	107,277
Pass-through University of North Carolina Chapel Hill	R01AG065394	93.866	—	6,854
Pass-through University of North Carolina Greensboro	R01AG058919	93.866	—	22,333
Pass-through University of Pittsburgh	R01AG074971	93.866	—	386,851
Pass-through University of Pittsburgh	R21AG060732	93.866	—	13,358
Pass-through University of Pittsburgh	R21AG074094	93.866	—	14,302
Pass-through University of Pittsburgh	U19AG074866-01A1	93.866	—	99,802
Pass-through University of South Florida	RF1AG079141	93.866	—	85,925
Pass-through University of Southern California	R21AG071790	93.866	—	14,615
Pass-through University of Southern California	U24AG057437	93.866	—	179,019
Pass-through University of Texas San Antonio	R01AG077554	93.866	—	5,139
Pass-through University of Washington	U24AG072122	93.866	—	26,780
Pass-through University of Washington Saint Louis	U19AG032438	93.866	—	(125)
Pass-through University of Wisconsin-Madison	R01AG070883	93.866	—	81,412
Pass-through Vanderbilt University	R01AG068606	93.866	—	17,174
Pass-through Vanderbilt University	R01AG069900	93.866	—	253,539
Pass-through Wake Forest University	R01AG075959	93.866	—	54,658
Pass-through Washington University	R01AG067505	93.866	—	782,873
Pass-through Washington University	U19AG030249	93.866	—	134,486
Pass-through Washington University	U19AG071754	93.866	—	491,251
Pass-through Yale University	R33AG058926	93.866	—	48,459
Total AL No. 93.866			10,925,993	59,341,022
Vision Research	7R01EY016435-15	93.867	—	86,017
Vision Research	F30EY035173	93.867	—	4,524
Vision Research	F31EY033691	93.867	—	46,087
Vision Research	P30EY006360	93.867	—	673,195
Vision Research	R00EY029010	93.867	—	262,648
Vision Research	R01EY021592	93.867	—	266,583
Vision Research	R01EY028450	93.867	—	365,957
Vision Research	R01EY028859	93.867	31,776	244,642
Vision Research	R01EY029724	93.867	—	456,897
Vision Research	R01EY030871	93.867	280,877	411,712
Vision Research	R01EY031042	93.867	—	557,111
Vision Research	R21EY028320	93.867	—	6,453
Vision Research	R21EY035136	93.867	—	44,910
Vision Research	T32EY007092	93.867	61,093	225,354
Pass-through George Mason University	R21EY032152	93.867	—	50,588
Pass-through Georgia Institute of Technology	R01EY016435	93.867	—	13,960
Pass-through Jaehs Center For Health Research	UG1EY011751	93.867	—	16,864
Pass-through Johns Hopkins University	UG1EY028091	93.867	—	41,663
Pass-through New England College of Optometry	R01EY025307	93.867	—	28,153
Pass-through University of Alabama Birmingham	R01EY028578	93.867	—	25,772
Pass-through University of California San Francisco	UG1EY023939	93.867	—	15,560
Pass-through University of Houston	R01EY032508	93.867	—	42,114
Pass-through University of Nebraska Medical Center	R01EY029594	93.867	—	85,841
Pass-through University of North Texas	R01EY030967	93.867	—	31,251
Total AL No. 93.867			373,746	4,003,616
Medical Library Assistance	G13LM013010	93.879	—	11,399
Medical Library Assistance	K01LM012924	93.879	—	1,495
Medical Library Assistance	R01LM013049	93.879	105,333	209,204
Medical Library Assistance	R01LM013323	93.879	—	216,908
Medical Library Assistance	R01LM013864	93.879	26,006	258,187
Pass-through University of California San Diego	R01LM013712	93.879	—	78,281
Pass-through Yale University	R01LM013712	93.879	—	44,303
Total AL No. 93.879			131,339	819,857
National Bioterrorism Hospital Preparedness Program: Pass-through Baylor College of Medicine	U3REP220671	93.889	—	179,740
Total AL No. 93.889			—	179,740
Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations: Pass-through Georgia Dept of Public Health	NU58DP006352	93.898	—	430,852
Total AL No. 93.898			—	430,852
Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement	G2846273	93.912	22,102	159,413
Total AL No. 93.912			22,102	159,413
Hiv Emergency Relief Project Grants: Pass-through Fulton County	HA89HA00007-32	93.914	—	31,928
Total AL No. 93.914			—	31,928
HIV Prevention Activities Non-Governmental Organization Based	NU62PS924790	93.939	3,857,319	6,001,882
Total AL No. 93.939			3,857,319	6,001,882
Hiv Demonstration, Research, Public And Professional Education Projects Hiv Demonstration, Research, Public And Professional Education Projects	5U01PS003322-04 REVI U01PS005181	93.941 93.941	— —	(37,175) (84)
Total AL No. 93.941			—	(37,259)
Assistance Programs For Chronic Disease Prevention And Control: Pass-through Tulane University Pass-through University of Florida	U18DP006523 U18DP006512	93.945 93.945	— —	7,963 24,584
Total AL No. 93.945			—	32,547
Block Grants for Prevention and Treatment of Substance Abuse: Pass-through Georgia Department of Behavioral Health	B08T1084637	93.959	—	42,162
Total AL No. 93.959			—	42,162
PPHF Geriatric Education Centers	U10Q33070	93.969	175,466	799,305
Total AL No. 93.969			175,466	799,305
International Research and Research Training	D43TW007124	93.989	63,144	238,124
International Research and Research Training	D43TW009127	93.989	37,616	366,878
International Research and Research Training	D43TW010934	93.989	30,940	341,734
International Research and Research Training	D43TW011404	93.989	54,810	363,867
International Research and Research Training	D43TW012188	93.989	133,376	218,950
International Research and Research Training	D43TW012459	93.989	—	32,976
International Research and Research Training	R01TW010664	93.989	133,877	174,508
International Research and Research Training	R21TW012010	93.989	24,803	98,397

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
International Research and Research Training	U2RTW010114	93.989	\$ 189,518	294,276
Pass-through Addis Ababa University	R25TW011214	93.989	—	62,868
Pass-through Aga Khan University	D43TW010905	93.989	—	27,306
Pass-through Brown University	D43TW010565	93.989	—	2,356
Pass-through University of Virginia	R01TW012183	93.989	—	15,715
Pass-through Vanderbilt University	D43TW009337	93.989	—	6,261
Pass-through Vanderbilt University Medical Center	D43TW009337	93.989	15,164	83,010
Total AL No. 93.989			683,348	2,327,246
Maternal and Child Health Services Block Grant to the States: Pass-through University of South Florida	B04MC40124	93.994	—	59,998
Total AL No. 93.994			—	59,998
Contract	00HCVJCG-2018-25346	93.CTR	—	64
Contract	75D30118C02645	93.CTR	80,769	275,453
Contract	75D30119C06635	93.CTR	—	(545)
Contract	75D30119C06765	93.CTR	—	4,256
Contract	75D30119P06734	93.CTR	—	5,633
Contract	75D30120P07242	93.CTR	—	(5,562)
Contract	75D30120P09338	93.CTR	—	1,422
Contract	75D30121C10084	93.CTR	—	65,910
Contract	75D30121C12018	93.CTR	—	396,064
Contract	75D30121D10817	93.CTR	—	29,063
Contract	75D30121P11776	93.CTR	—	(1,070)
Contract	75D30122C14198	93.CTR	—	195,292
Contract	75D30122C14484	93.CTR	—	108,072
Contract	75D30122C14631	93.CTR	—	178,102
Contract	75D30122P13467	93.CTR	—	220,108
Contract	75D30122P13545	93.CTR	—	6,075
Contract	75D30122P15586	93.CTR	—	244,320
Contract	75D30123C16053	93.CTR	—	40,005
Contract	75N91021P00843	93.CTR	—	128,489
Contract	75N91022P00641	93.CTR	—	25,000
Contract	75N92022D00015	93.CTR	834,893	2,141,893
Contract	75N92022F00003	93.CTR	—	155,944
Contract	75N92022F00004	93.CTR	—	48,236
Contract	75N93020D00005	93.CTR	—	3,152,173
Contract	75N93021C00017	93.CTR	269,120	2,472,361
Contract	75N93022F00002	93.CTR	—	18,008
Contract	75N94020D00009	93.CTR	—	10,617
Contract	75N96022P00015	93.CTR	—	74,799
Contract	75P00122P00020	93.CTR	—	655,411
Contract	HHS4258201800013C	93.CTR	—	43,524
Contract	HHSN261201800003I	93.CTR	—	3,105,289
Contract	HHSN272201300018I	93.CTR	—	3,149
Contract	HHSN272201300018I	93.CTR	1,158,382	3,287,966
Contract	HHSN272201300018I HHSN272	93.CTR	—	37,775
Contract	HHSN272201400004C	93.CTR	353,569	374,273
Contract	HHSN275201500001I	93.CTR	—	32,579
Contract	HHSN61201800003I	93.CTR	—	(1,228)
Contract	6NU360E000009-05-01	93.CTR	—	24,035
Contract	75D30120C09782	93.CTR	—	34
Contract	75F40120C00207	93.CTR	—	206,745
Contract	75R60220C00011	93.CTR	—	507
Contract	75N93019C00059	93.CTR	—	396,278
Contract	IDRI COVID-19	93.CTR	—	37,103
Contract	75N93019C00046	93.CTR	—	409,827
Contract	75N93019C00051	93.CTR	—	1,647,338
Contract	75D30118F03426	93.CTR	—	28,290
Contract	HHSD2002013M54955B	93.CTR	—	8,696
Contract	75N92020D00021	93.CTR	—	13,798
Contract	OT2HL154977	93.CTR	—	24,019
Contract	75N93022C00052	93.CTR	—	269,807
Contract	75N92020D00018 75N92020F00001	93.CTR	—	71,102
Contract	NCATS-P00438-B	93.CTR	—	46,369
Contract	75N93022C00024	93.CTR	—	5,095
Contract	75N93021C00015	93.CTR	—	94,183
Contract	HHSN272201800008C	93.CTR	—	100,446
Contract	75D30121C11656	93.CTR	—	227,225
Contract	75D30122C12914	93.CTR	—	13,149
Contract	75D30122C14944	93.CTR	—	157,613
Contract	75D30122C15605	93.CTR	—	13,100
Total AL No. 93.CRT			2,696,733	21,323,861
U.S. Department of Health and Human Services Total			121,431,936	642,703,196
U.S. Department of Homeland Security: Assistance Listing Program Title: Pass-through George Mason University	17STCIN00001	97.601	—	89,392
Total AL No. 97.601			—	89,392
U.S. Department of Homeland Security Total			—	89,392
U.S. Agency for International Development: Usaid Foreign Assistance For Programs Overseas: Pass-through FHI 360 LLC Pass-through Intl Aids Vaccine Initiative Pass-through Technoserve	7200AA20CA00016 AID-OAAA-16-00032 7200AA22LE00002	98.001 98.001 98.001	— — —	23,869 653,612 267,866
Total AL No. 98.001			—	945,347
U.S. Agency for International Development Total			—	945,347
Total Research and Development Cluster			126,463,773	676,944,962
Student Financial Assistance Cluster (notes 2 through 5): U.S. Department of Education: Federal Work-Study Program Federal Supplemental Educational Opportunity Grants Federal Pell Grant Program Federal Direct Loan Program Federal Direct PLUS Loan Program Federal Perkins Loan (FPL)		84.033 84.007 84.063 84.268 84.268 84.038	— — — — — —	1,900,864 1,129,983 8,469,600 84,941,176 75,946,415 2,940,607
Total U.S. Department of Education			—	175,328,645
U.S. Department of Health and Human Services: Nursing Faculty Loan Program (NFLP) Health Professions Student Loans, Including Primary Care Loans and Loans for Disadvantaged Students (HPSL) Nursing Student Loans (NSL)		93.264 93.342 93.364	— — —	386,925 538,817 846,304
Total U.S. Department of Health and Human Services			—	1,772,046
Total Student Financial Assistance Cluster			—	177,100,691
U.S. Department of Commerce: Cluster Grants	ED20HQDQ200045	11.020	55,711	55,711
Total AL No. 11.020			55,711	55,711
U.S. Department of Commerce Total			55,711	55,711

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department Of Defense: Language Grant Program	H98230-22-1-0048	12.900	\$ —	94,831
Total AL No. 12.900			—	94,831
U.S. Department of Defense Total			—	94,831
U.S. Department of Housing and Urban Development: Contract: Pass-through Atlanta Regional Commission	ARC-AH AG2027.1	14.CTR	—	16,956
Total AL No. 14.CTR			—	16,956
U.S. Department of Housing and Urban Development Total			—	16,956
U.S. Department of Justice: Community-Based Violence Intervention and Prevention Initiative: Pass-through Dekalb County	15PBJA22GG04712CVIP	16.045	—	27,961
Total AL No. 16.045			—	27,961
U.S. Department of Justice Total			—	27,961
National Endowment for Humanities: Promotion of the Arts Grants to Organizations and Individuals	1885290-44-21	45.024	—	30,000
Promotion of the Arts Grants to Organizations and Individuals	1886761-42-21	45.024	—	(3,218)
Total AL No. 45.024			—	26,782
Promotion of the Humanities Division of Preservation and Access	PW-285174-22	45.149	—	28,761
Total AL No. 45.149			—	28,761
National Endowment for Humanities Total			—	55,543
U.S. Department of Veterans Affairs: Contract	36C24722C0090	64.CTR	—	356,859
Contract	508-21-2-144-0022	64.CTR	—	387,275
Total AL No. 64.CTR			—	744,134
U.S. Department of Veterans Affairs Total			—	744,134
U.S. Department of Education: COVID-19 – Higher Education Emergency Relief Fund -- Higher Education Emergency Relief Fund – Student Portion		84.425E	—	3,217
Total AL No. 84.425E			—	3,217
COVID-19 – Education Stabilization Fund – Higher Education Emergency Relief Fund Institutional Portion		84.425F	—	3,645,412
Total AL No. 84.425F			—	3,645,412
Total AL No. 84.425			—	3,648,629
U.S. Department of Education Total			—	3,648,629
U.S. Department of Health and Human Services: National Organizations of State and Local Officials: Pass-through The Center For Global Health Innovation	U3U45470	93.011	—	112,410
Total AL No. 93.011			—	112,410
National Family Caregiver Support, Title III, Part E: Pass-through Atlanta Regional Commission	2001GAOAFc	93.052	—	18,756
Total AL No. 93.052			—	18,756
Maternal And Child Health Federal Consolidated Programs Pass-through Hemophilia of Georgia	UH7MC30772	93.110	64,344	417,408
Pass-through Hemophilia of Georgia	H3024046	93.110	—	13,380
Pass-through Hemophilia of Georgia	H30MC24046	93.110	—	51,423
Total AL No. 93.110			64,344	482,211
Project Grants and Cooperative Agreements for Tuberculosis Control Programs: Pass-through Georgia Dept of Public Health	40500-046-20203197	93.116	—	30,900
Total AL No. 93.116			—	30,900
Emergency Medical Services for Children: Pass-through Rhode Island Hospital	U03MC33155	93.127	—	315,716
Total AL No. 93.127			—	315,716
HIV-Related Training and Technical Assistance: Pass-through University of Washington	6 UO1HA33252-02-01	93.145	—	3,204
Pass-through University of Washington	U1032104	93.145	—	48,347
Total AL No. 93.145			—	51,551
Scaling the National Diabetes Prevention Program to Priority Populations: Pass-through Amer Assoc of Diabetes Educators	NU58DP006361	93.261	—	12,516
Total AL No. 93.261			—	12,516
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	216,061	1,614,701
Total AL No. 93.318			216,061	1,614,701
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC): Pass-through Georgia Dept of Public Health	NU50CK000529	93.323	—	165,945
Total AL No. 93.323			—	165,945
The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels: Pass-through Alzheimers Association	NU58DP006744	93.334	—	327,564
Pass-through Alzheimers Association	NU58DP006912	93.334	—	52,342
Pass-through Alzheimers Association	NU58DP006912-02-01	93.334	—	18,016
Total AL No. 93.334			—	397,922
Public Health Emergency Response: Cooperative Agreement for Emergency Response: Public Health Crisis Response: Pass-through Kentucky Hospital Association	6 NU90TP922182-01-01	93.354	22,702	72,496
Total AL No. 93.354			22,702	72,496
Sickle Cell Treatment Demonstration Program: Pass-through University of Alabama Birmingham	U1EMCA42461	93.365	15,733	123,638
Total AL No. 93.365			15,733	123,638
COVID-19 – Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	NU50CK000617	93.421	192,246	952,698
Pass-through Amer College of Preventive Medicine	NU3803000289	93.421	—	32,874
Pass-through Amer College of Preventive Medicine	NU38OT000289	93.421	49,686	282,393
Pass-through CDC Foundation	NU38OT000288	93.421	—	15,663
Pass-through Natl Assoc of Chronic Disease Directors	NU38OT000286	93.421	—	16,958
Total AL No. 93.421			241,932	1,300,586
The National Cardiovascular Health Program: Pass-through Adcare Educational Institute	NU58DP006518	93.426	—	3,894
Pass-through Alabama Department of Public Health	NU58DP006527	93.426	—	42,247
Pass-through Georgia Dept of Public Health	NU58DP006463	93.426	—	143,113
Pass-through Kentucky Department of Public Health	NU58DP006612	93.426	—	282,888
Pass-through Minnesota Department of Health	NU58DP006522	93.426	—	23,543

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2023

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Mississippi State Department of Health	NU58DP006546	93.426	\$ —	10,687
Pass-through Missouri Dept Health and Senior Services	5NU58DP006520-03A	93.426	—	2,500
Pass-through Nebraska Department of Health and Human	5NU58DP006548	93.426	—	10,750
Pass-through South Dakota Department of Health	NU58DP006526	93.426	—	239,933
Pass-through Tennessee Department of Health	NU58DP006552	93.426	—	85,226
Total AL No. 93.426			—	844,781
Networking2Save™. CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations: Pass-through Patient Advocate Foundation	NU58DP006468	93.431	—	213,028
Total AL No. 93.431			—	213,028
The Innovative Cardiovascular Health Program: Pass-through Adcare Educational Institute	NU58DP006518	93.435	—	2,500
Pass-through Adcare Educational Institute	NU58DP006623	93.435	—	3,969
Pass-through Georgia Dept of Public Health	NU58DP006623	93.435	—	39,112
Pass-through Kentucky Department for Public Health	NU58DP006612	93.435	—	(6,008)
Pass-through Utah Department of Health	NU58DP006609	93.435	—	25,253
Pass-through Wisconsin Department of Health and Famil	NU58DP006607	93.435	—	1,153
Total AL No. 93.435			—	65,979
COVID-19 – Provider Relief Fund and American Rescue Plan Rural Distribution		93.498	—	30,615,606
Total AL No. 93.498			—	30,615,606
Community-Based Child Abuse Prevention Grants: Pass-through Georgia Department of Human Services	58-0566256	93.590	—	21,465
Total AL No. 93.590			—	21,465
Children's Justice Grants to States: Pass-through Georgia Department of Human Services	42700-040-0000103366	93.643	—	6,899
Pass-through Georgia Department of Human Services	42700-040-0000107717	93.643	—	98,457
Total AL No. 93.643			—	105,356
PPHF: Racial And Ethnic Approaches To Community Health Program Financed Solely By Public Prevention And Health Funds: Pass-through Georgia Dept of Public Health	NU58DP006580	93.738	—	95,751
Total AL No. 93.738			—	95,751
Medical Assistance Program: Pass-through Georgia Department of Behavioral Health	2205GA5MAP	93.778	—	(2,469)
Total AL No. 93.778 (Medicaid Cluster)			—	(2,469)
Opioid STR: Pass-through Atlanta Harm Reduction Coalition	H79TI083292	93.788	—	29,882
Total AL No. 93.788			—	29,882
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	HITEP210054	93.817	725,189	1,375,965
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	U3REP220673	93.817	49,473	495,466
Pass-through Georgia Dept of Public Health	U3REP150546	93.817	99,999	723,388
Total AL No. 93.817			874,661	2,594,819
HIV Emergency Relief Project Grants: Pass-through Fulton County	HA89HA00007-32	93.914	—	621,243
Total AL No. 93.914			—	621,243
Grants To Provide Outpatient Early Intervention Services With Respect To HIV Disease Total AL No. 93.918	H7607848	93.918	—	680,350
Assistance Programs for Chronic Disease Prevention and Control: Pass-through Natl Assoc of Chronic Disease Directors	NU58DP006979	93.945	—	7,014
Total AL No. 93.945			—	7,014
Block Grants for Prevention and Treatment of Substance Abuse: Pass-through Georgia Department of Behavioral Health	B08TI10061-20; FY20 SAPT BG	93.959	—	526
Pass-through Georgia Department of Behavioral Health	B08TI083442	93.959	—	54,857
Pass-through Georgia Department of Behavioral Health	B08TI084637	93.959	—	187,313
Pass-through Hazelden Betty Ford Foundation	44100-906-0000168740	93.959	—	16,353
Total AL No. 93.959			—	259,049
Sexually Transmitted Diseases (STD) Provider Education Grants: Pass-through University of Washington	NU62PS924588	93.978	—	28,801
Total AL No. 93.978			—	28,801
Cooperative Agreements for Diabetes Control Programs Total AL No. 93.988	NU58DP007422	93.988	—	213,654
Contract	75D30120C07672	93.CTR	—	1,446,649
Contract	75D30120P09249	93.CTR	—	20,230
Contract	HHSD2002017M95146B	93.CTR	—	30,284
Pass-through Amer College of Preventive Medicine	NU5903000269	93.CTR	—	9,500
Pass-through Assoc of State & Territorial Dent	5 NU58DP006573	93.CTR	—	25,988
Pass-through Childrens Healthcare of Atlanta	UM1CA228823	93.CTR	—	19,581
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	90,377
Pass-through Georgia Dept of Public Health	40500-035-21213721	93.CTR	—	194,991
Pass-through Univ of Arkansas for Medical Services	75N91019D00024	93.CTR	—	17,398
Total AL No. 93.CTR			—	1,854,996
U.S. Department of Health and Human Services Total			1,435,433	42,948,653
U.S. Homeland Security: Disaster Grants – Public Assistance (Presidentially Declared Disasters) Total AL No. 97.036		97.036	—	31,226,145
U.S. Homeland Security Total			—	31,226,145
Total Non-Research and Development Programs			1,491,144	78,818,563
Total Student Financial Assistance Cluster and Non-Research and Development Programs			1,491,144	255,919,254
Total Expenditures of Federal Awards			\$ 127,954,917	932,864,216

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2023

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Pro	\$ 868,342	90,629
2205GA5MAP	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2020-2021 Emory Neuro Developmental Exposure Clinic (ENEC)	361,000	(2,469)
40500-035-21213721	GEORGIA DEPT OF PUBLIC HEALTH	Georgia B-SEEN // CDC's BOLD Act	60,000	194,991
40500-046-20203197	GEORGIA DEPT OF PUBLIC HEALTH	GEORGIA DEPARTMENT OF PUBLIC HEALTH – Blumberg 2022	22,467	30,900
42700-040-0000103366	GEORGIA DEPARTMENT OF HUMAN SERVICES	Summer Child Advocacy Program 2021	66,061	6,899
42700-040-0000107717	GEORGIA DEPARTMENT OF HUMAN SERVICES	Summer Child Advocacy Program 2021	45,681	98,457
69A375193000405BGAH	GOVERNORS OFFICE OF HIGHWAY SAFETY	2022 Statewide Seatbelt Use Survey	179,661	48,116
69A3752030000405BGAH	GOVERNORS OFFICE OF HIGHWAY SAFETY	2023 Statewide Seatbelt Use Survey	103,969	209,800
90TP0070	Georgia Department of Early Care and Lea	Impact of Socio-emotional learning with Georgia Home Health Visiting Programs	45,430	20,950
B08T1083442	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2021-2022 Fetal Alcohol and Drug Screening project: MSACD	41,667	54,857
B08T1084637	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2022-2023 Fetal Alcohol and Drug Screening project: MSACD	123,760	167,313
B08T1084637	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2023 Opioid Prevention Curriculum	30,121	42,162
HA89HA00007-32	FULTON COUNTY	Ryan White HIV/AIDS Treatment	1,843,361	653,171
NU50CK000529	GEORGIA DEPT OF PUBLIC HEALTH	GA DPH NWSS Training	168,692	165,945
NU58DP006352	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	626,429	430,852
NU58DP006463	GEORGIA DEPT OF PUBLIC HEALTH	GA DPH DPP Lifestyle Coach Training and Support	(40,655)	143,113
NU58DP006580	GEORGIA DEPT OF PUBLIC HEALTH	Evaluation of the REACH Grant	62,347	95,751
NU58DP006607	WISCONSIN DEPARTEMNT OF HEALTH AND FAMIL	WI DHS DPP Advanced Learning	18,975	1,153
NU58DP006623	GEORGIA DEPT OF PUBLIC HEALTH	GA Department of Health_DPP Support_1817	32,395	39,112
U3REP150546	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program	1,062,579	1,224,017
			<u>\$ 5,722,282</u>	<u>3,735,719</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2023

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLPL) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution (AL # 93.498) includes reimbursements for lost revenues during the period from July 1, 2020 to June 30, 2023, based upon the PRF report that is required to be submitted to the HRSA reporting portal.

(3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the FDSLPL and revolving loan programs, such as the Federal Perkins Loan Program.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2023

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>AL #</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 2,482,459
Unsubsidized Stafford Loan Program	84.268	<u>82,458,717</u>
Total Direct Stafford Loan Program		84,941,176
Federal Direct PLUS Loan Program	84.268	<u>75,946,415</u>
Total Federal Direct Student Loan Programs		\$ <u><u>160,887,591</u></u>

The Federal Perkins Loan (FPL) program, Nurse Faculty Loan Program (NFLP), Health Professions Student Loans (HPSL) program, and Nursing Student Loans (NSL) program are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amounts presented on the Schedule include the FPL, NFLP, HPSL, and NSL outstanding as of August 31, 2022 plus any loans issued in the current year, as applicable. FPL, NFLP, HPSL, and NSL outstanding at August 31, 2023 totaled \$1,974,766, \$294,337, \$479,254, and \$743,796, respectively. NFLP, HPSL, and NSL issued \$121,833, \$82,530, and \$113,238 in new loans during the year ended August 31, 2023. No FPL were issued in the current year.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2023. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$282,496 in funds awarded to students for the year ended August 31, 2023 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$518,266 in total compensation to students for the year ended August 31, 2023 in addition to the federal share of expenditures included in the Schedule.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2023

(5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$52,774 for the year ended August 31, 2023. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

(6) Indirect Costs

For the year ended August 31, 2023, the University did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

**Independent Auditors' Report on Compliance for Each Major Federal Program;
Report on Internal Control Over Compliance; and Report on Supplementary
Schedules of Expenditures of Federal Awards Required by the Uniform Guidance
and Cash Receipts and Expenditures of State of Georgia Awards**

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Emory University and its subsidiaries' (the University) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2023. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not



absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of the University as of and for the year ended August 31, 2023, and have issued our report thereon dated December 19, 2023, which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Atlanta, Georgia
March 18, 2024

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2023

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
- Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
- Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (e) Type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **None reported**
- (g) Major programs:
- **Research and Development Cluster** – various AL numbers
 - **COVID-19 – Education Stabilization Fund – Higher Education Emergency Relief Fund (HEERF) Student Aid Portion** – AL# 84.425E and **HEERF Institutional Portion** – AL# 84.425F
 - **COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution** – AL# 93.498
 - **Disaster Grants – Public Assistance (Presidentially Declared Disasters)** – AL# 97.036
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

(3) Findings and Questioned Costs Relating to Federal Awards

None